 
 
 
A Phase 3 Randomized, Open -Label Study Comparing Pexa -Vec (Vaccinia GM-CSF  / 
Thymidine Kinase -Deactivated Virus) Followed by [CONTACT_315080] (HCC) Without Prior Systemic Therapy  
 
STUDY PROTOCOL NUMBER:  JX594 -HEP024  
INVESTIGATIONAL PRODUCT:  Pexastimogene D evacirepvec ( Pexa -Vec)  
PHASE:  3 
IND NUMBER:  BB-IND [ADDRESS_387689] NUMBER:  2014- 001985- 86 
SPONSOR:  SillaJen Inc.  
[ADDRESS_387690]  
San Francisco, CA [ZIP_CODE]-  [LOCATION_003] 
EU LEGAL REPRESENTATIVE:  Quality Regulatory Clinical Ireland Ltd  
(QRC Consultants Ltd ) 
21 Priory Office Park, Stillorgan  
Dublin A94F660, Ireland  
Tel: [PHONE_6607]  
MEDICAL MONITOR:  Kyoungsoo Ha  
Mobile: +82- 10-7471 -4145  
Fax: +82- 2-783-7555  
Email: [EMAIL_6170]  
PROTOCOL DATE:  17 February 2015  
AMENDMENT  1: 3 October 2017  
AMENDMENT 2:  26 June 2019  
 
Confidentiality Statement  
This document contains confidential information.  It is intended solely for the use of the principal 
investigator, co -investigators, staff, appropr iate institutional review boards or ethical committees, and other 
required regulatory bodies.  
CONFIDENTIAL an d PROPRIETARY  Page 3 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  26 June 2019 INVESTIGATOR SIGNATURE P AGE 
PROTOCOL TITLE:  A Phase 3 Randomized, Open- Label Study 
Comparing Pexa- Vec (Vaccinia GM CSF / 
Thymidine Kinase -Deactivated Virus) Followed by 
[CONTACT_315081] (HCC) 
Without Prior Systemic Ther apy 
PROTOCOL NUMBER:  JX594- HEP024  
INVESTIGATIONAL PROD UCT:   Pexa- Vec 
SPONS OR: SillaJen Inc.  
[ADDRESS_387691]  
San Francisco, CA [ZIP_CODE]-  [LOCATION_003] 
PROTOCOL  DATE  17 February 2015  
AMENDMENT  1: 3 October 2017  
AMENDMENT 2:  [ADDRESS_387692] this study as outlined herein 
and will make a reasonable effort to complete the study within the time de signated.  I will work 
according to the principles of Good Clinical Pr actice (GCP) as described (for the US) in the Code 
of Federal Regulations (CFR) Section 21, Parts 11, 50, 54, 56, and 312, The Declaration of 
Helsinki (2008), and GCP as described in the  International Conference on Harmonization (ICH) 
document “Guidance for Industry – E6 Good Clinical Practice: Consolidated Guidance” .  Further, 
I will conduct the study in keepi[INVESTIGATOR_315012].  
I will provide copi[INVESTIGATOR_315013].  I will discuss this material with them to ensure that they are fully informed about 
the drug and the study.  
   
Principal Investigator [INVESTIGATOR_315014] (Printed)    
CONFIDENTIAL an d PROPRIETARY  Page 4 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  [ADDRESS_387693] OF ABBREVIATION S ..................................................................................................11  
2 PROTOCOL S YNOPSIS  ........................................................................................................15  
3 BACKGROUND  .....................................................................................................................26  
3.A Hepatocellular Carcinoma (HCC) ................................................................................26  
3.A.1  Current Treatment for HCC  ...........................................................................26  
3.B Oncolytic Immunotherapy ...........................................................................................28  
3.B.1  Pexa- Vec: Selective Tumo r Infection and Active Immunotherapy  ...............29  
3.C Preclinical Experience with Pexa- Vec .........................................................................30  
3.C.1  Efficacy of Pexa -Vec in Rabbit VX -2 Carcinoma Model and Rat 
Carcinogen -Induced Pri mary Liver Tumors  ..................................................30  
3.C.2  Efficacy of Repeated Doses of Pexa- Vec Followed by [CONTACT_315082] a Human Tumor Xenograft Model of Hepatocellular 
Carcinoma  ......................................................................................................31  
3.C.3  Toxicity and Biodistribution of Single or Repeated IV Doses of 
Pexa- Vec in the Rabbit  ..................................................................................31  
3.D Clinical Experience ......................................................................................................32  
3.D.1  Overview of Clinical Experience with Pexa- Vec ..........................................32  
3.D.2  Pexa- Vec Evaluation in Non- HCC Indications  .............................................34  
3.D.3  Treatment of Solid Tumors within the Liver with Pexa -Vec.........................35  
3.D.3.a  Phase 1 Liver Tumor Trial  .............................................................35  
3.D.3.b  Phase 2 Liver Cancer (HCC) T rial (JX594- IT-HEP007)  ..............35  
3.D.3.c  Phase 2 Study of HCC Patients Treated IV and IT with 
Pexa- Vec Prior to  Sorafenib (JX594- HEP016)  .............................[ADDRESS_387694] Failed 
Sorafenib Treatment (JX594- HEP018/TRAVERSE)  ....................37  
3.E Rationale  ......................................................................................................................38  
3.E.1  Rationale for Study  ........................................................................................38  
3.E.2  Rationale for Pexa- Vec Dose  and Schedule and Sequential Sor afenib 
Therapy  ..........................................................................................................39  
3.E.2.a  Pexa- Vec Dose, Route and Interval Rationale  ...............................39  
3.E.2.b  Rationale for Sequential Therapy with Sorafenib  ..........................40  
4 OBJECTIVES  ..........................................................................................................................41  
4.A Primary Objective  ........................................................................................................41  
CONFIDENTIAL an d PROPRIETARY  Page 5 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  26 June 2019 4.B Secondary Objectives ...................................................................................................41  
4.C Exploratory Objectives  ................................................................................................41  
5 STUDY DESIGN .....................................................................................................................43  
5.A Study Overview  ...........................................................................................................43  
5.B Study Endpoints  ...........................................................................................................44  
5.B.1  Primary Endpoint  ...........................................................................................44  
5.B.2  Secondary Endpoi nts .....................................................................................44  
5.B.3  Exploratory Endpoints  ...................................................................................45  
5.C Dose and Regimen  .......................................................................................................45  
5.C.1  Dose Modifications, Delays, and Cancellations  ............................................46  
5.C.1.a  Dose Modifications  ........................................................................46  
5.C.1.b  Dose Delays  ...................................................................................46  
5.C.1.c  Dose Cancellations .........................................................................46  
5.C.1.d  Treatment Withdrawal  ...................................................................47  
5.D Overall Study Duration  ................................................................................................47  
5.D.1  Active Study Participation Phase  ...................................................................47  
5.D.2  Survival Follow Up Phase ..............................................................................48  
6 SELECTION OF PATIENTS  ..................................................................................................49  
6.A Inclusion Criteria  .........................................................................................................49  
6.B Exclusion Criteria  ........................................................................................................50  
6.C Screening, Eligibility, Arm As signment, Study Completion, and Study 
Discontinuation ............................................................................................................53  
6.C.1  Screening  ........................................................................................................53  
6.C.1.a  Screen Fai lures  ...............................................................................53  
6.C.2  Eligibility  .......................................................................................................53  
6.C.2.a  Laboratory Eligibility .....................................................................54  
6.C.3  Patient Allocation to Treatment Arms  ...........................................................54  
6.C.4  Premature Study Discontinuation ..................................................................55  
6.C.4.a  Data Collection for Premature Discontinued  Patients  ...................55  
7 STUDY PROCEDURES AND TREATMENT  ......................................................................57  
7.A Screening ......................................................................................................................57  
7.B Initial Treatment Phase (Baseline and Day 1 Until Week 6)  .......................................58  
7.B.1  Randomization (Upon Investigator Confirmation of Eligibility)  ..................58  
7.B.2  Arm A and Arm B:  Baseline Visit  ................................................................59  
CONFIDENTIAL an d PROPRIETARY  Page 6 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  26 June 2019 7.B.3  Arm A and Ar m B:  Visit 1 (“Day 1”)  ...........................................................60  
7.B.3.a  Arm A:  Pexa -Vec Treatment #1 (Day 1)  ......................................60  
7.B.3.b  Arm B:  Sorafenib Treatment Start (Day 1) ...................................61  
7.B.4  Arm A:  Visit 2 (Pre -Day 15 or Pre -Week 2); Arm B: Visit 2 (Day  15 
or Week  2) ......................................................................................................62  
7.B.4.a  Arm A:  Visit 2/ P re-Day 15 or Pre -Week 2  ..................................62  
7.B.4.b  Arm B:  Visit 2/ Day 15 (Week 2)  .................................................63  
7.B.5  Arm A:  Visit 3 / Pexa -Vec Treatment #2 (Day 15/Week 2)  .........................63  
7.B.6  Arm A:  Visit 4 (Pre -Day 29/Pre -Week 4); Arm B:  Visit 3 
(Day  29/Week 4)  ............................................................................................64  
7.B.6.a  Arm A:  Vi sit 4/ Pre -Day 29 (Pre -Week 4)  ...................................64  
7.B.6.b  Arm B:  Visit 3 / Day 29 (Week 4)  ................................................65  
7.B.7  Arm A:  Visit 5 / Pexa -Vec Treatment #3 (Day 29 / Week 4)  .......................65  
7.B.8  Arm A:  Visit 6 (Day 43/Week 6)/ Arm B: Visit 4 (“Day 43/Week 6”)  .......66  
7.B.8.a  Arm A:  Visit 6/Day 43 (Week 6)  ..................................................66  
7.B.8.b  Arm B:  Visit 4/Day 43 (Week 6)  ..................................................67  
7.C Follow -up Pha se...........................................................................................................68  
7.C.1  Long -Term Follow -Up Visits and Monitoring (Arm A and Arm B)  .............68  
7.C.1.a  Every 3 Weeks ±4 Days:  Clinical Status Visits  ............................68  
7.C.1.b  Every 6 Weeks ±7 Days:  Symptomatic, QoL, and 
Radiographic Status Visits  .............................................................68  
7.D End of Treatment Visit (ARM A and Arm B)  .............................................................69  
7.E Safety Follow -Up .........................................................................................................70  
7.F Follow -Up Visits for Progression Free SURVIVAL  ...................................................70  
7.G Survival Follow -up Phase  ............................................................................................71  
8 PATIENT MANAGEMENT  ...................................................................................................72  
8.A Treatments ....................................................................................................................72  
8.A.1  Expected Toxicities of Pexa- Vec Treatment  .................................................72  
8.A.2  Notable Safety Findings  .................................................................................74  
8.A.3  Risks L inked to IT Injection Procedure  .........................................................76  
8.A.4  Concomitant Authorized and Contraindicated Treatments  ............................76  
8.A.4.a  Definitions and Reporting of Concomitant Medicat ion and 
Non-Drug Therapy  .........................................................................76  
8.A.4.b  Concomitant Authorized & Contraindicated Treatments  ..............77  
8.A.5  Potential Mechanisms of Pexa- Vec Sh edding to the Environment, 
Biodissemination and Prevention of Transmission  ........................................80  
CONFIDENTIAL an d PROPRIETARY  Page 7 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  26 June 2019 8.A.5.a  Superficial Skin Pustules  ...............................................................80  
8.A.5.b  Urine, Fe ces, Blood, Throat and/or Saliva  .....................................81  
8.A.6  Expected Toxicities of Sorafenib Treatment  .................................................81  
8.B Safety, Clinical, Demography, and Diagnos is Assessments........................................81  
8.C Efficacy Assessments ...................................................................................................82  
8.C.1  Biomarker/Immune Assessments  ...................................................................82  
8.C.2  Imaging Data Acquisition and Evaluations  ...................................................82  
8.C.2.a  Imaging Data Acquisition  ..............................................................82  
8.C.2.b  Imaging Data Eva luation s ..............................................................84  
8.D Symptomatic and Quality of Life Assessments  ...........................................................89  
8.E Pharmacoeconomic Assessments .................................................................................89  
9 MANAGEMENT OF NON- PATIENT EXPOSURE TO PE XA-VEC  ..................................91  
9.A Expo sure to Pexa- Vec ..................................................................................................91  
9.B Contacts Exhibiting Symptom s of Viral Infection .......................................................91  
10 INVESTIGATIONAL PRODUCTS (IP)  ................................................................................92  
10.A  Pexa- Vec (JX -594).......................................................................................................92  
10.A.1  Nomenclature of Pexa- Vec ............................................................................92  
10.A.2  Pharmaceutical Form of Pexa- Vec ................................................................92  
10.A.3  Packaging and Labeling of Pexa- Vec ............................................................92  
10.A.4  Biosafety /Containment Level Classification of Pexa -Vec ............................93  
10.A.5  Transport of Pexa -Vec ...................................................................................93  
10.A.5.a  Interstate and International Transport  ............................................93  
10.A.5.b  Drug Receipt and Approval of Shipment .......................................93  
10.A.5.c  Transport within the Institution  .....................................................93  
10.A.6  Storage of Pexa- Vec ......................................................................................94  
10.A.7  Dispensing of Pexa -Vec .................................................................................94  
10.A.8  Handling of Pexa- Vec ....................................................................................94  
10.A.8.a  Preparation of Pexa- Vec ................................................................94  
10.A.8.b  Administration of Pexa- Vec ..........................................................95  
10.A.8.c  Cleaning / Disinfection and Disposal  ............................................95  
10.A.8.d  Spi[INVESTIGATOR_315015] .........................................95  
10.A.8.e  Unused Drug Return or Destruction  ..............................................96  
10.A.9  Drug Ac countability  .......................................................................................96  
10.B  Sorafen ib ......................................................................................................................96  
10.B.1  Nomenclature  .................................................................................................96  
CONFIDENTIAL an d PROPRIETARY  Page 8 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  [ADDRESS_387695]-Study SAE  ...........................................................................................107  
11.F.2  Pregnanc y .....................................................................................................107  
11.F.3  Overdose  ......................................................................................................108  
11.F.4  Death  ............................................................................................................108  
CONFIDENTIAL an d PROPRIETARY  Page 9 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  26 June 2019 12 STATISTICAL CONSIDER ATIO NS...................................................................................109  
12.A  Overview  ....................................................................................................................109  
12.B  Sample Size Determination ........................................................................................109  
12.C  Analy sis Populations  ..................................................................................................110  
12.D  Methods of Analysis  ..................................................................................................111  
12.D.1  General Considerations  ................................................................................111  
12.D.2  Disposition of Patien ts .................................................................................111  
12.D.3  Demographic and Baseline Characteristics  .................................................112  
12.D.4  Treatments (Study Treatme nt, Concomitant Therapi[INVESTIGATOR_014])  ..............................112  
12.D.4.a  Study T reatments (Pexa- Vec and Sorafenib)  ...............................113  
12.D.4.b  Concomitant Medications  ............................................................113  
12.D.5  Efficacy  ........................................................................................................113  
12.D.5.a  Prima ry Efficacy Analysis:  Overall Survival  .............................113  
12.D.5.b  Secondary Efficacy Analyses  ......................................................114  
12.D.5.c  Exploratory Efficacy Analysis  .....................................................118  
12.D.6  Safety  ...........................................................................................................120  
12.D.7  Quality of Life (QoL)  ...................................................................................121  
12.D.8  Pharmacoeconomic Methods  .......................................................................122  
13 ETHICAL REQUIREMENTS ...............................................................................................125  
13.A  Patient Privacy  ...........................................................................................................125  
13.B  IRB/IEC/REB  ............................................................................................................126  
13.C  Institutional Biosafety  Committee (IBC)  ...................................................................126  
13.D  Informe d Consent .......................................................................................................126  
13.E  Review Committee .....................................................................................................127  
13.E.1  Data Monitoring Committee (DMC)  ...........................................................127  
13.E.2  Steering Committee  .....................................................................................127  
14 STUDY ADMINISTRATION ...............................................................................................128  
14.A  Documents  .................................................................................................................128  
14.A.1  Investigator’s Brochure  ................................................................................128  
14.A.2  Protocol Amendments  ..................................................................................128  
14.A.3  Case Report Forms  .......................................................................................128  
14.B  Quality Control and Quality Assurance  .....................................................................128  
14.B.1  Study Monitoring .........................................................................................128  
14.B.2  Audit and Inspection  ....................................................................................129  
CONFIDENTIAL an d PROPRIETARY  Page 10 of 142 
Protocol JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  [ADDRESS_387696] Retention  .......................................................................................................129  
14.D  Study Termination  .....................................................................................................129  
14.E  Publication and Presentation Policy ...........................................................................130  
14.F  Archiving ...................................................................................................................131  
14.F.1  Investigator Site File  ....................................................................................131  
14.F.2  Trial Master File  ..........................................................................................131  
15 REFERENCES  ......................................................................................................................132  
APPENDIX A: SCHEDULE  OF ACTIVITIES  ..........................................................................140  
CONFIDENTIAL and PROPRIETARY  Page 11 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387697] Adverse Drug Reaction  
AE(s)  Adverse Event(s)  
AFP Alfa-Fetoprotein  
ALT  Alanine Aminotransferase  
ANC  Absolute Neutrophil Count  
AST  Aspartate Transaminase  
BCLC Barcelona Clinic Liver Cancer  
BID Twice daily (bis in die)  
BSC Best Supportive Care  
BUN  Blood Urea Nitrogen  
CBC Complete Blood Count  
CDC  Centers for Disease Control and Prevention ([LOCATION_002])  
CFR Code of Federal Regulations ([LOCATION_002])  
CI(s)  Confident Interval(s)  
CLIP  Cancer of the Liver Italian Program  
CR Complete Response  
CRO  Contract Research Organization  
CSRI Client Service Receipt Inventory  
CT Computerized Tomography 
CTCAE  Common Terminology Criteria for Adverse Events  
DCE MRI  Dynamic Contrast -Enhanced Magnetic Resonance Imaging  
DCR  Disease Control Rate  
DLT(s) Dose L imiting Toxicity(ies)  
DMC  Data Mon itoring Committee  
DoR  Duration of Response  
EASL European Association for the Study of the Liver  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group 
eCRF  Electronic Case Report Form  
CONFIDENTIAL and PROPRIETARY  Page 12 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Abbreviation  Definition  
EGF(EGFR)  Epi[INVESTIGATOR_315016] (Receptor)  
EORTC  Europe an Organization for Research and Treatment of Cancer  
FACT -Hep Functional Assessment of Cancer Therapy – Hepatobiliary  
FDA Food and Drug Administration ([LOCATION_002])  
FDG -PET Fluorodeoxyglucose Positron Emission Tomogr aphy  
FHSI -8 Cancer Therapy –Hepato biliary Symptom Index [ADDRESS_387698] Ratio  
HRQoL  Health -Related Quality of Life  
IB Investigators’ Brochure  
IBC Institutional Biosafet y Committee  
ICF Informed Consent F orm 
ICH International Conference on Harmonization  
IEC Institutional Ethics Committee  
INN International Nonproprietary Name  
[CONTACT_315198] -To-Treat 
IV Intravenous  
IVRS  Interactive Voice Response System  
IWRS  Interactive Web Response System  
LD Longest Diameter  
LDH Lactate Dehydrogenase  
LMWH  Low Molecular Weight Heparin  
CONFIDENTIAL and PROPRIETARY  Page 13 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387699]  
MRI  Magnetic Resonance Imaging  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute ([LOCATION_002])  
NIH National Institutes of Health ([LOCATION_002])  
ORR  Overall  Response Rate 
PBS Phosphate Buffe red Saline  
PD Progressive Disease  
PEG -IFN Pegylated I nterferon  
PEIT  Percutaneous Ethanol Injection Therapy  
PET Positron Emission Tomography  
PET-CT Positron Emission Tomography- Computerized Tomography  
Pexa -Vec Pexast imogene Devacirepvec, JX-594 
PFS Progression Free Survival  
pfu Plaque Forming Units  
PP Per Protocol  
PR Partial Response  
PROs  Patient Reported Outcomes  
PT/INR  Prothrombin Time/International Normalized Ratio  
PTT Partial Thromboplastin Time  
QoL Qualit y of Life  
REB Research Ethics Boar d 
RECIST  Response Evaluation Criteria in Solid Tumors  
RFA  Radiofrequency Ablation  
SAE(s)  Serious Adverse Event(s)  
SAP Statistical Analysis Plan  
SCID  Severe Combined Immunodeficiency  
SD Stable Disease  
SLD  Sum of Long est Diameters  
SmPC  Summary of Pro duct Characteristics  
CONFIDENTIAL and PROPRIETARY  Page 14 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387700] Upper Limit of Normal  
US [LOCATION_002]  
VEGFR 1, 2, 3  Vascular Endothelial Growth Factor Receptor 1, 2, 3  
VIG Vaccinia Immune Globulin  
WBC White Blood Cel l 
WNL  Within Normal Limits  
 
CONFIDENTIAL and PROPRIETARY  Page 15 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 2 PROTO COL SYNOPSIS  
 
Title  A Phase 3 Randomized, Open -Label Study Comparing Pexa -Vec (Vaccinia GM-CSF / 
Thymidine Kinase -Deactivated Virus) Followed by [CONTACT_315083] a (HCC) Without Prior Systemic Ther apy 
Investigational 
Product  The f ollowing products are considered as Investigational Product  (IP): 
• Pexa -Vec 
• Sorafenib (standard of care [SOC ]) 
Pexa -Vec 
Pexa -Vec (pexastimogene d evacirepvec; investigational product code:  JX-594) is a 
replication -competent , transgene -expressing therapeutic vaccinia virus derived from the 
Wyeth vaccine strain (Dryvax®, Wyeth Laboratories).  Three genetic modifications are 
included:  
1. thymidine kinase (TK) gene deactivation,  
2. granulocyt e macrophage colony stimulating fac tor (GM-CSF) gene insertion under control 
of the synthetic early -late promoter, and  
3. lac-Z gene insertion under control of the p7.[ADDRESS_387701] ic agents, protein kinase 
inhibitor s, ATC code:  L01XE05.  
Sorafenib is a multi -kinase inhibitor which has demonstrated both anti -proliferative and anti -
angiogenic properties in vitro  and in vivo. 
Sorafenib is approved for the treatment of advanced HCC and i s the SOC  of this disease . 
Phase  3 
Objectives  Primary Objective 
• To determine and compare the overall survival of patients with advanced HCC without 
prior systemic therapy, treated with Pexa -Vec followed by s orafenib (Arm A) versus 
sorafenib (Arm B)  
Seco ndary Objectives:  
• To determine and compare the 2 treatment arms response based on  central assessments 
using modified Response Evaluation Criteria i n Solid Tumors (mRECIST) for HCC  for 
the following endpoints:  
 Time -to-progression (TTP)  
 Progression free survival (PFS)  
 Overall response rate (ORR)  
 Disease control rate (DCR ) 
• To determine and compare the safety profiles of the 2 treatment arms  
• To determine and compare the t ime-to-symptomatic progression (TSP) of the  
2 treatment arms  
CONFIDENTIAL and PROPRIETARY  Page 16 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • To determine and compare the Quality of Life (QoL) of the 2 trea tment arms  
Exploratory Objectives:  
• To determine and compare the [ADDRESS_387702] 1.1 for the following endpoints:  
 TTP 
 PFS 
 ORR  
 DCR  
• To evaluate and compare t he effect of treatment with Pexa -Vec followed by [CONTACT_44369] 
(Arm A) versus sorafenib (Arm B) on the following endpoints , (based on local and 
central assessments  for radiology endpoints) : 
• Time to Initial Response (TIR) and Duration of overall Response (DoR)  
• Tumor size over time by [CONTACT_95761] t o the sum of the longest diameters of the target 
lesions at screening  
• Efficacy ( overall survival , PFS, TTP ) in patient subgroups to be defined in the S tatistical 
Analysis Plan (SAP)  
• Overall survival , PFS, TTP  in patients subdivided according to the presenc e or not of an 
objecti ve response (complete response [ CR], partial response [ PR] and/or at least 
3 months of stable disease ) (if the number of patients  is sufficient)  
• To determine and compare changes in clinical laborator y parameters in the [ADDRESS_387703] safety laboratory parameters , alpha -fetoprotein ( AFP), and 
CD4 /CD8 counts  
• To determine and compare the 2 treatment arms for overall survival  by [CONTACT_315084] 
• To describe the effects of Pexa -Vec on the immune response  and identify biomarkers of 
response  
• To evaluate the comparative cost -effectiveness of Pexa -Vec followed by [CONTACT_315085] -level resource and service -use informa tion 
Study Design  This is a Phase  3 multi -center, randomized, open -label study of Pexa -Vec followed by 
[CONTACT_44369] (Arm A) versus s orafenib (Arm B) in patients with advanced HCC without prior 
systemic therapy.  
A total of 600 patients will be randomized betw een one of  2 treatm ent arms in a 1 :1 ratio  
 (300 in each arm)  to reach at least 570 evaluable patients .  
Patients will be allocated to each arm via a dynamic stochastic minimi zation procedure  
performed independently for Asian and non- Asian patients.   The fo llowing criteria  will be 
used: 
1. Center  
2. Main etiology : hepatitis C, hepatitis B, alcohol or other reasons (such as 
hemochromatosis, Wilson’s disease, type 2 diabetes, NASH)  
3. Presence of extrahepatic disease or not  
4. Vascular invasion or not  
5. Perfo rmance status 0 or 1 
6. AFP levels (<200, 200– 400 or > 400 ng/mL)  
CONFIDENTIAL and PROPRIETARY  Page 17 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 In experimental Arm A, Pexa -Vec will be administered as 3 bi -weekly intratumoral (IT) 
injections ( Day 1, Week 2, W eek 4).  A radiological assessment will be performed at  
Screening,  Week [ADDRESS_387704] IT injection  but no earlier than Week 6. 
In Arm B, s orafenib will be started daily on D ay 1.  Radiological assessment s will be 
performed at Screening, on Week 6 and every 6 weeks .  
In both arms,  if a patient discontinues  the treatment phase prior to documented radiographic 
progression  (e.g., permanently stops taking the study medication) , the patient will perform 
PFS follow -up visits every [ADDRESS_387705] occurrence of documented progression.   
When study treatments are permanently stopped ( Pexa -Vec or sorafenib), patients will 
perform an End of Treatment  Visit and a Safety Follow -Up Visit at least 28  days (and no 
more than 2 months ) after last study treatment  administration .  
For patients in both arms, a site reader will perform local tumor assessments based on 
RECIST 1.[ADDRESS_387706]  1.1.  
Two interim analys es are planned; one futility analysis at 40% of  the death eve nts and one 
efficacy analysis at 80 % of the events.  
A Data Monitoring Committee (DMC) will be in charge of reviewing safety and efficacy data 
regularly during the course of the study and  at the time of the interim and final analyses.   The 
activities of the  DMC are defined in the DMC Charter  document.   The DMC’s main objective 
will be to ensure that the safety of the patients , to evaluate the benefit versus risk  and the 
integrity of the data are respected at all times throughout the stud y and to give 
recomme ndations on its further conduct.  
No. of Patients  A total of 600 patients will be enrolled  to obtain 570 evaluable patients : 
• Arm A:  300 patients  
• Arm B:  300 patients  
Study Population Inclusion Criteria:  
1. Male or female patients, age ≥ 18 years old 
2. Histological/cytological diagnosis of  primary HCC  
3.  Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per 
American Association for the Study of Liver Disease [AASLD] guidelines)  eligible f or 
systemic therapy excluding cholangiocarcinoma,  hepatocholangiocarcinoma, 
fibrola mellar carcinoma and hepatoblastoma  
4. Tumor status (as determined by [CONTACT_315086]):   At least one m easurable viable 
tumor in the liver , ≥[ADDRESS_387707] diameter ( LD), using a dynamic imaging technique 
(arterial ph ase of triphasic computerized tomography [ CT] scan, or dynamic contrast -
enhanced magnetic resonance imaging [MRI ]), and injectable under imaging -guidance 
(CT and/or ultrasound)   
5. At least one tumor that ha s not received prior local -regional treatment, or  that has 
exhibited >25% increase in viable tumor size since prior local -regional treatment  
CONFIDENTIAL and PROPRIETARY  Page 18 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 6. Child -Pugh Class A .  NOTE :  paracentesis , albumin infusion  or diuretic treatment 
canno t be used to down score  Child -Pugh score (e.g. , to improve from severe to 
moderate/mild or from moderate to mild  ascites ) 
7. Performance status  0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale  
8. Adequate hematological, hepatic, and renal funct ion: 
a. Hemoglobin ≥ 9 g/dL  
b. Platelet count ≥ 75 x 109/L 
c. International normalized ratio (INR) ≤1.7  
d. White blood cell (WBC) count ≥2 x 109/L  
e. Absolute neutrophil count (ANC) ≥1 x 109/L 
f. Albumin ≥ 2.8 g/dL, total bilirubin ≤3 .0 mg/dL (51.3 µmol/L);  alanine 
aminotransferase (ALT), aspartate transaminase (AST) ≤5 times upper  limit of 
normal  (ULN)  
g. Serum chemistries s odium, potassium, and c alcium within normal limits (WNL) or 
Grade  1  
h. Serum creatinine <2.0  mg/dL or creatinine clearan ce >60  mL/min according to 
Cockroft -Gault formula  
9. For patients who are sexually  active:  willing to use adequate barrier contraception 
method for at least [ADDRESS_387708] 3  months  
11. Written informed consent  
Exclusion Criteria:  
1. Major surgery within 4  weeks  of study treatment s (minor surgical procedures are 
allowed e .g., intravascular access line or Port -a-Cath® ) 
2. Local -regional the rapy of HCC  within 4 weeks  prior to randomization  
3. Histological diagnosis  of cholangiocarcinoma, hepatocholangiocarcinoma, 
fibrolamellar carcinoma and hepatoblastoma  
4. History of moderate or severe ascites, bleeding esophageal varices, hepatic 
encephal opathy  or pleural effusions related to liver insufficiency  within 6  months o f 
screening  
5.  Bulky disease patients  - tumors encompassing > 50% of the liver  volume and / or inferior 
vena cava invasion  
6.  Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or 
immune -suppressive medication including high -dose corticosteroids (defined as 
≥20 mg/day prednisone or equivalent which is ongoing at the time of randomi zation  
and/or was taken for more than 4 weeks  within the preceding 2  months of study 
treatment)  
7. Ongoing severe inflammatory skin condition (as d etermined by [CONTACT_737]) 
requiring medical treatment  
8. History of severe eczema (as determined by [CONTACT_737]) requiring medical 
treatment  
CONFIDENTIAL and PROPRIETARY  Page 19 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 9. Tumor(s) invading a major  vascular structure (e.g., carotid artery) or other key 
anatomical structure  (e.g., pulmonary airway) in the event of post -injection tumor 
swelling and/or necrosis  (hepatic and portal vein involvement allowed)  
10. Clinically significant and/or rapi[INVESTIGATOR_315017], pericardial and/or pleural 
effusions.   Mild ascites that d oes not preclude safe IT injection of Pexa -Vec is allowed 
at the discretion of the treating physician.  
11. Symptomatic cardiovascular disease, including but not limited to significant coronary 
artery disease (e.g., requiring angioplasty or s tenting) or co ngestive heart failure within 
the preceding [ADDRESS_387709] history of cardiovascular  disease ( e.g., past history of myocardial 
infarction, ischemic cardiomyopathy ) unless cardiology consultation and clearance has 
been obtained for study part icipation  
13.  Medical conditions , per the investigator’s judgment, that predispose the patient to 
untoward medical risk in the event of volume loading (e .g., intravenous [ IV] fluid bolus 
infusion), tachycardia, or hypotension during or follo wing treatment  with Pexa -Vec 
14. Viable central nervous system malignancy (history of completely resected or irradiated 
brain metastases allowed)  
15. Prior systemic therapy for HCC (NOTE:   Patie nts receiving 7  days or less exposure to 
systemic therapy are allowed)  
16. Known contraindications to sorafenib according to the drug prescribing  information 
and/or severe hypersensitivity to s orafenib or any other component of s orafenib, or 
known intolera nce to s orafenib  
17. Other medical condition or laboratory abnormality or ac tive infection that in the 
judgment of the Principal Investigator [INVESTIGATOR_315018] d/or otherwise make 
the patient inappropriate fo r entry into this study  
18. Hepatitis C virus  therapy including interferon/pegylated interferon or ribavirin that 
cannot be discontinued within 14 days prior to any Pexa -Vec injection.  Medical 
Monitor should  be consulted if the patient is taking any other  antiviral medications to 
determine eligibility.  
19. Prior malignancies are not allowed  except for the following:  adequately treated basal 
or squamous cell skin cancer, in situ  cervical cancer, adequately tr eated cancer from 
which the patient has been disease -free for  at least [ADDRESS_387710] 12 months  that places the patient at risk for 
intrahep atic IT injection procedure  based on Investigator assessment  
21. Anticoagula nt or anti -platelet medication that cannot be interrupted prior to Pexa -Vec 
IT injections , including:  
• Aspi[INVESTIGATOR_315019] 7 days prior to  Pexa -Vec IT injections   
• Coumadin that cannot be discontinued for 7  days prior to Pexa -Vec IT injec tions   
• Low molecular weight heparin (LMWH) that cannot be discontinued >24  hours 
prior to Pexa -Vec IT injections  
• Unfractionated heparin  (UFH) that cannot be discontinued >4  hours p rior to  
Pexa -Vec IT injection  
• Oral direct thrombin inhibitor (dabigatran) o r direct Factor Xa inhibitor 
(rivaroxaban, api[INVESTIGATOR_106757], and endoxaban) that cannot be discontinued  for 4  days prior 
to Pexa -Vec IT injection  
CONFIDENTIAL and PROPRIETARY  Page 20 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 NOTE : LMWH or UFH may be used to transitio n patients on and off of the above anti -
coagulants (if deemed appropriate by  [CONTACT_1963]) prior to Pexa -Vec 
treatments as long as the last dose of LMWH is administered >[ADDRESS_387711] do se of UFH is administered >[ADDRESS_387712] the Sponsor for questions regarding the m anagement of other anticoagulant 
prior to treatments.  
22. Inability to suspend treatment with anti -hypertensive medication (including but not 
limited to:  diuretics, beta -blockers,  angiotensin converting enzyme [ACE] inhibitors, 
aldosterone antagonists, et c.) for 48 hours prior to and 48 hours after each Pexa -Vec 
injection . 
23. Any p rior or planned organ transplant (e.g. , liver transplant)  
24. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a 
female after conception and unt il the termination of gestation. Child -bearing potential 
patients  with a positive hCG laboratory test (>10  mIU/mL) at screening and/or  a urinary 
pregnancy test at B aseline will perform an  ultrasound to confirm the pregnancy.  
25. Patients who e xperienced a severe systemic reaction or side- effect as a result of a 
previous  vaccination  with vaccinia  
26. Participation in a clinical study and treatment with an active IP within 4  weeks pri or to 
randomization  
27. Patient unable or unwilling to comply with the proto col requirements   
28. Previous treatment with Pexa -Vec or other vaccinia vector based treatment  
29. Pulse oximetry O 2 saturation <90% at rest on room air  
Drug Dosage  Pexa -Vec:  1 × 109 plaque -forming units (pfu)  (equivalent to 9.0 Log pfu)  per treatment   
Sorafenib:  400 mg twice daily (BID), according to the package insert (including dose 
reductions)  
Treatment Plan  Arm A  
Three IT injections ( Day 1, Week  2, Week  4) of Pexa -Vec suspended in buffered saline will 
be made into [ADDRESS_387713] 
or other trained physician using imaging- guidance (ultrasound and/or CT).  As much as 
possible viable, safely injectable tumors  ≥[ADDRESS_387714] be treated with a maximum of 
5 tumors treated on a given treatment day.  Different tumors may be treated on each treatment 
day.  The total prepared injection volume will be divided proportionally between 1 to  
5 tumors, relative to individua l tumor volumes (specific instructions are described in IT  
Injection M anual and W orksheet ). 
Patients will be observed in the clinic or hospi[INVESTIGATOR_34092] a minimum of 8  hours after each IT 
injection.  Longer hospi[INVESTIGATOR_315020].  
Patients will be eligible for each of the 3 Pexa -Vec injections if all of the following criteria 
are met prior to each treatment : 
• The patient continues to meet the following clinical and laboratory criteria:  
 Adequate liver fun ction ( total bilirubin ≤ 3 mg/ dL [51.3 µmol/L]; ALT and AST  
≤5 × ULN)  
 Platelets ≥ 75 × 109/L (correction with transfusion or thrombopoietin based therapy 
allowed to meet re -treatment eligibility criteria)  
CONFIDENTIAL and PROPRIETARY  Page 21 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  Hemoglobin ≥ 9 g/dL (correction with transfusion or erythrop oietin based the rapy 
allowed to meet re -treatment eligibility criteria)  
 INR ≤ 1.7 (correction with plasma protein support allowed to meet re -treatment 
eligibility criteria [ e.g., fresh -frozen plasma] ) 
 Patient is still expected to have at least one viable, i njectable intrah epatic tumor  
≥1 cm LD  
 No clinically significant and/or rapi[INVESTIGATOR_315021], pericardial and/or 
pleural effusions.  Minimal ascites that does not preclude safe IT injection of 
Pexa -Vec is allowed at the discretion of th e treating ph ysician  
Sorafeni b will be started daily at Week  6, or [ADDRESS_387715] IT injection  (whichever is 
later)  and no earlier than Week  6.  Sorafenib is allowed as long as the patient is clinically 
benefiting from the treatment and at least until progression or until unac ceptable toxicity 
occurs.  
Arm B  
Daily sorafenib will be initiated on Day  [ADDRESS_387716] until progression or until unacceptable toxicity 
occurs .  
Pre-Medicat ions 
and Support ive 
Care  The use of the following drugs will not be restricted during the course of the study:  
thrombopoietin, erythropoietin, G -CSF, antiemetics, antipyretics, antidepressants, steroids 
(NOTE :  oral or parenteral steroids are not allowed during the Pexa -Vec treatment period, 
and for 1 week  prior to and 2  weeks  after Pexa -Vec treatment), topi[INVESTIGATOR_315022] -foot skin reaction and rash related to s orafenib, biphosphonates, 
vitamin B12 , and vitamin D.  
Antihyperten sives (including diuretic s) must be discontinued at least 48 hours prior to each  
Pexa -Vec injection and restarted no earlier than 48  hours after the injection .  
All patients in experimental Arm A should be pre -medicated with acetaminophen 
(paracetamol) or equivalent antip yretics  (e.g., NSAIDs)  at the discretion of the treating 
physician , (unless contraindicated) on each Pexa -Vec treatment day.  For acetaminophen , the 
following regimen may be used:  
• 500– 1000 mg at 2 hours pre -infusion/injection,  
• 500– [ADDRESS_387717] -procedure,  
• 500– 1000 mg every 6  hours thereafter, as needed  (the total acetaminophen dose should 
be carefully assessed to avoid cumulative toxicity).  
Fevers may be associated with onset of rigors.  Meperidine or equivalent may be used for 
severe rigors.  
Patients should also be pre -hydrated with approximately [ADDRESS_387718] -treatment 
observation period, patients should receive IV solute -conta ining fluids or other appropriate 
treatment as needed for blood pressure support.  
Protocol 
Assessments  Safety  and Clinical Laboratory Assessments:  
Clinical assessments include  laboratory assessment s (hematology, biochemistry, coagulation , 
AFP, CD4/CD8 counts ), physical exam ination and vital signs.   Adverse events (AEs) and 
serious adverse events (SAEs) will be reported and graded according to National Cancer 
Institute’s Common Toxicity Criteria for Adverse Events (NCI CTCAE), version 4.03 .  From 
signature [CONTACT_315199] , only SAEs caused by a protocol -required 
CONFIDENTIAL and PROPRIETARY  Page 22 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 procedure will be collected.  After IP initiation , all SAEs/A Es will be collected up to [ADDRESS_387719] IP administration ( Pexa -Vec or sorafenib).  
Hematology  and biochemistry  will be assesse d every 2  weeks  until W eek 6, every 3  weeks 
during the Long Term Follow -Up phase,  at the End of Treatment Visit and at the Safety 
Follow -Up Visit .  Coagulation will be assessed every 2  weeks  until W eek 6 and at the End of 
Treatment Visit.  
AFP levels will b e assessed at S creening , at Week  6, every 6  weeks  during the Long Term 
Follow -Up phase and at the End of Treatment Visit.  CD4 /CD8 counts will be assessed at 
Screening , at Week  6 and at the End of Treatment Visit.  
All laboratory analyses w ill be performed  in central laborato ries except for  the clinical 
investigational sites participating in China where laboratory testing will be completed by [CONTACT_315087].  
Radiographic Assessments:  
Patients will undergo  imaging of the ch est, abdomen and  pelvis using helical/spi[INVESTIGATOR_315023]-
enhanced CT scanning (preferentially) or MRI with non- contrast CT of the chest  at Screening, 
at Week  6 and every 6  weeks  thereafter .  If study treatments are stopped before documented 
radiological progr ession, PFS visits (scan collected) will be performed for every [ADDRESS_387720] 1.1 as defined in the imaging charter document . 
• CT Scan:  Tri-phasic cont rast-enhanced imaging of the liver will include pre -contrast, 
arterial, and portal venous phases.   If additional delayed phase imaging is performed, 
these images should also be provided for independent evaluation.  
• MRI Scan:  on either a 1. 5T or 3T MRI sca nner using a body array coil.  Gadolinium 
should be administered as an IV bolus.  
Symptomatic Assessments:  
Symptomatic progression will be assessed through the disease- specific questionnaire  FACT 
Hepatobiliary Symptom Index 8 (FHSI -8), a sub set of the FACT -Hep questionnaire  
(Herdman  2011; Scalone  2012 ) and through the ECOG  performance status.  
Questionnaires will be completed  prior to any other visit procedures at Screening (for ECOG 
performance status  only), at Baseline , at Week  6, and then e very [ADDRESS_387721] be performed 
regardless of whether a Pexa -Vec or sorafenib treatment is given or cancelled (missed) for 
any reason.  
After symptom atic progression is determ ined, active  patients will continue to visit the 
hospi[INVESTIGATOR_307]/clinic for scheduled protocol visits but  symptomatic progression will no longer be 
assessed . 
 
Quality of Life:  
Generic and disease -specific measures are essential to provide a comprehensive pi[INVESTIGATOR_315024] -Related Quality of Life ( HRQoL ) in HCC.  Patients will complete the  FACT -Hep that  
is a [ADDRESS_387722] -General (FACT -G), which assesses generi c HRQoL con cerns 
using 5 s ubscales, and the 18 -item hepatobiliary subscale, which assesses specific symptoms 
of hepatobiliary cancer and side effects of treatmen t. 
CONFIDENTIAL and PROPRIETARY  Page 23 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Patient utility will be assessed with the EQ5D -3L questionnaire  (Herdman  2011 ; 
Scalone  2012) . 
All qu estionnaires will be completed by [CONTACT_315088], at Week  6, and then every 6  weeks .  Beyond 12 months of treatment, the 
questionnaires should be completed every 12  weeks.   Questionnaires will also be completed 
at the End of Trea tment Visit.  
Biomarker  Analysis:  
Serum  samples collected at Baseline , [ADDRESS_387723]-IT (Arm A only), at Week  6 and at End of 
Treatment Visit, will be archived.  These samples will allow further assessments of immune 
response  and identification  of response biomarkers.  
Pharmacoeconom ic Assessm ents: 
To determine a trial -based economic evaluation, patient -level resource and service- use will 
be collected to evaluate the comparative cost -effectiveness of Pexa -Vec followed by 
[CONTACT_315089] b alone.  Detai led costs related data will be collected during the 
Phase 3 trial using data entered in electronic Case Report Forms (eCRF) , hospi[INVESTIGATOR_315025], 
pharmacy worksheet and 2  other questionnaires: “health care resource utilization” and 
“patient ac commodation and  transport” derived fro m client service receipt inventory (CSRI) 
(Beecham  2001 ).  
The questionnaire “health care resource utilization” is designed to capture direct -medical 
costs related data non -documented neither in the CRF nor in hospi[INVESTIGATOR_315026].   The 
questionnaire will be completed by [CONTACT_315090], 
Week  6, and then every 6  weeks  until End of Treatment Visit.   Beyond 12 months  of 
treatment, the questionnaires should be completed every 12  weeks until end of  treatment visit.  
The “ patient accommodation and transport” covers all expenses related to indirect -medical 
costs .  The questionnaire  will be completed by [CONTACT_315091] , at Week  12, and at the En d of Treatment Visit.  
Utility values collected throughout the EQ5D- 3L, the QoL questionnaire  will also be used to 
produce  generic measure for economic appraisal.   
Endpoints:  For secondary endpoints, central  radiological assessments will be evaluated with mRECIST 
for H CC. 
For exploratory endpoints, local and c entral radiological assessments will be used and 
evaluated with RECIST 1.1.  
Primary Endpoint:  
• Overall Survival :  time from date of randomization to the date of death due to any cause.   
If a patient i s not known to have died at the cut -off date for analysis, survival will be 
censored at the date of last contact.  
Secondary Endpoints:  
• Time to Progression (TTP ):  time from randomization to the date of first documented 
radiographic tumor progression; TTP d oes not include  deaths.   If a patient has not had a 
TTP event at the cut -off date for analysis, TTP will be censored at the date of last 
evaluable tumor assess ment before the cut -off. 
• Progression Free Survival (PFS):  time from randomization to the date of  first 
document ed radiographic tumor progression or death due to any cause, whichever 
occurs first.  If a patient has not had a PFS event at the cut -off date for analysis, PFS 
will be censored at the date of last evalu able tumor assessment before the cut -off.  
CONFIDENTIAL and PROPRIETARY  Page 24 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Overall re sponse rate (ORR):  proportion of patients whose best overall response during 
their participation in the study is either CR or PR.   The best overall response is the best 
response recorded from the random ization until disease progression.  
• Disease control rate (DCR):   proportion of patients whose best overall response during 
their participation in the study is either CR, PR , or stable disease ( SD). 
• Safety:  assessed by [CONTACT_315092] (version 4.03).  Incidence of AEs and SAEs will 
be reported . 
• Time to Symptoma tic Progression (TSP): time from randomization until the first 
documented event of symptomatic progression defined as a decrease of 4  points or more 
from  baseline in the FHSI -8 questionnaire ( sub-part of the  FACT -Hep questionnaire)  or 
a decr ease in perform ance status to 4, or death.  
• Changes in the QoL assessed by  [CONTACT_315093] -Hep and EQ5D -3L 
questionnaires.  
Exploratory Endpoints:  
• TTP, PFS, ORR , and DCR as described above will also be assessed centrally . 
• Duration of overall Response (Do R):  applies on ly to patients whose best overall 
response is CR or PR.  The start date is the date of first documented response (CR or 
PR) and the end date is the date of first documented disease progression or the date of 
death due to underlying cancer.  
• Time to Initial Response (TIR):  the start date is the date of randomization and the end 
date is the date of first documented response (CR or PR).  
• Relative change o f tumor size over time.  Baseline tumor size is defined as the sum of 
the longest diameters f or all target lesions as identified during screening.  
• Changes in clinical laboratory  parameters  will be described includ ing standard safety 
assessments , AFP levels , CD4 and CD8 counts  (all assessed centrally ). 
• Additional immunology assays  may be performed on archived sam ples to further assess 
the immune mechanisms involved  and identify biomarkers of response .  
Pharmacoeconom y:  information obtained from questionnaires collecting patient -level 
resource and service -use (Health Care Resource Utilization, Patie nt accommodatio n and 
Transport and EQ5D -3L questionnaires ) will be analyzed .  Detailed costs collected 
using data in  eCRF, hospi[INVESTIGATOR_315027] y analyses.  
Statistical 
Considerati ons This is a m ulticenter, randomized,  open -label,  Phase 3 study, comparing Pexa -Vec followed 
by [CONTACT_315094] s orafenib.  The primary efficacy population is defined as the Intent to Treat  
(ITT) population, which consists of all randomized patients.  All pr imary efficacy analyses 
will be performed based on data from this population.  Following the ITT pr inciple, patients 
will be analyzed according to the treatment arm they were assigned to at randomization.  The 
Safety Population  will consist of all patients who received at least one dose of the study 
treatment ( Pexa -Vec or sorafenib ).  For safety analyses, patients will be analyzed according 
to treatment actually received.  
The analyses of the primary and secondary efficacy endpoints will be performed on the I TT 
population and on a subset of the more significant endpoints repeated on the Per Protocol (PP) 
population which consists of patients without any major protocol deviations.  
It is assumed that Pexa -Vec does not reduce the hazard of death during the first 6  months of 
treatment ( hazard ratio [HR] = 1.[ADDRESS_387724] 6  months), while it reduces the hazard by 
40% thereafter (HR  = 0.6 after 6  months ).  The median overall survival  in the control arm is 
expected to be approximately 11 months.  
Based on the aforem entioned assum ptions, and assuming a 1:[ADDRESS_387725] 
CONFIDENTIAL and PROPRIETARY  Page 25 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 with a power of 86% (assuming that HR  = [ADDRESS_387726] 6 months and 0.6 thereafter) using a 
stratified log -rank test at a 1 -sided cumulative 2.5% level of significance.  This corresponds 
to a HR smaller than or equal to 0.8 3 at the final analysis to declare a significant treatment 
benefit.   At the final analysis, the p -value of the re -randomization tes t (based on t he stratified 
log-rank test) will be computed and compared to the threshold defin ed as 0.021 (if the analysis 
is performed at 474  events exactly) due to the alpha adjustment induced by [CONTACT_315095] (as presented below).  If the p -value  is lower than this boundary, the 
treatment will be considered as effective.  
A first interim analysis for futility will be performed when 190 deaths (40% of the required 
events for final analysis) are documented in the ITT population  with a s toppi[INVESTIGATOR_315028]  = 1.1.  The p -value of the re -randomization test (based on the stratified log -
rank test) will be computed and compared to the threshold corresponding to HR  = 1.1.  If 
exactly [ADDRESS_387727] 
been crossed.  
A second interim analysis for efficacy will be performed when  379 deaths ( 80% of the 
required events for fina l analysis) are documented in the ITT population.  An α-spending 
function due to Lan -DeMets with O’Brien -Fleming type stoppi[INVESTIGATOR_3106] (as implemented 
in EAST® 6.3) will be used for the interim efficacy analysis.   If the interim analysis is 
performed after  exactly 379 events, the O’Brien -Fleming boundary for efficacy consists in 
using a significance level equal to 0.012, (corresponding to a HR equal to 0.79) .  If the p -
value of the re -randomization test (based on t he stratified log -rank test) is lower than this 
threshol d, the efficacy boundary will have been crossed . 
The nominal p -value s and critical values  used to declare statistical significance at the time of 
interim analysis may be slightly different as  based on  the actual number of deaths that have 
been  documented a t the time of analysis.  
Assuming a non- uniform enrolment and about 5% loss to follow -up or withdrawal of consent 
rate, a total of [ADDRESS_387728] pa tient.  
The primary analysis ( overall survival ) will be done using a stratified re -randomization test.  
For secondary endpoints, a hierarchical testing strat egy will be adopted, TTP will be 
compared between the 2  treatment arms if the primary endpoint overal l survival  is statistically 
significant.   If TTP is statistically significant (i.e., p < 0.025) then PFS will be compared 
between the treatment groups and f inally ORR will be analyzed.  This approach ensures that 
the overall Type I error rate of the study i s maintaine d at 2.5% (one -sided).  
CONFIDENTIAL and PROPRIETARY  Page 26 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 3 BACKGROUND  
3.A HEPATOCELLULAR CARCI NOMA (HCC)  
Hepatocellular carcinoma (HCC) is estimated to be the third most common cause of cancer -related 
deaths world- wide  (Ferlay 2010; Hoos  2012) , the 5th most common cancer diagnosis in  men 
worldw ide and the 7th most common cancer in women (El-Serag 2012) .  Approximately  
750,000 people develop HCC world- wide each year  with ~80% of cases reported in developi[INVESTIGATOR_315029] a high prevalence of hepat itis (El-Serag 2012 ).  However, HCC is one of the 
only cancers whose incidence is increasing in developed countries  (Siegel  2014; El -Serag 2001; 
Goodgame  2003; Deuffic  1998) .  Approximately 25,000 new cases of HCC are diagnosed annually 
in the Uni ted States  (US) (Siegel  2014) .  The incidence of HCC is 1,550 new cases in Canada  
(Canadian Cancer Society  2008) and approximately 50,000 in Europe  (Ferlay 2013) .  Most HCC 
cases (approximately 90%) develop in the c ontext of liver disease, in particular hepatocellular 
cirrhosis  (Simonetti  1991; Bosch 1999) .  The most common causes of cirrhosis include chronic 
hepatitis B or C, and chemical substances such as excessive alcohol or aflatoxins  (Chen  2003) .  
Nonalcoholic steatohepatitis, a liver disease triggered by [CONTACT_315096], may 
also be a risk factor f or the development of HCC  (Hashimoto 2009; Mori  2004) .  The risk of death 
from HCC is increased both in males and females with increasing body ma ss index c lass, linking 
obesity to development of HCC ( Calle  2003) .  Furthermore, diabetes has been shown to lead to 
increased risk of development of HCC in the pre sence of hepatitis B, hepatitis C, or alcoholic 
cirrhosis  (El-Serag  2001 ).  Hemochromatosis, a disease which results from inappropriate iron 
absorption, leading to excessive iron deposition in liver (leading to liver cirrhosis) and other 
organs, is another risk factor for the development of HCC ( Niederau  1985) .  Patients with HCC 
generally present with advanced disease with a poor prognosis of 6 to 9 months me dian survival  
(Yoo 2003) .  Therefore, development of effective methods for the prevention and early diagnosis 
of HCC methods are critical.   In addition, there e xists a continued need for new therapi[INVESTIGATOR_315030]. 
 
3.A.1 Current Treatment for HCC  
Surgical resection and liver transplant are the only curative treatments for HCC.   Small HCC 
tumor(s) (less than 3  cm in diameter) can be resected by [CONTACT_315097], the most effective treatment.  
Surgery is associated with a reported 50 –60% five -year survival rate, but unfortunately is feasible 
in only 10–15% of cases; most patients presen t with disease that is either too adva nced or di sease 
is accompanied by [CONTACT_315098]  (Gondolesi  2004) .  Resection in 
cirrhotic patients carries high morbidity and mortality.  
CONFIDENTIAL and PROPRIETARY  Page 27 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 For patients with unresectable HCC and who cannot re ceive liver transplantation, a large array of 
local-regional therapi[INVESTIGATOR_315031] (PEIT), 
radiofrequency ablation (RFA), transarterial chemoembolization (TACE), Yttrium -90 and/or 
radio -embolization.  The choice of local -regional therapy depen ds on the size  and location of the 
intrahepatic tumors and on the underlying liver function ( Bruix  2005) . 
Sorafenib is the only systemic therapy approved for the treatment of patients with advanced HCC .  
Sorafenib is a small molecule which inhibits growth signaling and pro -angiogenic pathways 
(Wilhelm  2004; Chang 2007)  by [CONTACT_315099]/threonine kinases Raf -1 and B -Raf as well as 
receptor tyrosine kinases platelet -derived growth factor receptor β (P DGFR -β) and vascular 
endothelial growth factor recep tors 1, 2, and 3 (VEGFR1, 2, 3)  (Wilhelm  2004; Chang 2004) .  
These sorafenib targets have been shown to be involved in the pathogenesis of HCC  (Ito 1998; 
Villanueva 2007; Calvisi  2006; Semela 2004) .  Results of a Phase  3 randomized trial with 
sorafenib conducted  in 21 countries (n = 602; SHARP Trial) demonstrated a statistically significant 
survival advantage for s orafenib over placebo treatment (10.7 months versus 7.9 months , 
respectively; p <0.001).  Partial response by [CONTACT_315100] (RECIST) 
criteria was demonstrated in 2% of the sorafenib group and no patients had a complete response  
(Llovet  2008b) .  A subsequent Phase  3 randomized trial with  sorafenib was completed in sites in 
Asia (n = 226 patients; Asia -Pacific Trial).   Results demonstrated a statistically significant survival 
advantage for sorafenib (n = 150 patients) over placebo (n = 76 patients) (median 66.5 months  
versus 4.2 m onths, res pectively; p = 0.014)  (Cheng 2009) .  The disease control rate (DCR) with 
sorafenib was 35% (confirmed at 12 weeks after treatment initiation); disease control was defined 
as an objective response (partial or complete) or stable disease (SD) that lasted at least 4 4 weeks   
The objective response rate (by [CONTACT_13407]) was only 3% on sor afenib.  Sorafenib is now 
approved in multiple countries for patients with unresectable HCC.  
Nevertheless, despi[INVESTIGATOR_040] a 2 –3 month survival benefit in the front -line setting, s orafenib has 
significant toxicities and dose -reductions or treatment discontinuation is often required; this is 
currently being studied under non- protocol practice conditions on the GIDEON trial  
(Lencioni  2013; Lencioni  2012) .  In addition, disea se stabilization is transient and tumor 
progression occurs in all patients ( Cheng 2009; Llove t 2008a) .  
Several other systemic therapeutic agents have been tested  in advanced HCC patients.  In the 1st 
line setting, 3 receptor tyrosine kinase  inhibitors  – sunitinib, brivanib, linifanib – have been 
compared directly against sorafenib  (Cainap 2012; Cheng 2011; Johnson 2013) .  In a fourth 1st 
line Phase 3 trial of a tyrosine kinase inhibitor  (SEARCH), the combination of erlotinib plus 
sorafenib was compared to placebo pl us sorafenib ( Zhu 2014a) .  In these trials sorafenib had a 
CONFIDENTIAL and PROPRIETARY  Page 28 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 consistent  performance, demonstrating a median overall survival  of 8.5–[ADDRESS_387729] (Onyx -015 adenovirus) entered a Phase  3 clinical trial 
in the US, and a similar virus, H101, was approved for use in combination with chemotherapy as  
a treatment for head and neck cancer by [CONTACT_315101] 2005.  More recently,  a Phase 3 pi[INVESTIGATOR_315032]  (T-VEC) , an 
oncolytic herpes virus expressing granulocyte -macrophage colony stimul ating fact or (GM-CSF) 
in patients with advanced melanoma  met its primary endpoint, demonstrating a significant 
improvement in durable response rate versus GM -CSF alone (16% vs 2%, p<0.0001)  
(Andtbacka 2013) .  Furthermore, a Phase [ADDRESS_387730] in advanced head and neck cancer.  
Oncolytic immunotherap ies kill cancer cells through a novel mechanism of action “oncolysis”, or 
virus replication -associated necrosis  (Parato 2005; Kirn 2009)  and can be targeted to cancer cells 
with ac tivated genetic pathways and/or loss of tumor suppressor function (Heise 1997; 
Stojdl  2000; Martuza 1991) .  Selective intratumoral (IT) replication of the virus leads to lysis of 
the infected cancer cell and spread to adjacent  cancer cells.  In addition, t hese viruses can kill 
through other mechanisms, including induction or amplification of a tumor -specific cytotoxic 
T-lymphocyte response.  Oncolytic immunotherapi[INVESTIGATOR_315033]  (Chase 1998; Todo 2001; Hermiston 2002; Hermiston 2005) .  The latter 
can lead to by[CONTACT_315102] (e.g., expression of 
cytokines such as GM -CSF).  Oncolytic immunotherapi[INVESTIGATOR_315034] -
approved treatments.  
 
CONFIDENTIAL and PROPRIETARY  Page 29 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 3.B.1 Pexa -Vec: Selective Tumor Infection and Active Immunotherapy  
Pexa- Vec (Pexastimogene Devacirepvec, JX -594) is an oncolytic and  immunother apeutic vac cinia 
virus engineered to express GM -CSF.  Pexa- Vec mechanisms -of-actions include tumor cell 
infection and lysis ( Breitbach  2011; Kim  2006; Park  2008) , anti -tumor immune response 
induction (Heo 2013; Kim  2013)  as well as acute vascular disruption (Breitbach  2013) .  Pexa- Vec 
is derived from the commonly used Wyeth vaccine strain (Dryvax®, Wyeth laboratories) .  
Three genetic modifications are included in Pexa- Vec:  
1. thymidine kinase (TK) gene deactivation,  
2. GM-CSF gene insertion under the cont rol of the synthetic early -late promoter, and  
3. lac-Z gene insertion under control of the p7.5 promoter. 
Selective targeting of tumor cells by [CONTACT_315103]- Vec is attributed to both engineered mechanisms as well 
as to inherent vaccinia selectivity for  cancers  (Parato 2012) .  TK gene inactivation renders viral 
replication dependent on the high cellular TK  activity that is a hallmark of cancer cells  
(Hengstschlage r 1998) .  Vaccinia vaccine strains have been shown to be inherently tumor 
targeting  (Thorne  2007; Yu 2004) .  This may be attributable to the fact that many of the hallmarks 
of cancer ( Hanahan 2000)  (e.g., blocks in apoptotic pathways, dysregulation of cell  cycle control 
and immune evasion) are also optimal cellular conditions for successful vacci nia virus r eplication.   
Furthermore, vaccinia replication and spread is dependent on epi[INVESTIGATOR_3506] 
(EGFR) signaling  (Katsafanas  2004) , a pathway that is activated in most cancers (Hanahan 2000) . 
GM-CSF is reportedly an effective cytokine  for stimul ating tumor -specific anti -tumoral immunity  
(Dranoff  1993) .  Furthermore,  the combination of vaccinia infection with GM -CSF production has 
been shown to result in enhanced efficacy in preclinical models, presumably due to additional 
immune stimulation due t o GM-CSF expression within the tumor microenvironment  
(Thorne  2007) .  GM-CSF is also expressed by [CONTACT_315104] T -Vec or Oncos -102.  
In addition, in melanoma patients GM -CSF when added to ipi[INVESTIGATOR_315035] 
(Hodi 2013) . 
Protective anti -tumor immunity has been demonstrated following vaccinia infection of murine 
tumors in vivo  (Kirn 2007) .  Pexa- Vec has also been shown to function as an immunotherapeutic 
in patients.  GM-CSF expression was associated with increased  neutrophil,  monocyte and 
eosinophil production in Pexa- Vec treated patients ( Breitbach  2011; Park  2008) .  Furthermore, 
inflammatory cell infiltration into tumors was also demonstrated with Pexa- Vec treatment 
(Hwang 2011; Mastrangelo 1999) .  Finally, funct ional  anti-tumor antibodies mediating 
CONFIDENTIAL and PROPRIETARY  Page 30 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 complement dependent cytotoxicity were induced after Pexa- Vec treatment of patients with liver 
tumors ( Heo 2013; Kim  2013) . 
 
3.C PRECLINICAL EXPERIENCE WITH PEXA -VEC 
3.C.[ADDRESS_387731] 
expressed by [CONTACT_315103]- Vec, hGM -CSF, is biologically active  in rabbit s, a species in which vaccinia 
virus replic ates.  Accordingl y, the virus was tested versus the transplantable orthotopic rabbit 
carcinoma VX -2 model in which cells are implanted under the liver capsule forming liver tumors 
and metastases in  liver and lung ( Kim 2006) .  Tumor -bearing rabbits were treated with a single 
dose of 109 plaque forming units (pfu) of Pexa- Vec via IT or intravenous (IV) injection.  Seven  
weeks post therapy, mean tumor volume in both Pexa -Vec treated groups was significantly smaller 
when compared to the phosphate buffered sa line (PB S) control g roup.   Furthermore, Pexa- Vec 
treatment prevented formation of metastases.   Median survival time of rabbits in the PBS control 
group was 50 days while median survival was not reached in either Pexa- Vec treated group at 
70 days (Kim 2006 ).  Rabbi ts treated w ith Pexa- Vec exhibited weight gain while control rabbits 
lost weight over the course of the study, presumably due to tumor progression.  The dose response 
of the effects of Pexa- Vec treatment was determined by [CONTACT_315105] a single  IV dose 
of 108 pfu used in a subsequent study with the results discussed above  with application of 109 pfu.  
Whereas a dose of 109 pfu resulted in 88% inhibition of primary tumor growth and 100% inhibition 
of metastases at 7  weeks, the lower dose of 108 pfu inhibited primary growth by [INVESTIGATOR_13701] 10%, while 
inhibiting the incidence of metastases by 48%.  
Pexa- Vec efficacy against primary liver tumors was investigated in an orthotopic primary liver 
tumor model.  Cirrhosis and liver cancers were induced in rats by [CONTACT_315106] 
N-nitrosodiethylamine and N -nitrosomorpholine (Kim 2006) .  Tumor -bearing  rats received 3 IV 
infusions of Pexa- Vec every 2  weeks.   Over 10 weeks,  5 of 6 animals treated with Pexa- Vec 
exhibited complete responses by [CONTACT_2207] w hile tumors in all PBS control animals increased in 
size.  These preclinical studies provide rationale  for the use of Pexa- Vec as a novel therapy for 
HCC (refer to the Investigator’s Brochure [IB] for further details). 
 
CONFIDENTIAL and PROPRIETARY  Page 31 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387732] has been definitively demonstrated ( Yang 2005) .  Therefore, as with 
other inhibitors of this EGFR pathway, sorafenib can be utilized to block Pexa- Vec replication 
(Heo 2011) .  
As a result, different Pexa- Vec and sorafenib treatment sequences were explored.  In vivo  
experiments were carried out with Pexa- Vec and sorafenib in a HepG2 (human HCC cancer cell 
line) xenograft tumor model in severe combined immunodeficiency (S CID) mice on ce tumors 
reached a size of ap proximately [ADDRESS_387733] of sorafenib on Pexa- Vec 
replication  in vitro , simultaneous treatment resulted in efficacy that was equivalent to sorafen ib 
alone  (Heo 2011) . 
 
3.C.3 Toxicity and Biodistribution of Single or Repeated IV Doses of Pexa -Vec in the Rabbit  
An exploratory study in New Zealand White rabbits was conducted.   Animals in this study received 
one (n = 1M, 1F) or 3 (n = 3M, 3F) weekly IV doses of Pexa- Vec (1010 pfu/dose; approximately  
4 × 109 pfu/kg).  The treatments were well -tolerated: no overt clinical signs were observed 
throughout the [ADDRESS_387734] 
approximately 5% of their body weight by [CONTACT_2006]  6.  Thereafter, body weight rose intermittently 
until the en d of measure ments on Day  33.  Control animals gained weight steadily throughout the 
study  (Kim 2006) .  While the numbers of animals in this exploratory study are limited, histological 
and hematological findings are consistent with vaccinia virus infection.   Reversible lymphoid 
depletion in the thymus and lymphoid hyperplasia with red pulp expansion in the spleen were also 
considered physiopathological adaptations.  All of these findings appeared to be resolved by 
[CONTACT_315107] 32 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Day 92 and none are considered to be of toxi cological significance (refer to the IB for further 
details).  
A study entitled “ Toxicity and Biodistribution of Recombinant Vaccinia Virus Pexa -Vec in the 
Rabbits ” has been conducted in compliance with Good Laboratory Practices (GLP) guidelines.  
Nine groups  of 5 rabbits/sex/group received IV administrations of a clinical lot (Lot No. C173 -3) 
at doses of 3 ×  106 and 3 ×  107 pfu/kg (~0.2 and 2- fold the 109 pfu/patient dose on a pfu/kg basis).  
Rabbits were assigned to groups that received 3 weekly infusions of  low dose or high dose 
Pexa- Vec or a single high dose Pexa- Vec.  Rabbits in a vehicle control group received 3 infusions.  
Pexa- Vec triggered treatment -related inappetence, and dose -related, reversible, early loss of body 
weight at both dose levels.  There were some mild, dose –related, reversible changes in hematology 
and clinical chemistry parameters.  Mild anemia was considered secondary to spleen enlargement.  
At the high dose only, abscesses were observed in the testes.  All of the observed changes  appear 
to be r eversible (refer to the IB for further details). 
 
3.D CLINICAL EXPERIENCE  
3.D.[ADDRESS_387735] been treated by [CONTACT_315108]/or IT injection with > 900 IV infusions and > 900 IT injections.  
 
Table  1:  
Pexa -Vec Clinical D evelopment  
Study  Indication / administration  Phase  Status  No. of Patients  
 Melanoma Mastrangelo, 
investigator initiated  / IT 1 Completed  7 
HEP001  Liver metastases: dose escalation  / 
up to 8 doses  IT 1 Completed  14 
IV011 Solid tumors / 1 dose IV  1 Completed  23 
MEL005  Melanoma / 6 dose s IT 1/2 Completed  10 
P009  Pediatric tumors / 1 dose IT  1 Stopped  6 
HEP012  CRC – neoadjuvant the rapy /  
1 dose IT or IV  2a Stopped  2 
CONFIDENTIAL and PROPRIETARY  Page 33 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Study  Indication / administration  Phase  Status  No. of Patients  
HEP007  HCC  primarily  1st line : 2 dose 
levels / 3 doses IT  2a Completed  30 
HEP016  HCC 2nd line /  1 dose IV + 2 doses 
IT f/b Sorafenib  2 Enrolment 
completed;  data 
analysis 
ongoing  [ADDRESS_387736] line / 5 doses IV  2 Enrolment 
completed;  data 
analysis 
ongoing  16 
HEP018  TRAVERSE (RCT):   1 dose IV + 5 
doses IT (randomized 2:1)  
Arm A:  JX594 + BSC  
Arm B:  BSC  2b Completed  129 
Arm A: 86  
CRC014  CRC:  dose escalation /  4 doses IV  1 Completed  15 
CRC019  CRC:  single agent &  combo 
(irinotecan) / 5 doses IV + 3 doses 
IT 1/2a Enrolment 
completed;  data 
analysis 
ongoing  52 
REN022 RCC / 5 doses IV  1/2 Enrolment 
completed;  data 
analysis 
ongoing  17 
HEP024  PHOCUS  (HCC): 3 doses IT  vs 
Sorafenib  3 Ongoing 186 
REN026 RCC 
Part 1 = 4 I V infusions at  
2 dose levels  in combo with anti -
PD-1 
Part 2 = [ADDRESS_387737] common adverse events  (AEs) reported were acute, transient flu -like symptoms, 
including fever and chills.  Transi ent, hypotension responsive to fluid administration was also 
noted in a subset of patients within 24 hours of treatment.  Pexa- Vec related skin pustules were 
observed in less than 1 5% of patients receiving IT injections  (1.6% of all IT treatments).   The 
CONFIDENTIAL and PROPRIETARY  Page 34 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 pustules were self -limited and resolved without sequela within 2–[ADDRESS_387738]  
(mRECIST)  or mChoi response criteria.  In HCC, conventional RECIST responses are uncommon 
followi ng systemic treatment.  In the absence of decreased tumor size as measured by [CONTACT_102675], alternative methods for assessing anti -tumor response have been developed.  Modified 
RECIST criteria for HCC focuses on the contrast enhancing (or viable) portions of tumor with 
response defined as a ≥ 30% decrease in the sum of longest diameter ( SLD ) of the contrast 
enhancing areas of target tumors in the absence of non- target progression, progressive disease ( PD) 
as ≥20% increase in the SLD of target tumors or the non- target  progression, and SD as those not 
qualifying as PD  (Llovet  2008b; Lencioni  2010) .  Of note, Pexa- Vec replication in tumors may 
trigger an acute, local inflammatory response within tumors which may lead to transient tumor 
swelling (termed an “on colytic flar e response” or “pseudoprogression”).  In addition, the modified 
Choi  (mChoi)  criter ia is a  more qualitative radiographic assessment measures  which incorporates  
the impact of ant i-cancer treatment on tumor viability and necrosis .  The Choi response 
(Choi  2004; Choi  2007)  is a measure of decreased tumor density and is defined as a decrease in 
10% or more of the longest diameter (LD) of the tumor and/or  a decrease of 15% or more in the 
average tumor enhancement.  Despi[INVESTIGATOR_315036] s welling due to edema and/or 
inflammation, Pexa- Vec has demonstrated anti -tumor activity based o n mChoi or mRECIST for 
HCC criteria .  
 
3.D.2 Pexa -Vec Evaluation in Non-HCC Indications  
Pexa- Vec was initially evaluated in patients with metastatic melanoma and was w ell-tolerated in 
a total of 17 patients treated by [CONTACT_315109] 2 clinical trials  
(Mastrangelo 1999; Hwang 2011) .  Evidence of tumor infection and anti-tumor activity was 
observed in both injected and non- injected tumors.  
An IV dose es calation study (JX594- IV-011) has been completed and results published 
(Breitbach  2011) .  A total of 23 patients were treated and a maximum feasible dose (MFD) of  
3 × 107 pfu/kg was reached without definition of a maximum tolerable dose (MTD).  Pexa- Vec 
delivery to tumors following IV infusion of Pexa- Vec was demonstrated in tumor biopsies of 7 of 
8 evaluable patients treated at a dose of ≥1 × 109 pfu and in no patients treated at <1 × 109 pfu.  
Delayed reemergence of Pexa- Vec in blood was demonstrated in a  subset of patients and was 
CONFIDENTIAL and PROPRIETARY  Page 35 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 associated with GM-CSF expression and white blood cell induction.  Furthermore, tumor response, 
disease control, and suppression of new tumor outgrowth were observed more frequently in higher 
dose cohorts than in patients receiving lower systemic doses of Pexa- Vec.  
Additional information on non- HCC studies can be found in the IB.  
 
3.D.3 Treatment of Solid Tumors within the Liver with Pexa -Vec 
3.D.3.a  Phase 1 Liver Tumor Trial  
A Phase 1 dose -escalation trial of Pexa- Vec in patients with  prim ary or metastatic liver tumors  
(JX594- IT-HEP001)  has been completed and the results published (Park  2008) .  Pexa- Vec was 
administered by [CONTACT_315110] 3  weeks in patients with refractory, injectable tumors within 
the liver  at one of 4 dose levels  (1 × 108 pfu to 3 × 109 pfu).  Patients were scheduled  to receive  
2–4 treatments but could subsequently receive an additional 4 treatments if there was evidence 
response or clinical benefit .  Fourteen  patients, including 3 HCC patients were enrolled and treat ed. 
Pexa- Vec was well -tolerated in study patients.   All patients treated with Pex a-Vec experienced 
mild-to-moderate flu -like symptoms, which included fever, chills, anorexia, aches/pain, fatigue, 
headache, and/or nausea.  No significant organ toxicity was reported.  Two patients were treated 
at the 3  × 109 pfu dose and both patients ex perienced dose limiting toxicities ( DLTs ) after a single 
treatment with Pexa- Vec.  The DLTs experienced by [CONTACT_315111] 3 hyperbilirubinemia (n  = 2), and Grade 3  anorexia and right upper quadrant pain (n = 1).  
Hyperbilirubinemia was apparently due to tumor swelling post -treatment and occlusion of the 
adjacent bile duct.   The maximum -tolerated dose on the study was therefor e defined as 1 × 109 pfu. 
Response and/or stable disease were observed in [ADDRESS_387739] criteria and/or Choi criteria.   Responding 
patients had vari ous tumor types, inc luding HCC .  In 3 cases positron- emission tomography – 
computed tomog raphy (PET -CT) scans demonstrated a decrease in injected tumor metabolic 
activity (10 –100% decrease standardized uptake value [SUV]).  Eight patients (57%) survived for  
at least 8 months , and up to 72+  mont hs.  The median cancer -specific survival was 9 months . 
 
3.D.3.b Phase 2 Liver Cancer (HCC) Trial (JX594 -IT-HEP007)  
A Phase 2 randomized dose -finding trial of Pexa- Vec in patients with liver cancer (HCC)  
(JX594- IT-HEP007) has been completed and the results published (Heo 2013) .  Pexa- Vec was 
administered by [CONTACT_315112] 2  weeks for 3  total doses in patients with injectable tumors 
CONFIDENTIAL and PROPRIETARY  Page 36 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 within the liver.   Study dose levels were  1 × 108 pfu (Arm  A) and 1  × 109 pfu (Arm  B).   
Thirty patients were treated  (16 patients in Arm A, 14 patients in Arm  B).  Twenty -nine pati ents 
received all 3 planned injections; one low -dose patient received 2 Pexa- Vec treatments.   IT 
injection was well- tolerated at both dose levels in this population of patients with HCC.  One 
treatment -related serious adverse event (SAE) was reported in the high -dose group (nausea and 
vomiting requiring prolonged hospi[INVESTIGATOR_059]).  Flu-like symptoms ( Grade 1–2) occurred in all 
patients over the first 12 –[ADDRESS_387740] criteria (1 complete response; 3 partial 
responses).  Responses were observed in i njected and non- injected tumors .  Further, overall 
survival was significantly longer in the high -dose a rm compared with the low -dose arm (median 
14.[ADDRESS_387741] ratio  [HR]  0.39; p- value 0.020, Gehan- Breslow -Wilcoxon 
test; [ADDRESS_387742] for superiority of high -dose [Figure  1]).  The median overall  survival  was  
9.0 months  for the entire populati on.  
 
Figure  1: Kaplan -Meier Plot of Overall Survival by [CONTACT_50726]  
 
 
 
3.D.3.c  Phase 2 Study of HCC Patients Treated IV and IT with Pexa -Vec Prior to Sorafenib 
(JX594- HEP016)  
Twenty -five patient s were  enrolled on this Phase 2 study investigati ng one IV dose of Pexa- Vec, 
followed by 2 IT injections (one week and 3 weeks after the IV infusion), prior to i nitiation of 
standard sorafenib therapy.  Twenty patients were resistant to sorafenib therapy b efore Pexa- Vec 
treatment.   Transient flu -like symptoms following Pexa- Vec treatments were the most common 

CONFIDENTIAL and PROPRIETARY  Page 37 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 AEs.  Subsequent therapy with sorafenib was well -tolera ted.  The 2 agents were not used 
simultaneously, as sorafenib inhibits Pexa- Vec replication and  can potentially impair its activity .  
Transient decreases in white blood cell ( WBC ) counts, in particular neutrophils and lymphocytes, 
may occur within the first 24 hours following each Pexa- Vec treatment dose.  Modified Choi 
responses and/or disease stab ilization were observed following IV and IT Pexa- Vec therapy prior 
to and following standard sorafenib therapy.  One patient exhibited a partial response by [CONTACT_315113] a response by [CONTACT_273898].  
 
3.D.3.d Phase 2b Randomized Trial of Pexa- Vec Plus Best Supportive Care Versus Best 
Supportive Care in Patients with Advanced Hepatocellular Carcinoma Who Have 
Failed Sorafenib Treatment (JX594- HEP018/TRAVERSE)  
One hundred and twenty -nine patients having failed previous sorafenib therapy were enroll ed on 
this Phase 2b study and randomized 2:[ADDRESS_387743] supportive care ( BSC ) 
or BSC alone.  Eighty -six patients were assigned to the Pexa -Vec arm and were to receive one IV 
dose followed by [CONTACT_8622] 5  IT injections ( 1, 3, 6, 12 , and 18 weeks  after the IV infusion),  and [ADDRESS_387744] common AEs related to Pexa- Vec experienced by [CONTACT_315114] A included: pyrexia 
(78.6%), chills (50.0%), pustular rash (28.6%), hypotension (26.2%), and nausea (25%).  These 
AEs were gene rally mild -to-moderate in severity and tolerable w ith the exception of hypotension, 
which was more severe than previously observed in other trials of Pexa- Vec. 
Grade 3  AEs possibly or probably related to Pexa -Vec included pyrexia (8.3%), hypotension 
(8.3%) , blood bilirubin increased  (4.8%), anemia  (3.6%),  blood aspartate transaminase ( AST ) 
increased (3.6 %); fatigue, hepatic encephalopathy, hypertension, platelet count decreased, 
vomiting, (2.4% for each event);  abdominal pain and blood alanine aminotransferase ( ALT ) 
increased ( 1.2% for each event) .  Two Grade 4 or Grade 5  events were noted:   respi[INVESTIGATOR_315037] 
(Grade 4) and hepatic failure ( Grade 5).  
Six patients presented with at least one Grade 3–4 AE possibly or probably  related to IT injection 
procedure (7.1%):   these AEs included hypotension (2.4%), upper abdominal pain, acute 
respi[INVESTIGATOR_1399], anemi a, ascites, fluid overload, hepatic hemorrhage, pleural effusion, acute 
renal failure, staphylococcal sepsis, and troponin increase (1.2% for each event).   No procedure -
related AE resulted in the patient’ s death.  
CONFIDENTIAL and PROPRIETARY  Page 38 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387745] frequent Pexa -Vec-related SAE, whi ch occurred in 6 patients (8 SAEs ) was severe 
hypotension defined as a systolic blood pressure < [ADDRESS_387746] 24 hours after Pexa- Vec administration .  Notably, anti -hypertensive 
medication was ongoing at the time of treatment with Pexa- Vec prior to the development of 
hypotension in the majority of these patients, thereby [CONTACT_315115] f or 
hypotension.  
Treatment with Pexa- Vec did not i mprove  overall survival  or other efficacy measures, compared 
with BSC, in patients with advanced HCC in this open- label study.   No significant improvement 
of overall survival  was shown in Arm A compared to A rm B (p = 0.426, stratified log -rank test) 
for th e Intent -to-Treat ( ITT) population.  Median overall survival  was 4.2 (95% confidence interval 
[CI]: 3.3 to 5.4 months ) vs 4.4 months  (95% CI:  3.2 to 6.0 months ) for Arm A vs Arm B, 
respectively.  HR observe d was 1.19 (95% CI:   0.78 to 1.80).  The overall disease control rate 
(proportion of patients  with complete response [ CR], partial response [ PR], or SD) during the study 
was 13% (95% CI:  7% to 22%) vs 19% (95% CI:   8% to 33%) for Arm A vs Arm  B, respectiv ely.  
Notably, the majority of patients in TRAVER SE did not receive the complete protocol spe cified 
treatment regimen of JX -594.  In Arm A, 12 of 86 randomized patients (13.9%) received all 
6 planned treatments; and only half of the patients (51.2%) receiv ed at least 3 IT treatments (1 IV 
plus 3 IT) as a dministered in previous JX -594 HCC trials.   
The limited number of patients completing treatment on Arm A in conjunction with the 
significantly shorter median overall survival (~ 4.2 vs 4.4 months  on Arms A a nd B, respectively) 
observed in this study versus  studies of other agents for second line HCC  (~7–9 months ) suggests 
a relatively more advanced HCC patient population was included in TRAVERSE ( Llovet  2013; 
Zhu 2014b) . 
 
3.E RATIONALE  
3.E.1 Rationale for Study  
Novel t herapi[INVESTIGATOR_315038], unresectable HCC.  The only 
approved agent for advanced  HCC, sorafenib, prolongs survival by [INVESTIGATOR_13701] a few months, is not 
curative, and is generally cytostatic.  Furthermore, several agents wi th similar mechanisms -of-
action to sorafenib (including brivanib, sunitinib and linifanib) have failed to demonstrate 
improved outcome for advanced HCC patients when compared to sorafenib.  Pexa- Vec exhibits 
multiple different and complementary mechanis ms-of-action to sorafenib.  By [CONTACT_315116], 
CONFIDENTIAL and PROPRIETARY  Page 39 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 alternativ e mechanisms -of-action of Pexa- Vec relative to other investigational agents,  Pexa- Vec 
administration prior to sorafenib  may provide additional clinical benefit to sorafenib therapy alone.  
The rational e for Pexa-Vec treatment of HCC is based on:  
1. Exploiti ng novel, alternative mechanisms -of-action of Pexa -Vec relative to sorafenib as well 
as investigational agents in HCC.  
2. Preclinical liver cancer models that have demonstrated significant tumor respo nses wi th 
Pexa- Vec treatment ( Section  3.C.1) . 
3. Preclinical evidence that Pexa- Vec replication is driven by [CONTACT_315117] /Ras signaling  
(Section  3.B.1) . 
4. Preclinical and  clinical evidence suggest that anti -tumor activit y of Pexa- Vec is dependent 
on targeting of the tumor endothelium and that Pexa- Vec spread within and between tumors 
is dependent upon the IT vasculature (Section  3.B.1) .  High level tumor vascularity and 
angiog enesis is well esta blished in HCC  (Forner  2012) . 
5. In Phase 1 and 2 clinical trials of Pexa- Vec for HCC, IT administration to hepatic tumors has 
been associated with both local and distant tumor responses  (Section  3.D.3) . 
6. Improved survival with high- dose IT injections of Pexa- Vec in advanced HCC patients 
(Section  3.D.3.b) .  
7. Long survival of sorafenib naïve patient s who have received Pexa- Vec prior to sorafenib 
initiation ( Section  3.D.3.c ). 
NOTE : The rationale for sorafenib therapy after completion of Pexa- Vec therapy is outlined 
below . 
Results from this pi[INVESTIGATOR_315039]- Vec followed by [CONTACT_315118] b increases 
survival duration in advanced HCC patients compared to treatment with sorafenib alone, and 
whether sequential dosing with Pexa- Vec followed by [CONTACT_315119] a f avorable safety profile.  
 
3.E.2 Rationale  for Pexa -Vec Dose  and Schedule and Sequential So rafenib Therapy  
3.E.2.a  Pexa- Vec Dose, Route and Interval Rationale  
Due to the high rate of accessible tumors and clinical relevance of locoregional therapy in HCC, 
IT treatment is well established in all locoregion al therapi[INVESTIGATOR_014] .  IT injection of Pexa- Vec into live r 
tumors was well- tolerated at both the 1 ×  108 pfu and the 1 ×  109 pfu dose  (equivalent to 9.0 Log 
CONFIDENTIAL and PROPRIETARY  Page 40 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 pfu) in HCC patients treated in the JX594- IT-HEP007 protocol regimen (3 IT injections, each 
2 weeks apart) (Section  3.D.3.b) (Heo 2013) .  Of interest , overall survival was significantly longer 
in the high -dose arm compared with the low -dose arm (median 14.1 months  versus 6.7 months , 
HR 0.39; p- value 0.020, Gehan- Breslow-Wilcoxon test; [ADDRESS_387747] for superiority of  high-dose).  
Therefore, the 1 ×  [ADDRESS_387748] likelihood of benefiting patients with advanced HCC while m aintaining a tolerable safety 
profile of Pexa- Vec. 
 
3.E.2.b Rationale for Sequential Ther apy with Sorafenib  
Pexa- Vec and sorafenib cannot be used simultaneously since sorafenib inhibits Pexa- Vec 
replication and can potentially impair its activity.  Therefore, sequ ential treatment appears as an 
appropriate  option for therapeutic combination of t he 2 agents .  
The s equential use of Pexa -Vec and sorafenib holds  the potential for additive activity of these  
2 agents with unique mechanisms of action in HCC.  Preclinical and preliminary clinical data 
supports this  hypothesis (Heo 2011) .  Pexa- Vec acutel y induc es viral lytic effects and tumor 
vascular shutdown; in addition, Pexa- Vec is designed to induce a tumor -specific cytotoxic 
T lymphocyte response.  In contr ast, soraf enib is generally cytostatic (< 5% objective tumor 
response rate) with its main clin ical impact elicited via inhibition of  raf kinase signal transduction 
and angiogenesis (via inhibitory effects on the VEGF receptor in tumors).  The sequential 
combination of the two may lead to up- front Pexa-Vec mediated cell lysis  and induction of 
system ic anti-tumor immunity followed by [CONTACT_315120] . 
Sorafenib is currently the standard of care (SOC) and only approved systemic therapy for subjects 
with a dvanced HCC.  Based on the non- overlappi[INVESTIGATOR_315040] 2 agents, and the 
sequential design of the therapeutic regimen, the anticipated safet y profile of the combination is 
expected to be tolerable.  This hypothesis is supported by [CONTACT_41224] a Phase 2 study of 25 HCC 
patients  utilizing sequent ial Pexa- Vec followed by [CONTACT_315121]  (Section  3.D.3.c ).  Pexa- Vec has not resulted in sorafenib- associated toxicit ies 
with the exception of nausea/reduction of appe tite, and specifically has not been associated with 
the dose -limiting rash or diarrhea frequently associated with sorafenib dosing.  The most clinically 
impo rtant Pexa- Vec side effects (flu -like symptoms) o ccur within the first [ADDRESS_387749] -dosing.  
Ther efore, no additive toxicities are expected when in the timeframe sorafenib is initiated in this 
protocol . 
 
CONFIDENTIAL and PROPRIETARY  Page 41 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 4 OBJECTIVES  
4.A PRIMARY OBJECTIVE  
• To determine and compa re the overall survival  of patients with advanced HCC without prior 
systemic therapy, treated with  Pexa -Vec followed by s orafenib (A rm A) versus s orafenib 
(Arm  B) 
 
4.B SECONDARY OBJECTIVES  
• To determine and compare the [ADDRESS_387750] for HCC for the follow ing endpoints:  
 Time t o Progression (TTP) 
 Progress ion Free Survival (PFS)  
 Overall Response Rate (ORR)  
 Disease C ontrol R ate (DCR ) 
• To determine and compare the safety profiles of the 2 treatment arms  
• To determine and compare the Time to Symptomatic Progressio n (TSP) of the 2  treatment 
arms  
• To determine and compare the Quality of Lif e (QoL) of the 2 treatment arms  
 
4.C EXPLORATORY OBJECTIVES  
• To determine and compare the [ADDRESS_387751] 1.1 for the f ollowing endpoints:  
 Time t o Progression (TTP)  
 Progression Free Survival (PFS)  
 Overall Response Rate (ORR)  
 Disease Control Rate (DCR ) 
• To evaluate and compare the effect of treatment with Pexa- Vec followed by [CONTACT_44369] (Arm  A) 
versus sorafenib (Arm B) on the  following  endpoints  (based on local and central a ssessments 
for radiology endpoints) : 
CONFIDENTIAL and PROPRIETARY  Page 42 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  Time to Initial Response (TIR) and Duration of overall Response (DoR)   
 Tumor size over time by [CONTACT_315122] 
 Efficacy of Pexa- Vec (overall survival , PFS, TTP) in patient subgroups to be def ined in 
the Statistical Analysis Plan (SAP)  
 Overall survival , PFS, TTP  in patients subdivided according to the presence or not of an 
objective response (CR, PR and/or at  least 3  months of SD  [if the number of patients i s 
sufficient ]) 
• To determine and compa re changes in clinical laboratory parameters in the [ADDRESS_387752] laboratory parameters, alpha -fetoprotein ( AFP) and CD4/ CD8 counts  
• To determine an d compare the 2 treatment arms for overall surviva l by [CONTACT_315123]  
• To describe the effects of Pexa- Vec on the immune response and identify biomarkers of 
response  
• To evaluate the comparative cost -effectiveness of Pexa- Vec followed by [CONTACT_315124]- level resource and service- use information 
 
CONFIDENTIAL and PROPRIETARY  Page 43 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 5 STUDY DESIGN 
5.A STUDY OVERVIEW  
This is a multi- center, randomized, open- label, Phase 3 study  comparing Pexa- Vec followed by 
[CONTACT_44369] (Arm A) v ersus sorafenib (Arm B) in patients with advanced HCC without prior 
systemic therapy.  
A total of 600 patients will be randomized between the 2 treatment arms in a 1:1 ratio (300 in each 
arm)  to reach at least 570 evaluable patients . 
This study is expected to s tart in  Q3 2015 with recruitment to be comple ted by Q 1 2020.  The 
study treatment phase is expected to be completed by Q 1 2021.  
It is understood that this accrual rate is based on reasonable planning expectations.  The actual 
accrual rate should be com pared to the expected rate on an ongoing basis.  If problems of 
recruitment are identified (by [CONTACT_315125] [ CRO] through monthly reports 
or by [CONTACT_1578] [ DMC ]) this should be discussed between the Sponsor, the 
CRO  and the Investigators as early as possible in or der to define actions to meet the above 
timelines.  
Patients will be allocated to ea ch arm  via a dynamic stochastic minimization procedure performed 
independently for Asian and non- Asian patients.  The follow ing criteria  will be used : 
1. Center  
2. Main etiology: hepatitis C, hepatitis B, alcohol or other reasons (such as hemochromatosis, 
Wilson’s disease, type 2 diabetes, NASH)  
3. Presence of extrahepatic disease or not  
4. Vascular invasion or not  
5. Performan ce Status 0 or 1 on the ECOG scale.  
6. AFP levels  (<200, 200–400, >400 ng/mL ) 
Two interim analysis are planned; one futility analysis at 40% of the death events and one efficacy 
analysis at 80% of the events.  
 
CONFIDENTIAL and PROPRIETARY  Page 44 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 5.B STUDY ENDPOINTS  
5.B.1 Primary Endpoint  
• Overall survival:  time from date of randomization to the date  of death due to any cause.  If a 
patient is not known to have died at the c ut-off date for analysis, survival will be censored at 
the date of last contact.  
 
5.B.2 Secondary Endpoints  
• Central radiological assessme nts will be assessed with mRECIST for HCC : 
 Time to Progression (TTP): time from randomization to the date of first documented 
radiographic tumor progression; TTP does not include deaths.  If a patient has not had a 
TTP event at the cut -off date for analysi s, TTP will be censored at the date of last evalu able 
tumor  assessment before the cut -off. 
 Progression Free Survival (PFS): time from randomization to the date of first documented 
radiogr aphic tumor progression or death due to any cause, whichever occurs f irst.  If a 
patient has not had a PFS event at the  cut-off date for analysis, PFS will be censored at the 
date of last evaluable tumor assessment before the cut -off.  
 Overall response rat e (ORR):  proportion of patients whose best overall response during 
their participation in the study is either CR or P R.  The best overall response is the best 
response recorded from the randomization until disease progression.  
 Disease control rate (DCR):  proportion of patients whose best overall response during 
their part icipation in the study is either CR, PR , or SD.  
• Safety  will be assessed by [CONTACT_315126] ( NCI CTCAE ; version 4.03).  Inciden ce of AEs and SAEs will be reported . 
• Time to Symptomatic Progression (TSP ) is the time from randomization until the fir st 
documented event of symptomatic progression defined as a decrease of 4 points or more from 
baseline in the FHSI -8 questionnaire (sub-part of the FACT -Hep questionnaire) or a decrease 
in Eastern Cooperati ve Oncology Group ( ECOG ) performance status  to 4, or death.  
• Changes in QoL  will be assessed by [CONTACT_315127] -Hep and EQ5D -3L 
questionnaires .  
 
CONFIDENTIAL and PROPRIETARY  Page 45 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387753] 1.1 . 
• TTP, PFS, ORR , and DCR as described above will a lso be assessed centrally.  
• Duration of overall Response (DoR):  applies only to patients whose best overall response is 
CR or PR.  The start date is the date of first documented response (CR or PR) and the end date 
is the date of first documented disease progression or the date of death due to underlying 
cancer.  
• Time to Initial Response (TIR):  the start date is the date of randomization and the end date is 
the date of first documented response (CR or PR).  
• Relative change of t umor size over time:  Tumor si ze is defined as the sum of the longest 
diameters for all target lesions as identified at screening . 
Changes in clinical laboratory parameters , including standard safety assessments, AF P levels, 
CD4/CD8 counts (all assessed centrally).  
Additional immunolog y assays may be performed on archived samples to further as sess the 
immune mechanisms involved. 
Pharmacoeconomy analyses  include all information obtained from questionnaires collecting 
patient -level resource and service -use (Health Care Resource Utilizatio n questionnaire , patient 
accommodation and t ransport questionnaire derived from client service receipt inventory [ CSRI ] 
and EQ5D -3L questionnaire ).  Detailed costs collected using data entered in  electronic Case 
Report Form  (eCRF ), hospi[INVESTIGATOR_315041] d ata will also be used as 
information for pharmacoeconomics analyses . 
 
5.C DOSE AND REGIMEN 
Refer to Section  10 for more information about study trea tments.  
 
Arm A ( Pexa -Vec followed by [CONTACT_44369]) : 
Pexa-Vec:  Three IT Pexa -Vec treatments  are planned.  Each IT Pexa- Vec treatment will be 
administered at a dose of 1  × 109 pfu (equivalent to 9.0 Log pfu) .  This dose will be suspended in 
sterile normal saline buffered in sodium bicarbonate.  Refer to Section 10.A.8 for additional 
details.   Pexa- Vec has to be administered within a specified treatment window of –1 and +7 days.  
CONFIDENTIAL and PROPRIETARY  Page 46 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 While the IT treatment can be performe d anytime within the allowed window, it is prefer red that 
it occurs in the beginning of the treatment window. 
Sorafenib:  sorafenib dosing of 400 mg (oral, twice daily [ BID]) will be administered and managed 
according to the registered Summary of Product C haracteristics ( SmPC ).  Treatment will be 
initiate d at the visit W eek 6, [ADDRESS_387754] Pexa- Vec IT (whichever is later) .  If not all 
3 Pexa- Vec IT were performed, sorafenib should start no earlier than W eek 6. 
 
Arm B ( sorafenib ): 
Sorafenib dosing  of 400 mg (oral, BID) will be started on Day  1 and managed according to the 
registered SmPC . 
 
5.C.1 Dose Modifications, Delays, and Cancellations  
5.C.1.a  Dose Modifications  
Pexa -Vec:  No Pexa- Vec dose modifications are allowed. 
Sorafenib:  Dose modification will be allowed according to the registered SmPC.  
 
5.C.1.b Dose Dela ys 
Pexa -Vec:  Pexa- Vec must  be administered within the specified treatment window  
(–1/+7 days) and t here are no Pexa- Vec dose delays planned outside of this  window .  
Sorafenib:  Sorafenib will be managed according to the registered SmPC. 
 
5.C.1.c  Dose Cancellatio ns 
Pexa -Vec:  If for any reason a Pexa- Vec IT treatment is not given within the allowed treatment 
window , it will be cancelled (i.e. , missed for that  time point), but then IT treatments should be 
resumed at the next scheduled treatment visit if re -treatmen t eligibility criteria are met as outlined 
in Section  6.C.2.  
Sorafenib:  Sorafenib will be taken by [CONTACT_44126].   Drug accountability will be recorded  
by [CONTACT_16795].  The patient should be  counseled on the importance of not missing 
doses unless instructed by [CONTACT_737] (e.g., due to toxicity).   
 
CONFIDENTIAL and PROPRIETARY  Page 47 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 5.C.1.d Treatment Withdrawal   
All patients should remain on study until progression or until una cceptable toxicity occurs . 
Sorafenib treatment is allowed as long as the patient is clinically benefiting  according to the 
registered SmPC .  
If, however s orafenib  and/or Pexa- Vec treatment is withdrawn (i.e., no further treatment will be 
administered at future visits ), prior to Investigator determination of c linical benefit (e.g. , patient 
withdrew consent, AE , concurrent prohibited medical condition, etc.)  patients should complete an 
End of Treatment V isit.  Reason for treatment withdrawal should be recorded in the eCRF.  Patients 
should also return to the clinic  for a safety follow -up visit at least [ADDRESS_387755] of an active study participation phase  (which includes : the  
Treatment Phase, the Long -Term Follow -Up Vi sits (Section  7.C.1) , an End Of Treatment Visit 
(Section  7.D), a Safety Follow -Up (Section 7.E ), and PFS visits  (Section  7.F) if a pplicable ) and a 
survival follow -up phase  (consisting of patient and/or caregiver contact [INVESTIGATOR_135] 4 weeks ). 
 
5.D.[ADDRESS_387756] part of the active study part icipation phase :  will last from the first 
day of study administration until the last study treatment administration.  After this phase, i.e., at 
treatment discontinuation ( Pexa- Vec and/or sorafenib), an End of Treatment visit will b e 
performed, followed b y a safety follow -up at least [ADDRESS_387757] study drug administration.  
• Patients in both Arm A and Arm B will remain in active study phase  until they are no longer 
clinically benefiting from the treatment and at least until radiographic progression or 
unacceptable toxicity occurs .  In case a patient discontinues  the treatment phase  (e.g. 
permanently stops taking the study medication)  prior to documented radiographic progression, 
the patient will perfor m PFS follow -up visit(s) every 6 weeks  for radi ology evaluation, until 
documented progression or until premature study discontinuation (refer to Section  6.C.4) . 
 
CONFIDENTIAL and PROPRIETARY  Page 48 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 5.D.2 Survival Follow Up Phase  
After the active study p articipation phase , patients in both Arm A  and Arm B will enter survival 
follow -up.  During this phase, patients and/or their specified contacts will be contact[CONTACT_315128] 4 weeks  with the window of ± 7 days for follow -up and collection of 
inform ation on subsequent anti -cancer therapy received (e.g., type of therapy, start/stop date,  or 
ongoing, etc.) until the patient dies, is lost to follow -up, or specifically withdraws consent for 
further survival contacts.   
 
CONFIDENTIAL and PROPRIETARY  Page 49 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387758] meet the following inclusion criteria: 
1. Male or female patients, age ≥ 18 years old 
2. Histological/cytological diagnosis of primary HCC  
3. Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American 
Associatio n for the Study of Li ver Disease [AASLD] guidel ines) eligible for systemic 
therapy excluding cholangiocarcinoma, hepatocholangiocarcinomas, fibrolamellar 
carcinoma and hepatoblastoma.   
4. Tumor status (as determined by [CONTACT_315086]):   At least one m easurable viable tumor 
in the liver (≥[ADDRESS_387759] scan or MRI), and 
injectable under imaging -guidance (CT and/or ultrasound)   
5. At least one tumor that has not received prior local -regional treatment, or that ha s exhibited 
>25% increase in viable tumor size  since prior local -regional treatment  
6. Child -Pugh Class A .  NOTE :  paracentesis , albumin infusion or diuretic treatment can not be 
used to downscore Child -Pugh score (e.g. , to improve from severe to moderate/m ild or from 
moderate- to-mild ascites ) 
7. Perfo rmance status 0 or 1 on the  ECOG scale  
8. Adequate hematological, hepatic, and renal function:  
a. Hemoglobin ≥ 9 g/dL  
b. Platelet count ≥ 75 × 109/L 
c. International normalized ratio (INR) ≤1.7  
d. WBC count ≥2 ×  109/L  
e. Absolute neutrophil count (ANC) ≥1 ×  109/L 
f. Albumin ≥ 2.8 g/dL, total bilirubin ≤3 .0 mg/dL (51.3 µmol/L); ALT, AST ≤5  times 
upper li mit of normal (ULN)  
g. Serum chemistries s odium, potassium, and c alcium within normal limits (WNL) or 
Grade 1  
CONFIDENTIAL and PROPRIETARY  Page 50 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 h. Serum creatinine <2.0 mg/dL or creatinine clearance >60  mL/min according to 
Cockroft -Gault formula  
9. For patients who are sexually active:  willing to use adequate barrier contraception method 
for at least [ADDRESS_387760] not meet any of the following exclusion criteria:  
1. Major surgery within 4 weeks  of study treatment (minor surgical procedures are allowed e.g., 
intravascular access line or Port-a-Cath®) 
2. Local -regional therapy of HCC with in 4 weeks  prior to Arm assignment  
3. Histological diagnosis of cholangiocarcinoma, hepatocholangiocarcinomas, fibrolamellar 
carcinoma and hepatoblastoma  
4. History of moderate or severe ascites, bleeding esophageal varices, hepatic encephalopathy  
or pleural effusions related to liver insufficiency  within 6 months  of S creening  
5. Bulky disease patients - tumors encompassing > 50% of the liver  volume and or inferior vena 
cava invasion . 
6. Known significant immunodeficiency due to underlying illness (e.g., HIV/ AIDS) and/or 
immune -suppressive medication including high- dose corticosteroids (defined as ≥20 mg/day 
prednisone or equivalent which is ongoing at the time of randomization and/or was taken for 
more than 4 weeks  within the preceding 2 months of study treatment)  
7. Ongoing severe inflammatory skin condition (as determined by [CONTACT_737])  requiring 
medical treatment  
8. History of severe eczema (as determined by [CONTACT_737]) requiring prior medical 
treatment  
CONFIDENTIAL and PROPRIETARY  Page 51 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 9. Tumor(s) invading a major vascular structure (e.g., carotid artery) o r other key anatomical 
structure (e.g. , pulmonary airway) in the event of post -injection tumor swelling and/or 
necrosis.  Hepatic and portal vein involvement allowed.  
10. Clinically significant and/or rapi[INVESTIGATOR_315021], pericardial and/or pleura l 
effusions.  Mild ascites that does not preclude safe IT injection of Pexa- Vec is allowed at the 
discretion of the treating physician.  
11. Symptomatic cardiovascular disease, including but not limited to significant coronary artery 
disease (e.g., requiri ng angioplasty or stenting) or congestive heart failure within the 
preceding [ADDRESS_387761] histor y of cardiovascular disease (e.g ., past history of myocardial infarction, 
ischemic cardiomyopathy) unless cardiology consultation and clearance  has been obtained 
for study participation  
13. Medical conditions , per the investigator’s judgment, that predispose the patient to untoward 
medical risk in the event of volume loading (e.g.,  IV fluid bolus infusion), tachycardia, or 
hypotension during or following treatment with Pexa- Vec 
14. Viable central nervous system malignancy (history of completely resected or irradiated brain 
metastases allowed)  
15. Prior systemic therapy for HCC .  NOTE :  Patients receiving 7 days  or less exposure to 
systemic therap y are allowed . 
16. Known contraindications to sorafenib according to the drug prescribing information and/or 
severe hypersensitivity to s orafenib or any other component of s orafenib, or known 
intolerance to s orafenib  
17. Other medical condition or laborator y abnormality or active infection that in the judgment 
of the Principal Investigator [INVESTIGATOR_315042]/or otherwise make the patient inappropriate 
for entry i nto this study  
18. Hepatitis C virus  therapy including interferon/pegylated interferon or ribavirin t hat cannot 
be discontinued within 14  days  prior to any Pexa- Vec injection.  Medical Monitor should be 
consulted if the patient is taking any other anti- viral medications to determine eligibility . 
19. Prior malignancies are not allowed except for the following:  adequately treated basal or 
squamous cell skin cancer, in situ  cervical cancer, adequately treated cancer from which the 
CONFIDENTIAL and PROPRIETARY  Page 52 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387762] 12 months  that places the patient at risk for 
intrahepatic IT injection procedure based on Investigator assess ment 
21. Anticoagulant or anti -platelet medication that cannot be interrupted prior to Pexa- Vec IT 
injections , including:  
a. Aspi[INVESTIGATOR_315043] 7 days  prior to Pexa- Vec IT injections   
b. Coumadin that cannot be discontinued for 7 days  prior to Pexa- Vec IT injections  
c. Low molecular weight heparin (LMWH) that cannot be discontinued >24 hours prior 
to Pexa- Vec IT injections  
d. Unfractionated heparin (UFH) that cannot be discontinued >[ADDRESS_387763]  thrombin inhibitor (dabigatran) or direct Factor Xa inhibitor (rivaroxaban, 
api[INVESTIGATOR_106757], and endoxaban) that cannot be discontinued for 4 days prior to Pexa- Vec IT 
injection  
NOTE : LMWH or UFH may be used to transition patients on and off of the above 
anti-coagulants (if deemed appropriate by [CONTACT_1963]) prior to 
Pexa- Vec treatments as long as the last dose of LMWH is administered 
>[ADDRESS_387764] dose of UFH is administered >[ADDRESS_387765] the Sponsor for questions regarding the management of other ant icoagulant 
prior to treatments.  
22. Inability to suspend treatment with anti- hypertensive medication (including but not limited 
to: diuretics, beta -blockers, angiotensin converting enzyme [ACE] inhibi tors, aldosterone 
antagonists, etc.) for 48 hours prior to and 48 hours after each Pexa- Vec injection   
23. Any p rior or planned organ transplant (e.g., liver transplant)  
24. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a  female 
after conception and until the termination of gestation.  Child -bearing potential patients with 
a positive hCG laboratory test (>10 mIU/mL) at Screening  and/or a pos itive urinary test at 
Baseline will perform an  ultrasound to assess the pregnancy.  
CONFIDENTIAL and PROPRIETARY  Page 53 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387766] within 4  weeks prior 
to randomization  
27. Patient unab le or unwilling to comply with the protocol requirements  
28. Previous treatment with Pexa- Vec or other vaccinia vector based trea tment 
29. Pulse oximetry O 2 saturation <90% at rest on room air  
 
6.C  SCREENING, ELIGIBILI TY, ARM ASSIGNMENT,  STUDY COMPLETION, 
AND S TUDY DISCONTINUATION 
6.C.[ADDRESS_387767] screening procedure.  Screening window can be extended beyond  21 days with prior 
Sponsor’s approval.  
 
6.C.1.a  Screen Failures  
The status and reason for failure will be reported in the eCRF .  Patients who do not meet all 
eligibility  criteria  during  Screening should be screen- failed.  Any patients who are deemed “screen 
failures” cannot be re-screened for participation  unless prior Sponsor’s approval was granted.  
 
6.C.2 Eligibility  
The Principal Investigator [INVESTIGATOR_315044](s) meet 
all eligibilit y criteria ( Inclusion/ Exclusion C riteria ) prior to randomization  
Patients will be eligible for each of the  3 Pexa- Vec IT injections if all of the following clinical and 
laboratory criteria are met prior to each Pexa- Vec IT treatment:  
• Adequate li ver funct ion (total bilirubin ≤ 3.0 mg/dL [51.3 µmol/L]; ALT and AST  
≤5 × ULN)  
CONFIDENTIAL and PROPRIETARY  Page 54 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Platelets ≥ 75 × 109/L (correction with transfusion or thrombopoietin based therapy allowed to 
meet re- treatment eligibility criteria)  
• Hemoglobin ≥ 9 g/dL (correction with transfusion or e rythropoietin based therapy allowed to 
meet re- treatment eligibility criteria)  
• INR ≤ 1.7 (correction with plasma protein support allowed to meet re -treatment eligibility 
criteria [ e.g., fresh -frozen plasma ]) 
• Patient is still expected to have at least one via ble, injectable intrahepatic tumor  
≥1 cm LD  
• No clinically significant and/or rapi[INVESTIGATOR_315021], pericardial and/or pleural 
effusions.  Minimal ascites that does not preclude safe IT injection  of Pexa -Vec is allowed at 
the discretion of the tre ating physician  and interventional radiologist . 
 
6.C.2.a  Laboratory Eligibility  
Blood samples drawn at Screening to determine  study eligibility must be sent to the central 
laboratory except for the clinical investigational sites participating in China where labora tory 
testing will be completed by [CONTACT_315129] .  Local lab oratory  results may be used to 
determine patient re -treatment eligibility  before each Pexa- Vec IT injection (i.e., not for study 
eligibility) ; however, blood samples will need to be  sent to the central laboratory  in parallel  whic h 
will prevail over the local laboratory  results . 
During the screening period, hematology parameters can be re- tested after an authorized therapy.  
 
6.C.3 Patient Allocation to Treatment Arms  
A total of 600 patients  will be randomized between one of 2 treatment arms in a 1:1 ratio (300 in 
each arm).   Patients will be allocated to each arm via a dynamic stochastic minimi zation procedure 
performed independently for Asian and non -Asian patients.  T he following criteria  will be used :  
1. Center  
2. Main etiology :  hepatitis C, hepatitis B, alcohol or other reasons (such as hemochromatosis, 
Wilson’s disease, type 2 diabetes, NA SH) 
3. Presence of extrahepatic disease or not  
CONFIDENTIAL and PROPRIETARY  Page 55 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 4. Vascular invasion or not  
5. Performance s tatus 0  or 1 on the ECOG scale  
6. AFP levels (<200, 200–400 or ≥400 ng/mL)  
 
6.C.4 Premature Study Discontinuation  
Premature d iscontinuation from active study participation may occur at any time due to any of the 
following reasons:   
1. Any situation where, in the opi[INVESTIGATOR_155057], continued 
participation in the study would not be in the best inte rest of the patient . 
2. Patient initiates other anti- cancer therapy.  The anti -cancer therapy will be documented in 
the medical record and eCRF.  
3. An intercurrent illness develops that precludes objective clinical assessments . 
4. Prohibited concomitant me dications are required or used.  
5. Patient is unable or unwilling to comply with study procedures . 
6. Consent for active study participation is withdrawn. 
7. Termination of the study by [CONTACT_941] S ponsor . 
8. Request by a Health Authority . 
 
6.C.4.a  Data Collection for Premature Discontinued Patients  
The reason(s) for premature study discontinuation should be reported on eCRF and within the 
source documents.  AEs should be documented according to Section  11.  An End of Treatment 
Visit should be performed and will be followed by a Safety Visit  at least [ADDRESS_387768]  
study drug administration ( Pexa- Vec or sorafenib) to allow for collection and assessment of AEs 
and Concomitant Medications.  Refer to Section  7.C for details.   Patients who discontinue  
treatment s will continue to be followed for survival follow -up (to allow for analysis of the primary 
trial endpoint) , collection of other anti -cancer therapy data and EQ5D -3L questionnaire  
completion  (if the patient is at a site where EQ5D -3L questionnaire is planned to be completed) . 
In case a patient discontinues the treatment phase  prior to documented radiographic progressio n 
(e.g., permanently stops taking the study medication) , a PFS follow -up visit should be performed 
CONFIDENTIAL and PROPRIETARY  Page 56 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 every 6 weeks  for radiology evaluation, until documented progression or until premature study 
discontinuation ( Section  6.C.4) .  
If a patient withdraws consent from ac tive study participation (discontinues) , the site should 
initiate protocol -specified survival contacts every 4 weeks  with the window of ± 7 days unless the 
patient explicitly withdraws consent for survival follow -up.  This consent withdrawal will be 
documented in the source documents  and in the eCRF . 
Patients who discontinue the active study participation will not be replaced.  
 
CONFIDENTIAL and PROPRIETARY  Page 57 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 7 STUDY PROCEDURES AND TREATMENT  
7.A SCREENING  
Screening assessments will begin aft er: 
• The signature [CONTACT_56534] (ICF)  
• A patient study identification number is obtained (via Interactive Voice Response System 
[IVRS ] / Interactive Web Response System [ IWRS ]).  The patient study identification number 
is unique and remains w ith the patient for the entirety of the trial.  
Patient eligibility for the study will be determined up to 21  days before Day  1 for Arm  A or 
Baseline/Day  1 for Arm B.  Screening procedures may be completed in less than 21  days , which 
is preferred .  The 21 -day screening window starts when the firs t protocol -required screening 
procedure is performed and does not include the ICF signature [CONTACT_568].  Screening window can be 
extended beyond 21 days  with prior Sponsor’s approval. 
Central laboratory results must be obt ained prior to randomization and used for eligibility 
determination  except for the clinical investigational sites participating in China wher e laboratory 
testing will be completed by [CONTACT_315129] .  These results are also used for Arm  A 
patient eligibility to receive Day  1 IT injection.  Only central laboratory data can be used and will 
be entered into the clinical database.  
At the Screening visit, the following will occur:  
• Collection of detailed medical, surgical, and cancer history  
• Comple te physical exam including weight, height, and vital signs (blood pressure, pulse, 
temperature including  pulse oximetry for screening only ) 
• CT (preferred) or MRI (if CT not possible) (refer to Section  8.C.2):  tumors are numbered with 
unique number and identified as Target or Non- Targe t tumors.  Tumors should be assigned the 
next available chronological number wherever possible.  
• Electrocardiogram (ECG)  
• BCLC and Cancer of the Liver Italian Program ( CLIP ) scoring (including Child- Pugh scoring). 
• Histological HCC diagnosis .  If no pathology report available, perform biopsy  
• European Association for the Study of the Liver ( EASL ) / European Organization for Research 
and Treatment of Cancer ( EORTC ) criteria  
CONFIDENTIAL and PROPRIETARY  Page 58 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Blood sample  collection for central laboratory eligibility/safety assessment including:  
 Hematology, chemistry , and coagulation  
 CD4 and CD8 count  
 HIV, Hepatitis B and C testing  
 AFP 
 Pregnancy test for women of child- bearing potential  (if positive, an ultrasound will be  
performed to confirm pregnancy)  
NOTE :  Definition of women of child- bearing potential  = A sexually mature woman who 
has not undergone hysterectomy, or tubal ligation, vasectomy , or other means of permanent 
sterilization or who has not been naturally post -menopausal for at least 24 consecutive 
months for women ≤55 years or 12 consecutive months for women >55 years .  
• Standard urinalysis  
• ECOG performance status  
• Concomitant medications reporting  
• From the date of signature [CONTACT_315200], only SAEs caused 
by a pr otocol -required procedure will be collected and reported to the S ponsor  
• Refer to S ection  8.A.4.b for treatments to be stopped prior to Pexa- Vec tr eatment.  
 
7.B INITIAL TREATMENT PH ASE ( BASELINE AND DAY 1 UNTIL  WEEK 6)  
7.B.1 Randomization (Upon Investigator Confirmation of Eligibility)  
After patient eligibility has been confirmed by [CONTACT_737] (and by [CONTACT_1034], as applicable), 
site personnel will access the IVRS /IWRS  and provide relevant minimiz ation information to  obtain 
randomization assignment (to Arm A or Arm  B).  The patien t will keep the same number as the 
one given during the screening phase.   
If a patient  is randomized to Arm  A, a Pexa- Vec treatment kit number will be assigned for the 
Day [ADDRESS_387769] period .  Kits’ assignment to patients randomized in both Arms A and B 
are made through the IVRS/IWRS.  
CONFIDENTIAL and PROPRIETARY  Page 59 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Randomization and Baseline procedures ( Section  7.B.2) can be performed on the same day.  
 
7.B.2 Arm A and Arm B:   Baseline Visit  
At the Baseline visit,  up to 4 days  before Day  1, the following will occur:  
• Baseline for symptomatic progression assessments, Health -Related Quality of Life (HRQoL)  
assessments, and pharmacoeconomic evaluations (all questionnaires should be completed prior 
to any Baseline Visit protocol assessments/exams): 
 ECOG performance status  
 Functional Assessment of Cancer Therapy - Hepatobiliary ( FACT -Hep) questionnaire 
(FHSI -[ADDRESS_387770] -Hep questionnaire)  
 EQ5D- 3L questionnaire  
 Collection of pharmacoeconomic data through the Health Care Resource Utilization 
questionnaire and the P atient Accommodation and Transport questionnaire  
• Blood sample collection  for the following testing:  
 Hematology, chemistry, and c oagulation  
 Human leukocyte antigen (H LA) typi[INVESTIGATOR_007]  (selected sites only)  
 Urinary pregnancy test for women of child- bearing potenti al 
 Archival serum sample  
Refer to the Central Lab Manual for details on blood sample processing and shippi[INVESTIGATOR_3931].  
• Complete physical exam  
• Vital signs (e.g. , blood pressure, temperature, and pulse)  
• Concomitant medication s reporting  
• From the date of signature [CONTACT_315200], only SAEs caused 
by a protocol -required procedure will be collected and reported to the Sponsor  
• An ultrasound may be optionally performed to assess suitability of IT injection within selected  
liver lesions and to select lesions for injection (Arm A); or to rule out pregnancy for patients 
with a positive hCG laboratory test (> 10 mIU/mL). 
CONFIDENTIAL and PROPRIETARY  Page 60 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Pregn ancy test  (urine) for women of child- bearing potential (if positive, an ultrasound will be 
performed to  confirm pregnancy)  
Patient Contact [CONTACT_315130]:  include detailed contact [CONTACT_176543], 
family/caregivers, and preferred (to be updated periodically during study)  in compliance with local 
regulations.  
 
7.B.3 Arm A  and Arm B :  Visit 1 (“ Day 1”)  
All visit dates and visit windows will be counted from Day 1  
 
7.B.3.a  Arm A:  Pexa- Vec Treatment #1 ( Day 1) 
7.B.3.a.[ADDRESS_387771]/MRI scan (e.g., screening CT/MRI), a qualified and trained 
Interventional Radiologist will identify up to 5  intrahepatic tumors, each ≥[ADDRESS_387772]  will measure and document the LD of the tumors (with appropriate 
tumor numbers) selecte d for injection.  Tumor numbers and measurements will be documented by 
[CONTACT_315131] /physician performing the injection on the Pexa- Vec IT Injection 
Preparation Worksheet.  
The number(s) of the tumor(s) injected and the volume of solution injected into each tumor (among 
other data points) will be recorded in the e CRF.  
 
7.B.3.a.2 IT Injection Procedure  
The total Pexa- Vec dose for IT injection is 1 ×  109 pfu (equivalent to 9.0  Log pfu) which is diluted 
in sterile buffered normal saline.   The volume of saline used for dilution will vary according to the 
number and size of tumors to be injected.  Each tumor will be injected with Pexa- Vec diluted in  
buffered normal saline  solution in a volume that is approximately  25% of that tumor’s volume 
(percentage dep endent on the size of the tumor ) but will not exceed a specified upper limit.  After 
an appropriate pre -hydration ( refer to  Section  8.A.3) , injections will be performed by [CONTACT_315132] 61 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387773]  or other  trained physician using imaging -guidance (ultrasound and/or 
CT).  All viable, safely injectable intrahepatic tumors ≥ [ADDRESS_387774] developed since scr eening evaluation.  The total 
prepared injection volume will be divided proportionally between 1–5 intrahepatic tumors, relative 
to individual tumor volumes.  
Injection needles designed for percutaneous insertion into tissues will be used.  Depending on 
tumor size, either multi- pronged injection needles (provided by [CONTACT_941] S ponsor), or straight needles 
preferably with multiple side ports (not provided by [CONTACT_941] S ponsor), will be used.  
Refer to the “Pexa -Vec Intratumoral injection: Procedure Manual ” and to the “ Pexa-Vec 
Intratumoral  (IT) Injection:   Preparation Worksheet ” for mo re information about the specific 
calculation and preparation instructions and for the detailed injection procedure guidelines and 
needle use recommendations.  
 
7.B.3.a.3 Additional P rocedures  
Patient s will be observed in the clinic or hospi[INVESTIGATOR_34092] a minimum of 8 hours after IT Pexa- Vec 
treatment .  The  following evaluations will be performed:   
• Complete physical exam (before IT)  
• Medical, and surgical history update with any study procedure -related SAEs that would have 
occurred from the signature [CONTACT_48028] (before IT)  
• Reporting of AEs (that occurred during or after IT) and concomitant medications  
• Vital signs ( blood pressure, temperature, and pulse) within 60 minutes prior to injection to 
establish b aseline, 15 minutes (±5 minutes) after injection completion and then every hour 
(±15 minutes) for at least 8 hours  after treatment   
• Archival serum sample (8 hours with ± 15 minute s after treatment)  
 
7.B.3.b  Arm B:  Sorafenib Treatment  Start ( Day 1) 
For patients assigned  to Arm B, s orafenib will be started at Day  1 at a dose of 400 mg BID.  Dosing 
reductions may be performed according to the registered SmPC . 
Arm B patients will complete the following procedures: 
CONFIDENTIAL and PROPRIETARY  Page 62 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Complete physical exam  
• Vital signs (blood pressure, temperat ure, and pulse)  
• Medical, and surgical history update with any study procedure -related  SAEs that would have 
occurred from the signature [CONTACT_48028] (before sorafenib initiation)  
• AE and concomitant medications  reporting  from the first dose of sorafenib intake  
• Sorafenib:  counsel patient on use and IVRS/IWRS first kit dispensation  
 
7.B.4 Arm A:   Visit 2 (Pre -Day 15 or Pre -Week 2); Arm B : Visit 2 (Day  15 or W eek 2) 
7.B.4.a  Arm A:   Visit 2/ Pre -Day 15  or Pre -Week 2  
This visit will be performed up to 4 days  before Visit 3/Day 15 (Week  2).  This visit must occur 
regardless of whether the Day  15 IT injection will be given.   
The Principal Investigator  [INVESTIGATOR_315045](s) m eet 
the required clinical and laboratory criteria  prior to Pex a-Vec injection.  
Patients will be eligible for Treatment #2 if all of the following re -treatment criteria are met:  
1. Laboratory criteria:  
• Adequate liver function (total bilirubin ≤3 mg/dL [51.3 µmol/L]; ALT, and AST ≤5 ×  ULN)  
• Platelets ≥ 75 × 109/L (corre ction with transfusion or thrombopoietin based therapy allowed to 
meet re- treatment eligibility criteria)  
• Hemoglobin ≥ 9 g/dL (correction with transfusion or erythropoietin based therapy allowed to 
meet re- treatment eligibility criteria)  
• INR ≤1.7 (correctio n with plasma prote in support allowed to meet re -treatment eligibility 
criteria [ e.g., fresh -frozen plasma ]) 
2. The patient is still expected  to have at least one viable, injectable intrahepatic tumor ≥1 cm 
LD.  
3. No clinically significant and/or rapi[INVESTIGATOR_315021], pericardial and/or pleural 
effusions.  Minimal ascites that does not preclude safe IT injection of Pexa- Vec is allowed 
at the discretion of the treating physician.  
CONFIDENTIAL and PROPRIETARY  Page 63 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Re-treatment eligibility assessments may be repeated until the patient  becomes eligible for 
treatment within the specified  window of –1/+ [ADDRESS_387775] be ultimately 
confirmed within 4 days  prior to IT injection.  
Arm A patients will complete  the following procedures:  
• Complete physical examination including weight  and skin assessment   
• Vital signs (blood pressure, temper ature, and pulse)  
• Blood sample collection for central laboratory assessment including:  
 Hematology, chemistry and coagulation (in the interest of time, local analysis may be 
obtained t o confirm patient re -eligibility for treatment but samples should be sent  to central 
laboratory in parallel )  
• AEs and concomitant medications  reporting   
• If the patient meets eligibility criteria, contact [CONTACT_21926] /IWRS  to obtain Pexa- Vec kit number 
for Day  15 treatment.  
 
7.B.4.b  Arm B:   Visit 2/ Day  15 (Week  2) 
This visit can occur Day  15 ± [ADDRESS_387776]  as possible to D ay 15. 
Arm B patients will complete the following procedures: 
• Complete physical examination including weight   
• Vital signs ( blood pressure, temperature, and pulse)  
• Blood sample collection for central laboratory assessment including hematology, chemistry 
and coagulation parameters  
• AEs and concomitant medications  reporting  
• Sorafenib:  collection of returned medication and IVRS/IW RS new kit dispensation 
• Update of the Patient Contact [CONTACT_315133]  
 
7.B.5 Arm A:   Visit 3  / Pexa -Vec Treatment #2 ( Day 15/Week  2)  
This visit can occur Day  15 –1/+7 days ( Days 14–22) but preferentially the closest  as possib le to 
Day 15. 
CONFIDENTIAL and PROPRIETARY  Page 64 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387777] been confirmed at previous visit.  Refer to 
Section  6.C.2.  
All procedures are the same as Pexa- Vec Treatment #1 ( Day 1).  Patients will be observed in the 
clinic or hospi[INVESTIGATOR_34092] a minimum of 8 hours after IT Pexa- Vec treatment and following evaluations 
will be performed:  
• Complete physical exam (before IT)  
• Vital signs ( blood pressure, temperature, and pulse) within 60 min utes prior to injection to 
establish baseline, 15 minutes (±5 minutes) after injection completion and then every hour 
(±15 minutes) for at least 8 hours after treatment  
• An ultrasound may be optionally pe rformed to assess suitability of IT injection within  selected 
liver lesions and to select lesions for injection  
• Reporting of AEs and concomitant medications  
• Update of the Patient Contact [CONTACT_315134] -specified window for any 
reason,  this treatment must be  cancelled (i.e. , missed for this time point), but the patient should 
resume follow -up visits per the Schedule of Activities and IT treatments at the next scheduled 
treatment visit if th ere is still a n IT administration planned and re -treatment eligibility criteria are 
met as outlined above.   
 
7.B.6 Arm A:   Visit 4 (Pre -Day 2 9/Pre -Week 4); Arm B :  Visit 3 (Day  29/Week  4) 
7.B.6.a  Arm A:   Visit 4/ Pre -Day 29  (Pre -Week 4)  
This visit will be performed up to 4 days  before Visit 5/Day 29 (Week 4).  This visi t must occur 
regardless of whether the Day  29 IT injection will be given.   
Arm A patients will complete the following procedures: 
• Complete physical examination including weight  and skin assessment  
• Vital signs (blood pressure, temperature, and pulse)  
• Blood sa mple collection for central laboratory assessment including:  
CONFIDENTIAL and PROPRIETARY  Page 65 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  Hematology, chemistry and coagulation (in the interest of time, local analysis may be 
obtained to confirm patient re -eligibility for treatment but samples should be sent to central 
laboratory i n parallel)  
• AE and concomitant medication s reporting  
• Refer to Section  6.C.2 for re -treatment eligibility criteria : If the patient meets eligibility 
criteria, contact [CONTACT_21926] /IWR S to obtain Pexa- Vec kit number fo r Visit 4/Day  29 (Week 4) 
treatment.  
 
7.B.6.b  Arm B:   Visit 3  / Day  29 (Week  4) 
This visit can occur Day  29 ± [ADDRESS_387778]  to Day  29. 
Arm B patients will complete the following procedures: 
• Complete physical examination including weight   
• Vital signs (blood pressure, temperature, and pulse)  
• Blood sample collection for central laboratory assessment including:  
 Hematology, chemistry and c oagulation  
• AEs and concomitant medications  reporting  
• Sorafenib:  collection of returned medication and IVRS/IWRS  new kit  dispensation 
 
7.B.7 Arm A:   Visit 5 / Pexa -Vec Treatment #3 ( Day 29 / Week  4) 
This visit can occur Day  29 –1/+7 days (between Days 28 –36), but preferentially the closest to 
Day 29. 
Pexa- Vec IT doses  must be given at least [ADDRESS_387779] been confirmed at previous visit.  Refer to 
Section  6.C.2. 
All procedures are the same as P exa-Vec Treatment #1 and #2 ( Day 1 and Day  15), refer to 
Section  7.B.3.a  and Section  7.B.5, respectively .  Patients will be observed in the clinic or hospit al 
for a minimum of 8 hours after IT Pexa- Vec treatment and following evaluations w ill be 
performed:  
CONFIDENTIAL and PROPRIETARY  Page 66 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Complete physical exam (before IT)  
• Vital signs ( blood pressure, temperature, and pulse) within 60 minutes prior to injection to 
establish baseline, 15 minutes (±5 minutes) after injection completion and then every hour 
(±15 minutes) for at least 8 hours after treatment  
• An ultrasound may be optionally per formed to assess suitability of IT injection within selected 
liver lesions and to select lesions for injection  
• Reporting of AEs and concomitant medications  
If an IT treatment is ultimatel y not administered within the protocol -specified window for any 
reaso n, this treatment must be cancelled (i.e., missed for this time point), but the patient should 
resume follow -up visits per the Schedule of Activities. 
 
7.B.8 Arm A :  Visit 6 ( Day 43/Week  6)/ Ar m B: Visit 4  (“Day 43/Week  6”) 
7.B.8.a  Arm A:   Visit 6/Day  43 (Week  6) 
This visit should occur between Day  41 – Day  45.  
Sorafenib should be started 2 weeks  (±2 days) after the last IT injection.   
Arm A patients will complete the following procedures: 
• Symptomatic progression assessments, HRQoL assessments, and pharmacoeconomic 
evaluations (all questionnaires should be completed by [CONTACT_315135] 6 protocol 
assessments/exams):  
 ECOG performance status  
 FACT -Hep questionnaire  
 EQ5D- 3L questionnaire  
 Collection of pharmacoeconomic data through the Health Care Resource Utilization 
questionnaire  
• Complete physical examination including weight and skin assessment  
• Vital signs (blood pressure, temperature, and pulse)  
• Blood sample collection for central labor atory assessment including:  
 Hematology, chemistry and c oagulation  
CONFIDENTIAL and PROPRIETARY  Page 67 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  CD4 and CD8 count  
 AFP 
 Archival serum sample  
• AE and concomitant medication reporting  
• Update patient contact [CONTACT_26500]  
• Sorafenib  initiation :  patient counsel on use and IVRS/IWRS new kit dispensation 
• CT (preferred) or MRI (if CT not possible) (refer to Section  8.C.2).  
 
7.B.8.b  Arm B:   Visit 4/Day  43 (Week  6) 
This visit will occur at Day 43 ±2 days ( between Day 41 and Day 45).  Arm B patients will 
complete the followi ng procedures:  
• Symptomatic progression assessments, HRQoL assessments, and pharmacoeconomic 
evaluations ( all questionnaires should be completed by  [CONTACT_315136]/exams):  
 ECOG performance status  
 FACT -Hep questionnaire  
 EQ5D- 3L ques tionnaire  
 Collection of pharmacoeconomic data through the Health Care Resource Utilization 
questionnaire  
• Complete  physical examination including weight  
• Vital signs (blood pressure, temperature, and pulse)  
• Blood sample collection for central laboratory ass essment including:  
 Hematology, chemistry and c oagulation  
 CD4 and CD8 count  
 AFP 
 Archival serum sample  
CONFIDENTIAL and PROPRIETARY  Page 68 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • AE and concomi tant medication s reporting  
• Update patient contact [CONTACT_26500]  
• Sorafenib: collection of returned medication and IVRS/IWRS new kit dispensation 
• CT (pre ferred) or MRI (if CT not possible) (refer to Section  8.C.2).  
 
7.C FOLLOW -UP PHASE  
7.C.1 Long -Term Follow -Up Visits and Monitoring (Arm A and Arm B)  
7.C.1.a  Every 3 Weeks  ±4 D ays:  Clinical Status Visits  
After Week  6, safety and  clinical status will be assessed every 3 weeks  ±4 days starting from the 
Week  6 visit date  up to the End of Treatment visit.  The following procedures will be performed 
for both Arm A and Arm B patients:  
• Blood sample collection for  central laboratory assessment including:  
 Hematology  and chemistry  
• AEs and concomitant medications  reporting 
• Update patient contact [CONTACT_26500]  
• Sorafenib:  collection of returned medication and IVRS/IWRS new kit dispensation 
 
7.C.1.b Every 6 Weeks  ±7 Days:  Symptomatic , QoL , and Radiographic Sta tus Visits  
After Week  6, radiographic status will be evaluated every 6 weeks  ±7 days starting from the 
Week  6 visit date  up to the End of Treatment Visit .  
Beyond 12 months  of treatment, the evaluation will be performed every 12 weeks .  
Both Arm A and B pa tients will complete the following procedures every 6 weeks  (e.g., every 
other follow -up visit):  
• Symptomatic progression assessments, HRQoL assessments, and pharmacoeconomic 
evaluations  (questionnaires should be completed by [CONTACT_315137]/exams):  
 ECOG performance status  
CONFIDENTIAL and PROPRIETARY  Page 69 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  FACT -Hep questionnaire  
 EQ5D- 3L questionnaire  
 Collection of pharmacoeconomic data through the Health Care Resource Utilization 
questionnaire and the Patient Accommodation and Transport questionnaire  (only at 
Week 12) 
• Blood sample collection for central laboratory assessment including:  
 Hematolog y and  chemistry  
 AFP 
• Complete physical examination including weight and skin assessment for Arm  A patients  
• CT (preferred) or MRI (if CT not possible) (refer to Section  8.C.2)  
• AE and concomitant medication  reporting  
• Update patient contact [CONTACT_26500]  
• Sorafenib:  collection of returned medication and new IVRS/IWRS dispensation 
 
7.D END OF TREATMENT VIS IT (ARM A  AND ARM  B) 
This visit should be  completed as soon as the last Pexa- Vec or sorafenib dose is administered .  The 
following evaluations will be performed:  
• Complete physical examination including weight ( skin assessment in Arm A)  
• Vital signs (blood pressure, temperature, and pulse)  
• Symptom atic progression assessments, HRQoL assessments, and pharmacoeconomic 
evaluations:  
 ECOG performance status  
 FACT -Hep questionnaire  
 EQ5D- 3L questionnaire  
 Collection of pharmacoeconomic data through the Healt h Care Resource Utilization 
questionnaire and the Pa tient Accommodation and Transport questionnaire  
• ECG  
CONFIDENTIAL and PROPRIETARY  Page 70 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Blood sample collection for central laboratory assessment including:  
 Hematology, chemistry and c oagulation  
 CD4 and CD8 count  
 AFP 
 Archival serum sample  
• CT (preferred) or MRI (if CT not possible) (refer t o Section  8.C.2).  
• AE and concomitant medication s reporting  
• Update patient contact [CONTACT_26500]  
 
7.E SAFETY FOLLOW -UP 
This visit should occur not less than [ADDRESS_387780] study drug 
admi nistration (sorafenib or Pexa- Vec).  
The following evaluations will be performed:  
• Complete physical examination including weight (skin assessment in Arm A)  
• Vital signs (blood pressure, temperature, and pulse)  
• Reporting of AE having occurred within [ADDRESS_387781] study treatment administration  
• Reporting of concomitant medications (including potential anti- cancer therapi[INVESTIGATOR_014]) and 
significant non- drug therapi[INVESTIGATOR_6523] [ADDRESS_387782] study drug administration  
• Blood sample collection for centr al laborat ory assessment including:  
 Hematology, chemistry  
 
7.F FOLLOW -UP VISITS FOR  PROGRESSION FREE S URVIVAL  
For patients who complete the study treatment phase prior to documented radiographic 
progression, radiological evaluation should be obtained every 6 weeks  until documented 
progression.  Beyond 12 months , the evaluations will be performed every 12 weeks  until 
documented progression.   
CONFIDENTIAL and PROPRIETARY  Page 71 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 NOTE :  patients undergoing follow -up visits for PFS are still on the active study participation 
phase and may not receive other anti- cancer treatments.  
 
7.G SURVIVAL FOLLOW -UP PHASE  
After the Safety Follow -Up Visit , all patients will be monitored every  month for:  
• Survival  
• Reporting of  anti-cancer therapi[INVESTIGATOR_315046] -up contacts is implicit when patients consent  to study 
participation.  If a patient withdraws consent  from study procedures  (discontinues) , they will 
continue to be contact[CONTACT_315138] -specified survival follow -up unless the patient explicitly 
withdraws consent for survival follow -up.  
Due dil igence should be used in contact [CONTACT_315139]:  
• At least [ADDRESS_387783] attempts and certified letter sent  
• If a patient cannot be directly contact[INVESTIGATOR_530], utilize all contact [CONTACT_315140] g 
• If all contact [CONTACT_315141], death registries should be reviewed  
• These patient contact [CONTACT_315142] [ADDRESS_387784] to follow -up.  Death registry data should be accessed for al l patients 
until the study is completed.  
• If a patient explicitly withdraws conse nt for survival follow -up, or if the site is unable to contact 
[CONTACT_102], other methods to determine survival may be used, including referencing death 
registries, clinic/hosp ital visit records, primary oncologist or physician records, and/or 
newspaper obituaries, in compliance with local regulations.  
 
CONFIDENTIAL and PROPRIETARY  Page 72 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 8 PATIENT MANAGEMENT  
8.A TREATMENTS  
8.A.1 Expected Toxicities  of Pexa -Vec Treatment  
• Flu-Like Symptoms (mild -to-severe fever, rigors, anorexi a, aches/pain, fatigue, 
headache, and/or nausea)  
These flu -like symptoms typi[INVESTIGATOR_315047] 12 hours after Pexa- Vec treatment.  Acute, 
fever is expected within 4 –[ADDRESS_387785] -treatment and has a typi[INVESTIGATOR_129113] 18–[ADDRESS_387786] up to 72 hours. 
• Hypotension  
Across clin ical trials and indications, mild -to-moderate transient hypotension can be observed 
within 24 hours following treatment with Pexa- Vec (21% of all patients as of October  2018).  
However, in the TRAVERSE tri al (Study No. JX594- HEP018) for patients with advanced 2nd line 
HCC, 6  patients (8 total SAEs) have experienced severe hypotension following Pexa- Vec 
treatment, defined as a SBP <90 mmHg, lasting and/or  requiring >[ADDRESS_387787] space fluid accumulation and diur etic therapy as well as conf ounding effects of concurrent 
anti-hypertensive medications administration . 
To mitigate risk of hypotension following Pexa- Vec treatment, the following are required:  
 Prehydration with 1 liter of solute -containing fluid (p.o. or IV) prior to each treatment  
 Suspension of anti -hypertensive medication (including diuretics, beta -blockers, ACE 
inhibitors, aldosterone antagonists, etc.) for 48 hours prior to and 48 hours after each 
Pexa- Vec injection  
 Observation of patients for at least  8 hours following each IT i njection  
CONFIDENTIAL and PROPRIETARY  Page 73 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  For patients with a history of cardiovascular disease, cardiology consultation and creatinine 
clearance must be obtained prior to enrollment.  NOTE:   Patients with active cardiac 
disease within 12 months  of study entry  are excl uded from study participation. 
• Hematological E vents  
Transient decreases in WBC counts (including neutrophils and lymphocytes), platelets and 
hematocrit can occur.  Transient thrombocytopenia (including reduced platelet count) occurred 
within days of  treatment with Pexa-Vec and resolved within 1 week  of treatment without medical 
intervention.  Transient leukopenia (including reduced neutrophil and lymphocyte counts), has 
been observed with resolution generally occurring within 7 days  of treatment.  Leukopenia is a 
common finding associated with viral infection in general.  Conversely, transient leukocytosis 
(including neutrophil, eosinophil, and monocyte subsets) has also been observed.  An elevated 
WBC count is expected based on a GM -CSF mediated ef fect by [CONTACT_315103]- Vec and the infusion of an 
attenuated vaccinia virus.  
• Chemistry C hanges  
Chemistry changes included hyponatremia and hyperglycemia; the relationship to Pexa -Vec 
treatment is not yet known.  Dose -related direct hyperbilirubinemia (due to tumor s welling and 
occlusion of biliary tract drainage) has been noted in patients treated with Pexa- Vec whose liver 
tumors were adjacent to or impeding the biliary tract at baseline.  In addition, acute respi [INVESTIGATOR_315048].  Therefore, patients with liver tumors in a location that would potentially 
result in significant clinical adverse effects if p ost-treatment tumor swelling were to occur, 
including at the site of the common bile duct, should not be included as per  Exclusion Criteria  8.  
Biliary tract drainage should be considered as clinically indicated if biliary occlusion does not 
resolve quickly enough clinically.  Acute post -treatment tumor swellin g can result in 
hyperbilirubinemia within approximately one week following treatment; tu mor swelling may 
resolve over time.  
• Rashes  
Rashes related to latent virus reactivation have been reported, both with Varicella -Zoster (i.e., 
“shingles”) and herpes si mplex virus; whether these rashes are related to Pexa- Vec itself, or due 
to the fever indu ced, is unknown.  Small (<1 cm) superficial skin or oral mucous membrane 
pustules containing Pexa- Vec may develop after Pexa- Vec treatment.   If they develop, it is 
typi[INVESTIGATOR_16195] [ADDRESS_387788] rarely (<10%) been 
seen following IT injection.  These pustules generally resolve within approximately the following 
CONFIDENTIAL and PROPRIETARY  Page 74 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 2–3 weeks , a time course that is consistent with the usual cou rse following intentional vaccination 
with wild -type [non- attenuated] vaccinia vaccine.  All pustules to date have been self -limited and 
resolved without complications or the need for specific anti -viral treatment.  
 
8.A.2 Notable Safety Findings  
• Myocardial Infarct ion and/or Cardiac Ischemia  
On the PHOCUS trial  (Study No. JX594- HEP024), one patient e xperienced a Grade 2  acute 
myocardial infarction (MI) [MCN #2017SLU000230] approximately [ADDRESS_387789] pain diagnosed as stable angina.  Following recovery from the 
angina epi[INVESTIGATOR_315049] -initiated sorafenib , the patient developed unstable angina requiring 
re-hospi[INVESTIGATOR_315050] 6 weeks  after original sorafenib start date.   The Sponsor assessed 
the second epi[INVESTIGATOR_315051] -Vec 
and soraf enib in the patient with significant CAD and previous MI.  Please refer to  the IB for 
further details.  
A second patient who  experienced an MI Grade 3  (MCN  #2018SLU000115)  was a [ADDRESS_387790] that revealed no acute ischemic ECG changes but was 
overall non- diagnostic.  No major cardiac dysfunction was revealed by [CONTACT_315143].  
The patient was cleared for trial participation (understanding the risk of tachycardia and 
hypotension after treatment with Pexa -Vec).  The patient developed tachycardi a following 
Pexa- Vec treatment and prior to the development of chest pain symptoms and subsequent finding 
of elevated troponin blood levels.  Angiogram revealed un derlying CAD including significant 
narrowing of the ostium of one of the diagonal arteries .  These findings and clinical setting were 
CONFIDENTIAL and PROPRIETARY  Page 75 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 thought consistent with demand related MI secondary to tachycardia.  The patient was treated with 
medical therapy (atorvas tatin and aspi[INVESTIGATOR_248]) for underlying CAD with discharge after an 
uncomplicated post -MI clinic al course.  The Investigator assessed the causal relationship of 
deviated troponin level to investigational product Pexa -Vec as possibly related, and the Sponsor 
agreed with the Investigator’s assessment.  
The analysis of cardiac events demonstrated an inci dence rate of under 1% of MI following 
treatment with Pexa -Vec across all indications which is relatively stable since the prior report of 
myocardial ischemia (MCN  #2017SLU000230)  
Close monitoring of clinical trials for any cardiac toxicity including cardia c ischemia/MI will be 
continued.  Further , as outlined in Section  6.B, Exclusion Criteria , patients with  significant current 
or past cardiovascular disease are excluded from the study unless cardiology consulta tion and 
clearance has been obtained for study part icipation.  Additionally, patients with symptomatic 
cardiovascular disease within the preceding [ADDRESS_387791] medical risk in t he event of volume load, tachycardia, and/or 
hypotension during or following Pexa -Vec treatment are excluded from the study.   To increase the 
rigor of cardiology evaluation prior to study entry, independent, central cardiology review will be 
required for p atients who undergo local, pre -study cardiolo gy screening prior to enrollment in 
studies of Pexa -Vec to ensure a consistent approach to evaluation of potential study candidates.  
In the case of a suspected myocardial ischemia, cardiology consultation should be arranged and 
cardiac work up including an giography, echocardiography, electrocardiogram, and cardiac 
enzymes (e.g., cardiac troponin) should be performed, as clinically indicated. 
• Portal Vein Thrombosis  
One patient  has experienced acute portal vein thr ombosis (PVT) in JX594 -HEP024.  The patient 
experienced abdominal pain, abdominal distension, headache , and tonsillitis 
(MCN  #2017SLU000212).  The patient had significant thrombosis of the portal vein at baseline 
and was diagnosed with acute PVT 5 days fol lowing the second Pexa -Vec inje ction.  The same 
patient has subsequently developed liver rupture, Grade 3 (PT: tumor rupture, MCN 
#2017SLU000235) after approximately a 3- week course of sorafenib treatment assessed as related 
to Pexa -Vec by [CONTACT_315144] a rapid HCC progression by [CONTACT_941] S ponsor.  
Despi[INVESTIGATOR_315052], the Investigator concluded that the causal relationship of 
Pexa- Vec and acute PVT could not be completely ruled out and the Sponsor agreed with that 
assessm ent.  Notably, PVT is a common finding in patients with advanced HCC which is observed 
CONFIDENTIAL and PROPRIETARY  Page 76 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 in ~10− 60% of HCC patients according the literature reported data ( Catalano 2010; Quirk  2015; 
Chan 2016;  etc.).   
 
8.A.3 Risks Linked to IT  Injection P rocedure 
At the tumor or  skin injection th e following toxicities may be observed (r efer to the IB for further  
details on patient management) : 
• pain at the injection site,  
• general reactions (e.g. , vasovagal reaction, hypotension, bradycardia, pyrexia, anxie ty, nausea, 
vomiting, dia rrhea), 
• anesthetic reactions,  
• prolonged bleeding from the injection site or internal bleeding (e.g., subcapsular liver 
hematoma, hemoper itoneum, hemothorax, hemobilia), 
• infection at the injection site that may cause sepsis and other infections (e.g. , septi cemi a 
peritonitis , perihepatic abscess , pneumonia ), 
• hepatic encephalopathy,  
• ascites,  
• puncture of other organs (e.g., pleural effusion, pneumothorax), 
• fluctuat ions of biological parameters: anemia, transient  bilirubin and transaminases increases, 
creatinine incr ease.  
 
8.A.4 Concomitant Authorized and Contraindicated Treatments  
8.A.4.a  Definitions  and R eporting of C oncomitant M edication and N on-Drug Therapy  
Concomitant medications or significant non- drug therapi[INVESTIGATOR_014] ( therapeutic intervention [ e.g., surgery, 
blood transfusion] ) will be reported within the month before start of study treatment up to [ADDRESS_387792] dose of Pexa- Vec or sorafenib.  
All medic ations (International Nonproprietary Names  [INN] ), dosage, route of a dministration , 
frequency, duration of administra tion, and the indication will be recorded in the appropriate 
sections of the eCRF.  
CONFIDENTIAL and PROPRIETARY  Page 77 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387793] be made in the 
appropriate section of the eCRF. 
 
8.A.4.b Concomitant Authorized & Contra indicated Treatments  
8.A.4.b.1 Recommended Medications Related to F lu-like Symptoms (mild -to-severe fever, rigors, 
anorexia, aches/pain, fatigue, headache, and/or nausea)  – Arm  A 
Pre-Medication for Treatment Day  
Patients should receive approximate ly 1 liter of solute -containing fluids (e.g., normal saline) IV or 
orally within 12 hours of treatment initiation.  
All patients should be pre -medicated with acetaminophen ( and/or equivalent , e.g., NSAIDs , unless 
contrain dicated) on each treatment day.  For acetaminophen, the following regimen may be used:  
• 500–1000 mg 2 hours pre -infusion  
• 500–[ADDRESS_387794] -procedure  
• 500–1000 mg every 6 hours thereafter, as needed (the total acetaminophen dose should be 
carefully assessed to avoid cumulative toxici ty) 
 
Acute Post -Treatment Symptom Management  
During the observation period post -treatment, patients should receive IV solute -containing fluid 
and other measures (e.g., vasopressor therapy) per SOC  as needed for blood pressure support.  
Anti-rigor medicatio n (e.g., meperidine) or support medications m ay be used as needed.  
Anti-emetics may be used at the Investigator’s discretion for treatment of nausea or vomiting; it is 
noted, however, that corticosteroids should not be used. 
Analgesics, anti -pyretics (e.g. , prophylactic acetaminophen), antidepressant s, bisphosphonates, 
EPO growth factors and other supportive care measures may be used at the Investigator’s 
discretion. 
 
CONFIDENTIAL and PROPRIETARY  Page 78 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 8.A.4.b.2 Management of H ypotension and C ontraindicated T reatments  - Arm A  
To mitigate risk of hypot ensio n following Pexa- Vec treatment, the following are required:  
• Prehydration with 1 liter of solute -containing fluid (p.o. or IV) prior to each treatment  
• Suspension of anti -hypertensive medication  for 48 hours prior to and 48 hours after all 
Pexa- Vec trea tments  
• Anti-hypertensive medications include, but are not limited to, the following:  
 Diuretics  
 Beta-blockers  
 ACE inhibitors  
 Aldosterone agonists  
 
8.A.4.b.[ADDRESS_387795] Vaccinia Viruses  - Arm A  
In the extremely unlikely case of g eneralized vaccinia virus  infection, encephalitis or another 
clinically -significant, progressive toxicity that, in the opi[INVESTIGATOR_315053]- Vec replication, Investigators may consider the use of agents with vaccinia inhibito ry 
activity, if available  in their country for such clinical use.  Such agents may include  anti-vaccinia 
immune globulin (VIG), cidofovir, and/or Arestvyr ([LOCATION_003]N tecovirimat; ST -246).  In addition, 
based on limited preclinical data, interferon, ribavirin, a nd sorafenib may have ant i-vaccinia 
activity.  For clarity, no ne of these agents have been used or approved for this purpose to date.  
Since these agents have not been used in Pexa- Vec treated patients to date, clinical judgment 
should be used when determi ning the optimal regimen and duration of treatment.  
The availability of these or similar antiviral products is country -dependent; options will be 
investigated and a plan for a response to infection- related toxicities will be documented and 
communicated to  stud y staff prior to ini tiation of the clinical trial.  
 
8.A.4.b.4 Contraindicated A ntiviral T herapy Shown to I nhibit V accinia R eplication  
• Cidofovir (except to treat toxicities potentially related to uncontrolled Pexa- Vec replication)  
• Interferon/PEG -interferon , ribavirin (see also Exclusion C riteria 18)  
 
CONFIDENTIAL and PROPRIETARY  Page 79 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 8.A.4.b.5 Other Contraindicated T reatments  
• Anti-cancer  therapy once a patient has been randomized  
• High dose systemic corticosteroids (defined as ≥20 mg/day prednisone or equivalent which is 
ongoing at the time of arm allocati on and/or was taken for more than 4 weeks within the 
preceding 2 months  of randomization) or other immunosuppressive medications (Arm A)  
• Anti-coagulation or anti -platelet medication that cannot be interrupted prior to IT injections 
(Arm A), including:  
 Aspi[INVESTIGATOR_315043] 7 days  prior to treatment  
 Coumadin that cannot be discontinued for 7 days  prior to treatment  
 LMWH th at cannot be discontinued >24 hours prior to treatment and UFH that cannot be 
discontinued >4 hours prior to treatment (LMWH  or UFH may be used to transition 
patients on and off the above anti -coagulants, if deemed appropriate by [CONTACT_30780]) pr ior to Pexa- Vec treatments as long as the last dose of LMWH is administered 
24 hours prior to treatments and the las t dose o f UFH is administered > 4 hours prior to 
treatments)  
 Oral direct thrombin inhibitor (dabigatran) or direct Factor Xa inhibitor (rivar oxaban, 
api[INVESTIGATOR_106757], and endoxaban) that cannot be discontinued for 4 days  prior to treatments  
 
8.A.4.b.6 Other A uthorized C oncomitant T reatments  
• thrombopoietin, erythropoietin, G -CSF 
• antidepressants  
• steroids ( NOTE :  oral or parenteral steroids are not allowed during t he Pexa -Vec treatment 
period, and for 1 week  prior to and 2 weeks  after Pexa- Vec treatment)  
• topi[INVESTIGATOR_315054] -foot skin reaction and rash related to sorafenib  
• biphosphonates, vitamin B12 and vitamin D   
• Hepatitis B antivirals are ALLOWED as DO NOT inhibit vaccinia virus replication: 
lamivudine, adefovir (and adefovir dipi[INVESTIGATOR_315055]), telbivudine , tenofovir, emtricitabine, 
clevudine and entecavir.  The ability of combinations of these agents to inhibit vaccinia virus 
CONFIDENTIAL and PROPRIETARY  Page 80 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 replicat ion has however not been evaluated.  Therefore, combination therapy with anti -viral 
agents should be avoided if at all possi ble. 
NOTES : 
• Please contact [CONTACT_315145], 
anticoagulant, antihypertensive, or antiviral medications prior to treatments.  
• Sites will be notified as additional information regarding allowed and c ontra indicated antivirals 
becomes available  
 
8.A.5 Potential Mechanisms of Pexa -Vec Shedding to the Environment , Biodisseminat ion 
and Prevention of Transmission  
8.A.5.a  Superficial Skin Pustules  
As mentioned in Section  8.A.1, small (<1  cm) superficial skin or oral mucous membrane pustules 
containing Pexa- Vec may develop after Pexa- Vec treatment.   If pustules develop, they do so  
typi[INVESTIGATOR_16195] [ADDRESS_387796] administration .  These pustules generally resolve within 
approxi mately the following 2 –3 weeks , a time course that is consistent with the usual course 
following intentional vaccination with wild -type (non-attenuated ) vaccinia vaccine.   All pustules 
to date have been self -limited and resolved without complications or th e need for specific anti -
viral treatment.  
Since these pustules contain Pexa- Vec they should be managed as per  the “Recommendations for 
Pexa -Vec Handling and P atient M anagement ” (Appendix B  of the IB ).  
The following steps should be carried out in the event  of skin or oral mucosa pustule identification  
(patient or patient contact, which is unexpected) : 
1. Record the AE (event term for Pexa- Vec related pustules must be recorded as 
“papularpustular rash”).  
2. Instruct the patient/contact [CONTACT_315146] w ith non- occlusive dressing (or wear a mask 
when around other people if oral lesions are present) .  Refer to  the “Recommendations for 
Pexa -Vec Handling and Patient Management ” (Appendix B of the IB)  for further 
instructions . 
 
CONFIDENTIAL and PROPRIETARY  Page 81 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 8.A.5.b Urine, Feces, Blood, Throa t and /or Saliva  
Testing for the presence of Pexa- Vec after patient treatment has been conducted in several clinical 
studies in throat swabs, urine, feces , and blood samples.  
Refer to the current Pexa- Vec IB for available data on shedding and to  the “Pexa- Vec Guidelines ” 
for recommendations on the care of Pexa- Vec treated patients .  No person- to-person transmission 
of Pexa- Vec has been reported.  
 
8.A.[ADDRESS_387797] common adverse reactions observed with soraf enib are diarrhea, 
rash, alopecia and hand -foot syndrome (corresponds to palmar plantar erythrodysaesthesia 
syndrome in Medical Dictionary for Regulatory Activities [ MedDRA ]). 
For further details on sorafenib toxicities, please r efer to the registered  SmPC .  
 
8.B SAFETY , CLINICAL , DEMOGRAPHY,  AND DIAGNOSIS  ASSESSMENTS   
The following parameters will be evaluated during the course of the study : 
• Inclusion/Exclusion criteria:  patient eligibility by [CONTACT_315147]/exclusion criter ia.  Violation of any entry criterion excludes a patient from 
enrol lment into the study.   If violation is discovered after enrol lment, the patient may  be 
discontinued. 
• Demography:  Date of birth  (in countries where complete date of birth is not permitted, this 
will be de -identified as required) , gender, race, ethnicity, childbearing  potential status  
• History of studied disease including but not restricted to date of diagnosis and stage at 
diagnosis, histology  and prior HCC therapy  
• BCLC and CLIP scoring 
• Pre-treatment biopsy if no histological diagnosis is present in medical file  
• Occurrence of AEs /SAEs  (refer to Section  11) 
• Concomitant medications and significant non- drug therapi[INVESTIGATOR_315056]  
• Clinical laboratory eval uations:  
CONFIDENTIAL and PROPRIETARY  Page 82 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  HIV and HCV serology; detection of antigen HBs at Baseline (approximately 15 mL of 
blood)  
 Standard serum chemistry panel : sodium, potassium, chloride, CO2 content, blood urea 
nitrogen (BUN), creatinine, random glucose, total bilirubin, ALT, A ST, calcium, lactate 
dehydrogenase (LDH), total protein, albumin (approximately 5  mL of blood)  
 Hematology : complete blood count ( CBC ) with differential and platelet count 
(approximately 5 mL of blood)  
 Coagulation: partial thromboplastin time ( PTT) , prothrombin  time/international 
normalized ratio ( PT/INR ) (approximately 5 mL of blood)  
 CD4 and CD8 counts  (approximately 5 mL of blood)  
 AFP (approximately 5 mL of blood)  
 Blood pregnancy test at screening (approximately 5 mL of blood) and urinary pregnancy 
test at Bas eline (for women of childbearing potential)  
 Standard urinalysis ( Screening  only)  
• Physical examinations  of the major organ system including skin assessment in Arm  A patients 
(after Pexa- Vec treatment has been initiated ), weight  and vital signs ( blood pressure, pulse and 
temperature).  Height will be collected at Baseline . 
• Performance status  on the ECOG scale  
 
8.C EFFICACY ASSESSMENTS  
8.C.1 Biomarker /Immune  Assessments  
Archival serum sample  (10 mL of blood will be collected to prepare the serum sample) : further 
immune analysis including analysis of soluble mediators , cell populations , immunophenotypi[INVESTIGATOR_007], 
enzyme -linked immunosorbent assay (ELISA), CDC assay may be performed. 
 
8.C.2 Imaging Data Acqu isition and Evaluations  
8.C.2.a  Imaging Data Acquisition  
All patients  (Arm A and Arm B) will undergo imaging of the chest, abdomen , and pelvis using 
helical/spi[INVESTIGATOR_315023]- enhanced CT scanning (preferentially) or MRI with non- contrast CT of the 
CONFIDENTIAL and PROPRIETARY  Page 83 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387798] at Screening .  Tumors will be numbered with a unique number and identified as Target or 
Non-Targ et tumors  (refer to the  next paragraph for definitions) .  Tumors should be assigned the 
next available chronological number wherever possible.  
Collection of radiographic imaging scans  will then occur at Week  6 (±2 day window) and continue 
thereafter every  6 weeks  (±7 days)  for as long as the patient remains on sorafenib therapy.  
Beyond 12 months  of treatment, the evaluations will be performed every 12  weeks.  
If a patient discontinues the treatment phase prior to documented radiographic progression (e.g. 
permanently stops taking the study medication) , PFS Follow -up Visits will be performed every 
6 weeks for radiology evaluation until documented radiographic progression or until premature 
study discontinuation.  
Imaging studies will continue  after radio graphic progression has been documented as long as the 
patient continues to receive sorafenib therapy on -study .  
Specific imaging acquisition instructions are  provided in the Imaging Manual provided by [CONTACT_315148] . 
Preferred Modality :  Triphasic helical/spi[INVESTIGATOR_315057] (pre -contrast, arterial phase, and 
portal venous phase; delayed imaging of the abdomen is optional) and post -contrast helical/spi[INVESTIGATOR_315058].  All follow -up scans must also be CT.  If a CT IV contra st allergy 
(toxicity) develops after the patient has been randomized, then a DCE  MRI  of the abdomen and 
pelvis with gadolinium contrast will be required along with a non- contrast CT of the chest.  
Alternative Modality :  While triphasic CT remains the prefer red modality for the abdomen, if a 
patient is unable to undergo triphasic CT due to iodinated contrast allergy, then Dynamic Contrast 
Enhanced Magnetic Resonance Imaging ( DCE MRI ) of the abdomen and pelvis with gadolini um 
contrast will be required along wi th a non-contrast CT of the chest.   The abdominal MRI will be 
triphasic in nature, and the pelvic MRI will be performed following MRI of the abdomen.  If an 
MRI is performed at screening, all follow -up scans must also be DCE MRI of the abdomen and 
pelvis w ith gadolinium contrast with a non- contrast CT of the chest.  
The same method of assessment and the same technique should be used to assess each identified 
and reported lesion for the radiological baseline (screening CT /MRI) and each follow up scan 
collect ed during the study . 
 
CONFIDENTIAL and PROPRIETARY  Page 84 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387799] version 1.1 (Eisenhauer  2009) .  If the site reader 
determines that radiographic PD has occurred, the patient will be considered to have progressed 
radiographicall y.  
In addition, independent central efficacy reads of the images will be performed in a blinded manner 
with both mRECIST for HCC and RECIST 1.1, by a group of expert radiologists :  2 primary 
readers and 1 reader who acts as the adjudicator of differences betw een the 2 primary readers  (in 
the case of a disagreement about the date of progression or overall response) .  
Modifications to the standard RECIST criteria were proposed for patients with HCC.  This is due 
to a poor correlation between RECIST responses  (i.e., based solely on changes in tumor size), to 
molecularly targeted agents as well as locoregional therapy, an d clinical benefit ( Forner  2009; 
Llovet  2008a; Lencioni  2010) .  Definitions and methodology indicated hereafter are based on 
RECIST 1.1.  For the central imaging process (exploratory objectives), mRECIST methodology 
will be described within the Imaging C harter.  
Regarding the study objectives, secondary endpoints will be based on central review according to 
central mRECIST for HCC and exploratory  endpoints will be based on measurements according 
to both local and central RECIST 1.1.  
 
8.C.2.b.1 Measurability of T umor  
All measurements should be recorded in metric notation (mm) .  The radiological baseline will be 
defined according to the screening CT/MRI  and tumor  lesions/lymph nodes will be categorized as 
measurable (Target lesions) or non -measurable (Non -Target lesions) .  Lymph nodes that have a 
short axis < 10 mm at Baseline are considered non -pathologica l and should not be recorded or 
followed.  If no measur able lesions are identified at B aseline, the patient will not be allowed to 
enter the study.  
For tumor lesions :  the LD in the plane of measurement has to be recorded with a minimum size 
of [ADDRESS_387800] scan slice thickness is no greater than 5  mm.  
For nodal lesions :  at Baseline and in the follow -up, only the short axis of lymph node will be 
measured and followed.  To be considered pathologically enlarged and mea surable, a lymph node 
must b e >15 mm in short axis when assessed at B aseline.  
 
CONFIDENTIAL and PROPRIETARY  Page 85 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 8.C.2.b.2 Non- Meas urable Lesions  
Non-measurable lesions are defined as all other lesions present at baseline, including sm all lesions 
(longest diameter <10 mm or pathological lymph node with ≥10  mm to < 15 mm short axis) as well 
as truly non measurable lesions. 
 
8.C.2.b.3 Target /  Non Target Tumors  
Each lesion reported must be uniquely and sequentially numbered on the eCRF, even if it resides 
in the same organ, from baseline and throughout the study.  For the evaluation of lesions at baseline 
and throughout the study, the lesions a re classified as target and non -target lesions.  
Target Tumors:   Target tumors should be selected on the basis of their size (tumors with the LD 
which are able to be reproducibly measured across time points) and are preferred to be within the 
liver.   Howeve r, target tumors may be selected outside of the liver.  Up to a maximum of 5 tumors  
total, and a maximum of 2 tumors per organ (except for the liver  where 5 tumors can be selected 
as non- target for the purpose of this trial ), representative of all involved  organs will be identified 
as target tumors and will be recorded and measured at baseline by [CONTACT_315149].  
Selection of tumors outside the liver is subjec t to Sponsor’s approval.  
All post -baseline measurements must be performed using the same tumors and  methods as the 
baseline assessment.  
Response assessments for target tumors are defined as:  
• Complete Response (CR):   Disappearance of all target tumors.  Any pathological lymph nodes 
(whether target or non -target) must have reduction in short axis to <10 m m. 
• Partial Response (PR):   At least 30% decrease in the SLD of target tumors, taking as reference 
the baseline SLD of target tumors. 
• Progressive Disease (PD) :  Radiographic tumor progression for target tumors requires an 
increases in the SLD of target tumo rs of at least 20% taking as reference the smallest sum of 
diameters of target tumors recorded since the treatment started (this includes the baseline sum 
if that is the smallest on study).  
• Stable Disease (SD):   Neither sufficient shrinkage to qualify for  PR, nor sufficient increase to 
qualify for PD , taking as reference the smallest SLD while on study (including B aseline).  
Contingent upon minimum duration of 6  weeks from enrollment. 
CONFIDENTIAL and PROPRIETARY  Page 86 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Non-Evaluable (NE):   Progression has not been documented and one or more  target lesions 
have not been assessed or have been assessed using a different method than baseline.  Rules 
for selecting non -evaluable include the following: 
1. All target tumors are not evaluable.  
2. Or, if at least 1 target tumor is not evaluable, the targ et tumor SLD is still calculated 
using the remaining evaluable/measurable target tumors.  The only acceptable 
assessment in this situation is pr ogressive disease or non- evaluable.   If the SLD of 
target tumor has increased at least 20% from nadir (inclu ding Baseline if it is the nadir) 
then the response is PD .  Any other calculated result gives an assessment of non -
evaluable.  
NOTE : SLD = sum of the LDs of viable enhancing hepatic t arget tumors plus LDs of any non-
nodal extrahepatic target tumors plus the  short axis diameters of any nodal target 
tumors will be calculated.  
 
Non-Target Tumors:   All other lesions, including pathological lymph nodes, are considered non -
target lesions.   Measurements of these lesions are not required and these lesions should be foll owed 
as “present”, “absent”, “worsening” or in rare cases “unequivocal progression” (as defined in the 
below note) throughout the study.  Multiple non- target lesions involving the same organ can be 
assessed as a group and recorded as a single item (i.e., m ultiple enlarged pelvic lymph nodes ).  
Each non -target lesion identified at Baseline should be assessed at each sub sequent evaluation and 
be recorded in the eCRF.  
Furthermore, for the purposes of this trial, special assessments are recommended for the following: 
• Malignant portal vein thrombosis should be considered a non- measurable tumor due to the 
difficulty of perfo rming reliable repeat measurements of a malignant thrombus.  
• Porta hepatis lymph node can be considered as malignant if the lymph node short a xis is at 
least 20 mm.  
• Ascites, pleural effusion, and pericardial effusion:   these may not be used to assess response 
as non- target tumors, nor may they be selected as evidence of new disease as radiographic 
progression.  They may not be used due to t he incidence of therapeutic fluid removal and 
benign occurrence of these fluid collections which makes them unreliable as a marker of 
disease evolution.  
CONFIDENTIAL and PROPRIETARY  Page 87 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Response assessments for non -target tumors are defined as:  
• Complete Response (CR):   Disappearance of al l non- target tumors.   All lymph nodes must be 
non-pathological in size (<10 mm short axis) . 
• Incomplete Response / Stabl e Disease (SD):   Neither CR nor PD  
• Progressive Disease (PD):   Unequivocal progression of existing non- target tumors  
• Non-Evaluable (NE):   Progression has not been documented and one or more non- target 
lesions have not been assessed or have been assessed us ing a different method than baseline 
not allowing a reliable comparison.  
Rules for selecting non -evaluable for non -target tumors include the following:  
1. All non- target tumors are not evaluable.  
2. Or, if at least 1 non- target tumor is not evaluable and no other non- target tumor 
demonstrates unequivocal progression, the assessment is “NE”  
3. If at least [ADDRESS_387801] 1 other non- target tumor 
demonstrates unequivocal progression, the assessment is “unequivoc al progression.”  
NOTE:  To achieve “unequivocal progression” on the basis of the non- target disease, there must 
be an overall level of substantially wors ening in non- target disease such that, even in 
the presence of CR, PR , or SD in target disease, the over all tumor burden has increased 
sufficiently to merit discontinuation of therapy.   A “modest” increase in the size of one 
or more non- target lesions is u sually not sufficient to qualify for unequivocal 
progression status.  The designation of progression sol ely on the basis of change in 
non-target disease in the face of CR, PR , or SD of target disease will therefore be 
extremely rare.  
 
8.C.2.b.4 New Tumors:  
The appearan ce of new lesion is always associated with PD.  A lesion identified on a follow -up 
assessment in an anatomical location that was not scanned at baseline is also considered a new 
lesion.  If a new lesion is equivocal, for example because of its small si ze, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease.   If at t he next scheduled 
assessment, PD is confirmed, the date of progression would be the earlier date when PD was 
suspected.  
CONFIDENTIAL and PROPRIETARY  Page 88 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 New Tumor Progressive Disease (P D):  If a newly detected lesion is obviously a tumor, 
progression criteria is met at the current time po int.  The evaluation of overall response at each 
assessment is a composite of the target lesions response, non- target lesions response and presence 
of new lesions as shown below. 
 
Table  2: 
Overall Response Assessment in RECIST 1.11 
Target Tumors  Non-Target Tumors  New 
Tumors  Overall Re sponse  
CR CR No CR2 
CR Non-CR/non -PD No PR 
CR Non-PD or not all evaluated No PR 
PR Non-PD or not al l evaluated  No PR2 
SD Non-PD or not all evaluated  No SD2,3 
Not all evaluated  Non-PD No NE1 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
1 Responses for all possible combinations of tumor responses in target and non-target lesions with o r without the 
appearance of new lesions  
2 this overall lesion response also applies when there are no non-target lesions identified at baseline.  
3 once confirmed PR is achieved, all these assessments are considered PR.  
CR = complete response; PR  = partial response; SD  = stable disease; PD = progressive disease; NE  = non evaluable  
 
If no non- target lesions are identified at baseline, the non -target lesion response at each assessment 
will be considered “not applicable” (NA).  
In some circumstances, it may be difficult to distinguish residual disease from normal tissue.  
When the evaluation of CR depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspi[INVESTIGATOR_337] / biopsy) to confirm C R.  It may be sometimes 
reasonabl e to incorporate Fluorodeoxyglucose Positron Emission Tomography (FDG -PET) 
scanning to complement CT in assessment of progression (especially in case of possible “new” 
lesion) or in case where a residual radiographic abnorm ality is thought to represent fibrosi s or 
scarring.  
For equivocal findings of PD (e.g., very small and uncertain new lesions, cystic changes or necrosis 
in existing lesions) treatment may continue until the next scheduled assessment.  
CONFIDENTIAL and PROPRIETARY  Page 89 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  
8.D SYMPTOMATIC AND QUALI TY OF LIFE ASSESSMENTS  
Patient -Reported Outcomes (PROs), defined as report of the status of patient's health condition 
that comes directly from the patient, will be recorded to assess HRQoL.  HRQoL will take into 
account the patient's subjective perception of the treatment ( Pexa- Vec follo wed by [CONTACT_315150]) and the impact of HCC on their life.  Generic and disease- specific measures are 
essential to provide a comprehensive pi[INVESTIGATOR_315059].  
The FACT -Hep is a [ADDRESS_387802] -General (FACT -G), which assesses generic HRQoL 
concerns using [ADDRESS_387803] Hepatobiliary Symptom Index  8 (FHSI -8), will be used to assess 
symptomatic progression.   A decrease of 4  points or more from Baseline FHSI -8 is considered as 
symptoma tic progression.  ECOG performance status  will also be assessed by [CONTACT_315151]; a decrease in ECOG performance status  to 4 or death is 
considered symptomatic progression.  
The EQ -5D-3L, a generic, preference- based measure questionnaire will be used for PRO 
meas urement to  assess utility  (Herdman  2011; Scalone  2013) . 
All questionnaires (except ECOG performance status ) should be completed  by [CONTACT_102] .  Once 
done, a person (this person is often a nurse in outpatient or inpatient care, e.g., trial nurse or clinic al 
researcher) will  check all questions are answered.  Patients should not be shown their previous 
responses.  All questionnaires will be completed by [CONTACT_314673], at Week  [ADDRESS_387804] -effectiveness of Pexa- Vec followed by [CONTACT_315152].  Detailed costs will be collected during the Phase  3 trial using data entered in 
eCRF , hospi[INVESTIGATOR_315025], pharmacy worksheet data and 2 other questionnaires:   “health care 
resource utilization” and “patient accommodation and transport” derived from CSRI 
(Beecham  2001) .  
CONFIDENTIAL and PROPRIETARY  Page 90 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 The questionnaire “health care resource utilization” is designed to capture direct -medical costs 
non-documented neither in the CRF nor in hospi[INVESTIGATOR_315025].  The questionnaire will be complete d 
by [CONTACT_315090], W eek 6, and then every 6 weeks  until 
end of treatment visit.  Beyond 12 months of treatment, the questionnaires should be completed 
every 12 weeks  until end of treatment visit.  
The “patient a ccommodation and transport” covers all expenses related to indirect -medical costs.   
The questionnaire will be completed by [CONTACT_315090] , 
at Week  12, and at the E nd of T reatment V isit.  
Utility values collecte d throughout the study  with EQ 5D-3L questionnaire will also be assessed to 
produce  generic measure s for economic appraisal.    
CONFIDENTIAL and PROPRIETARY  Page 91 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387805] or caregivers has not been documented to date.  Nev ertheless, the 
following guidelines should be considered as also noted in the current Pexa- Vec IB and Pexa- Vec 
Guidelines  (Appendix B of the IB), to minimize the risk of potential transmission and to manage 
infected individuals should an unexpected transmi ssion occur.  
 
9.A EXPOSURE TO PEXA -VEC 
If an accidental human exposure to Pexa- Vec occurs, no specific interventions other than local 
wound care, as needed, and close observa tion are indicated.   Specifically, the following is 
recommended:  
1. Implementation of l ocal, institutional needle stick, or other exposure guidelines.  
2. Wash area thoroughly with soap and water.  
3. Cover area with non- occlusive dressing until complete re solution. 
4. Report the event to the Principal Investigator, the institution’s Biosafe ty Specialist, and/or 
physician knowledgeable in the care of individuals experienced with vaccinia infection.  
Record and report the event to the  Sponsor  by [CONTACT_315153] d submitting a Report of 
Exposure to Infectious Material  form as indicated on the r eport form . 
 
9.B CONTACTS EXHIBITING SYMPTOMS OF VIRAL IN FECTION  
If a contact [CONTACT_4007] a patient treated with Pexa- Vec reports symptoms of a possible Pexa- Vec related 
toxicity: 
1. Immediately notify the institution’s Biosafety  Specialist  
2. The individual should be re ferred to and medically monitored by a physician knowledgeable 
in the care and treatment of patients with vaccinia infections  
3. Report the event to the Sponsor  by [CONTACT_315154] a Report of Possible Pexa -Vec 
Toxicity  form.   Follow all instructions on the form regarding avoidance of e xcluded  
individuals , consideration (in conjunction with consultation with infectious diseases expert 
and the Sponsor ) of antivi ral treatment if warranted (refer to Section  8.A.3 ), obtaining 
clinical samples  if applicable , monitoring the individual for response to treatment (if any) , 
and resolution of symptoms. 
CONFIDENTIAL and PROPRIETARY  Page 92 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387806] S (IP)  
Pexa- Vec is in development  for an advanced HCC patient population in sequential combi nation 
with sorafenib (SOC).  Therefore , in this study Pexa- Vec and sorafenib are considered as 
Investigational Product  (IP).  
Pexa- Vec and sorafenib are provided free of charge by [CONTACT_1034] .  The Investigator /Pharmacist  
will not supply IP to any patient  not randomized in the study, nor to any physicians or scientis ts 
who are not  designated as s ub-Investigators.  The Investigator must ensure that patients receive IP 
only from personnel who fully understand the procedures for dosing and administering the dru gs. 
 
10.A PEXA -VEC ( JX-594) 
10.A.1 Nomenclature of Pexa -Vec 
• Sponsor  code designation:  Pexa- Vec; VACC -6.25.1 
• Synonyms:   Recombinant Vaccinia/ GM-CSF (VAC -6.25.1 [ GM-CSF1]),  
VAC GM -CSF 
Vaccinia/ GM-CSF (Pexa- Vec) 
• Generic Name:   [CONTACT_315201] -CSF; RAC VAC GM -CSF (thymidine kinase -
deactivated plus GM -CSF) 
Pexa- Vec is provided with a t echnical s heet detailing its characteristics.  
 
10.A.2 Pharmaceutical F orm of Pexa -Vec 
Pexa- Vec is a viral suspension supplied in individual 4- mL glass vials.   Each vial contains 
Pexa- Vec diluted in 30 mM Tris 10% Sucrose buffer.  The recoverable volume of Pexa- Vec in 
each vial is 2 mL with an infectious titer of 1 ×  109 pfu (9.0 Log pfu).  Each vial is intended for 
single use (i.e., 1 injection to 1 patient). 
 
10.A.[ADDRESS_387807] box (secondary packaging ) which constitutes a Pexa -Vec 
treatment kit (1 -vial treatment kit).  
CONFIDENTIAL and PROPRIETARY  Page 93 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387808] boxes are in the 
language of countries whe re the study is to be performed.  Labels are compliant with local 
regulatory requirements and contain information including, but not l imited to:  Sponsor name, 
product code, lot number, concentration, volume, storage conditions, route of administration and 
a cautionary statement in proper language.   
 
10.A.4 Biosafety/Containment Level Classification of Pexa -Vec 
Depending on the countr y, Pexa- Vec is classified a Biosafety /Containment  Level 1 or Level 2  
infectious substance .  All applicable  infection control policie s should be consulted and followed.  
Refer to the current Pexa- Vec IB and Pexa- Vec Guidelines (Appendix B of the IB) for 
recommendations on handling Pexa- Vec and for management of  Arm A patients treated with 
Pexa- Vec, as well as for any Arm A p atients who develop Pexa- Vec-related pustules . 
 
10.A.5 Transport of Pexa -Vec 
10.A.5.a  Interstate and International Transport  
Pexa- Vec is shipped on dry -ice with the official transport designation as a “Biological Substance, 
Category B” in compliance with International Air Transportation Association and Department of 
Transportation regulations and other local regulations  for air and road  transport of infectious 
substances (UN 3373 regulations) . 
 
10.A.5.b Drug Receipt and Approval of Shipment  
The supply  of Pexa- Vec is  managed automatically using an IVRS/IWRS .  
Detailed information on drug receipt instructions and approval of shipment process are provided 
in the Product Handling Manual .  
 
10.A.5.c  Transport within the Institution  
All transport of Pexa- Vec (in vial, IV bag or syringe containing the dose to b e administered) within 
the institution must be done using a leak -proof container/bag clearly -marked with a biohazard 
symbol.  
 
CONFIDENTIAL and PROPRIETARY  Page 94 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387809] be stored at or below –60°C  in an alarmed, temperature- monitored, secure freezer 
with restricted  access.  Detailed information on drug storage requirements and temperature 
excursions management are provided in the Product Handling Manual.  
 
10.A.7 Dispensing  of Pexa -Vec 
On either the day of Pexa- Vec treatment or the day before, site personnel will access IV RS/IWRS 
to obtain kit number assignment for Pex a-Vec treatment.   
Pexa- Vec will be dispensed only with the written authorization of the Investigator or a s ub-
Investigator to staff that have been specifically designated and trained for this study.  
Please ref er to site user guide for IVRS/IWRS and the Product Handling Manual for detailed 
instructions. 
 
10.A.8 Handling of Pexa -Vec 
All applicable  institutional policies for preparation, transport, and disposal of viral vectors should 
be consulted and followed.  During a ll Pexa- Vec manipulations gloves, gown, surgical mask and 
goggles (or safety glasses with side shields ) must be worn.  Headgear and overshoes are not 
mandatory.  
In addition, refer to the IB, Pexa- Vec Guidelines (Appendix B to the IB), and supplemental 
information (as available) for recommendations regarding proper handling during preparation, 
administration, and disposal of Pexa- Vec. 
 
10.A.8.a  Preparation of Pexa- Vec 
Preparation of Pexa- Vec will be carried out in accordance with local regulatory requirements for 
Biosafety/Conta inment level (Level 1 or Level 2 depending on countries) in a pharmacy or 
laboratory, according to site’s standard operating procedures (SOPs) and all applicable laws and 
regulations.  
Pexa- Vec is suspended in sterile normal saline buffered wit h sodium bic arbonate.   Detailed 
information on drug preparation is provided in the Pexa- Vec IT Injection Preparation Worksheet .  
 
CONFIDENTIAL and PROPRIETARY  Page 95 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 10.A.8.b Administration of Pexa- Vec 
The injection volume ( Pexa- Vec and sodium bicarbonate buffered sterile normal saline, when 
needed) will be approximately  25% of the size of the tumor to be injected (percentage dependent 
on the size [LD] of the tumor – refer to the IT injection of Pexa- Vec:  Procedure Manual for 
details), not to exceed a specified upper limit.  Tumor numbers and measure ments  will be 
documented at baseline and before each IT re -treatment and transmitted to the pharmacy for drug 
preparation purposes and to the study coordinator for eCRF completion.  Calculation and 
preparation instructions are provided in the Pexa- Vec IT Inject ion Preparation Wor ksheet . 
 
10.A.8.c  Cleaning / Disinfection and Disposal  
Standard institutional policies should be followed for cleaning and decontamination while 
handling vaccinia virus -based products.  Hospi[INVESTIGATOR_307] -grade chemical disinfectants containing:  bleach 
(with at least 0.6% of active chlor ine), alcohols (≥ 60%), aldehydes, hydrogen peroxide (3%), 
iodophor (75 ppm), phenols or quaternary ammonium compounds are adequate for routine 
cleaning and disinfe ction of work areas after Pexa- Vec handling.  The manufacturer’s instructions 
should be followed to ensure adequate contact [CONTACT_315155]. 
All contaminated material (e.g., syringes, cathete rs, needles, tubing, gloves, used or unused vials, 
containers, bandages, etc.) should be disposed of in a clearly -marked biomedical waste container 
and discarded according to regular institution  procedure for infectious waste i.e. , autoclaving, 
incineratio n, or treatment with sodium hypochlorite solution.   Biomedical waste will not be left 
unatten ded in a public area; autoclaved medical waste must not be disposed of as regular trash.  
Textiles and fabrics can be laundered in hot water (71°C) with detergent a nd hot air drying .  
 
10.A.8.d Spi[INVESTIGATOR_315060] a spi[INVESTIGATOR_4382], people in the immediate area will be alerted and other institutional personnel 
will be notified as required by [CONTACT_91341].   Refer to the current Pexa- Vec IB and  
Pexa- Vec Guidelines  (Appendix B of the IB) and the Technical Sheet, for detailed in struction s.  
Spi[INVESTIGATOR_315061].   Refer to Section  9.A. 
 
CONFIDENTIAL and PROPRIETARY  Page 96 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 10.A.8.e  Unused Drug Return or Destruction  
During the course of the study based on the S ponsor’s request and at termination of the study all 
unused Pexa-Vec patient kits will be destroyed locally or returned to the drug supply provider 
contracted by [CONTACT_941] S ponsor .  
For local destruction, the Investigator/Pharmacist or  delegated person will ensure that destruction 
is performed according to written instructions available in the Pexa- Vec IB and the Technical 
Sheet and will not expose humans to any risks from Pexa- Vec.  A certificate of destruction will be 
completed and pr ovided to the  Sponsor (copy retained by [CONTACT_779]).  The drug supply provider 
contracted by [CONTACT_315156]- Vec patient kits.   A 
certificate of return will be completed and provided to the drug supply provider  (copy  retained by 
[CONTACT_779]).  
Upon completion or termination of the study at a site, the monitor will verify that all used Pexa- Vec 
patient kits have been decontaminated  (if applicable)  and disposed, all unuse d Pexa- Vec patient 
kits have been returned or destroy ed, and no IP remains on site.   
 
10.A.9 Drug Accountability  
The Investigator/Pharmacist , or delegated person , will maintain a Pexa- Vec accountability log 
detailing the dates and quantities dispensed for each pa tient along with kit and vial numbers.  
Pexa- Vec acco untability records will be verified by [CONTACT_315157].  
All documentation related to Pexa -Vec shipment, receipt, authorization for use, dispensing, 
destruction, temperature monitoring, etc., must be filed in the Pharmacy Binder and must be 
available for inspection.  A copy of all drug accountability records will be returned to the  Sponsor  
at the end of the study.  
 
10.B SORAFENIB  
10.B.1 Nomenclature  
Sorafenib 200 mg film -coated tablets.  
Sorafenib is provided with its registered SmPC. 
 
CONFIDENTIAL and PROPRIETARY  Page 97 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387810] box that contains 1 
blister pack of 4 ×  7 tablets (i.e. , 28 tablets in total), that constitutes a sorafenib treatment kit.  
 
10.B.4 Transport  of Sorafenib  
10.B.4.a  Transport C onditions  
Sorafenib is shipped per manufacturer instructions. 
 
10.B.4.b  Drug Receipt and Approval of Shipment  
The supply of s orafenib is managed automatically using an IVRS/IWRS.  
Detailed information on drug receipt instructions and approval of shipment process are provided 
in the Product Handling Manual .  
 
10.B.4.c  Transport within the Institution  
No specific instructions.  
 
10.B.[ADDRESS_387811] be stored according to the manufacturer instructions  (refer to the  registered SmPC 
and Product Handling Manual ). 
 
10.B.6 Drug Dispens ing of Sorafenib 
Site personnel will access IVRS/IWRS to obtain kit number assignment for s orafenib treatment.  
CONFIDENTIAL and PROPRIETARY  Page 98 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387812] been specifically d esignated and tra ined for this study.  
Please refer to site user guide for IVRS/IWRS and the Product Handling Manual  for detailed 
instructions. 
 
10.B.7 Handling  of Sorafenib  
10.B.7.a  Posology  
Per registered  SmPC, t he recommended dose of s orafenib in adults is 400 mg  
(2 tablets of 200 mg) twice daily (equivalent to a total daily dose of 800 mg).  
Sorafenib is allowed as long as the patient is clinically benefiting from the treatment and at least 
until progression or until unacceptable toxicity occurs.  
 
10.B.7.b  Method of A dministra tion 
Sorafenib has to be administered according manufacturer instructions ( refer to the registered 
SmPC ). 
For oral use , it is recommended that s orafenib is administered without food or with a low or 
moderate fat meal.  If the patient in tends to have a high- fat meal, s orafenib tablets should be taken 
at least [ADDRESS_387813] or waste material should be disposed of in ac cordance with local 
requirements.  
 
10.B.7.d  Unused Drug Return or Destruction  
During the course of the study based on the S ponsor’s request and a t termination of the study  all 
unused sorafenib will be destroyed locally or returned to the drug supply provider contracted by 
[CONTACT_941] S ponsor .  
CONFIDENTIAL and PROPRIETARY  Page 99 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 For local destruction, the Investigator/Pharmacist or delegated person will ensure that destruction 
is performed according to local requirements.  A cert ificate of destruction will be completed and 
provided to the S ponsor (copy retained by [CONTACT_779]). 
The drug supply provider contracted by [CONTACT_315158].  A certificate of return will be completed  and provided to the drug supply 
provider (copy retained by [CONTACT_779]).  
Upon completion or termination of the study at a site, the monitor will verify that all used s orafenib 
patient kits have been disposed, and all unused s orafenib patient kits have been r eturned or 
destroyed.  
 
10.B.8 Drug Accountability  
The Investigator/Pharmacist or delegated person will maintain a s orafenib accountability log 
detailing the dates and quantities dispensed for each patient along with kit numbers.  Sorafenib 
accountability records will be verified by [CONTACT_315157].  
All documentation related to s orafenib shipment, receipt, authorization for use, dispensing, 
destruction, temperature monitoring, etc., must be filed in the Pharmacy Binder and must be 
available for insp ection.  A copy of all drug accountability records will be returned to the S ponsor 
at the end of the study.  
 
CONFIDENTIAL and PROPRIETARY  Page 100 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 11 SAFETY REPORTING  
The condition of the patient will be monitored throughout the study.  
 
11.A DEFINITIONS  
Adverse Event (AE) :  An AE for the purposes of this protocol is a medical occurrence or 
deterioration of a pre -existing medical condition occurring a fter first dosing with either study drug , 
and even if the event is not considered to be related to t he study treatment(s).   Prior to first on -
study treatment, only SAEs caused by a protocol -required procedure (e.g., SAEs related to invasive 
procedures such as biopsies) will be collected and reported to the Sponsor as specified in 
Section  11.E . 
Examples of AEs include:  
1. Pre-existing conditions (any sign, symptom, physical examination finding or laboratory 
result)  that worsens in nature, severity, or frequency compared to Day  1, before the first 
administration of the IP.   A pre -existing condition is one that is present prior to the first 
administration of the IP and is reported at Baseline or Day  1. 
2. Clinical lab oratory abnormality , vital signs measurements, physical examination s or ECG 
findings  should be reported as an AE only if it is considered clinically significant (i.e., with 
clinical manifestations or receiving treatment or clinical management) by [CONTACT_18413].   
3 All Grade 3 and Grade 4 clinical laboratory results tha t represent an increase in severity from 
Baseline will be reported as AEs.  
4. Leukocytosis will not be reported as an AE; however, any clinical signs or symptoms 
resulting from leukocytosis  will be recorded as an AE.  
5. All reactions from IP, including those occurring as a result of an overdose, abuse, withdrawal 
phenomena, sensitivity, or toxicity to the IP.  
6. Concurrent illness. 
7. Injury or accident.  
 
Adverse Drug Reaction (ADR) :  All no xious and unintended responses to the IP related to any 
dose or to a study specific procedure as determined by [CONTACT_29539]. 
 
CONFIDENTIAL and PROPRIETARY  Page 101 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Laboratory Abnormality :  A laboratory abnormality is reported as an AE if it is out of range  and 
consider ed by [CONTACT_152391] (i.e. , with clinical manifestations or 
requiring treatment or clinical management) . 
 
Other Significant AEs:   Any AE and any laboratory abnormality, other than those reported as 
SAEs, that are considered by t he Investigator or the Sponsor to be of special interest because of 
clinical importance whether or not they lead to an intervention, including:  
• withdrawal,  
• modification of the schedule of administration of Pexa- Vec, 
• modification of the schedule of administ ration  or the dose of sorafenib,  
• addition of significant concomitant therapy.  
 
Serious Adverse Event (SAE) :  Any untoward medical occurrence that at any dose fulfills one or 
more of the following criteria: 
• Results in death ; the death of a patient is not pe r se an AE but an outcome.  “Death” should be 
considered as a SAE only in case of “unexplained death" when no cause is identified.  The 
event that resulted in a fatal outcome should be determined and reported as a SAE. 
• Is life threatening ; this term refers  to an  event in which the patient was at immediate risk of 
death at the time of the event; it does not refer to an event that hypothetically might have caused 
death if it was more severe.  
• Requires inpatient hospi[INVESTIGATOR_315062]; the 
hospi[INVESTIGATOR_315063].  It should not be reported as a SAE, but the 
AE leading to hospi[INVESTIGATOR_059].  
• Results in persistent or significant disability/incapacity ; the disability is a substantial disruption 
of a p erson’ s ability to conduct normal life functions.  
• Is a congenital anomaly/birth defect ; a “congenital anomaly/birth defect” relates to events 
occurring to babies born after their mother and/or father have taken the IP at the time of 
pregnancy confirmation or dur ing pregnancy.  
CONFIDENTIAL and PROPRIETARY  Page 102 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Is a medically significant defined as an event that may not be immediately life threatening or 
result in death or hospi[INVESTIGATOR_315064] l isted above.  
NOTE:  Medical and scientific judgment should be exercised in deciding whether some events 
should be considered as serious because their quick reporting to the Sponsor or its 
representative may be of interest for the overall conduct of the stud y. 
NOTE ABOUT HOSPI[INVESTIGATOR_151617]:  
Planned hospi[INVESTIGATOR_315065] a SAE . 
It will not be considered an SAE if patients are hospi[INVESTIGATOR_315066]-treatment for observation of Grade [ADDRESS_387814] longer than 24 hours.  
Hospi[INVESTIGATOR_315067] a SAE in case 
it occurs for:  
• Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition;  
• Elective or pre- planned treatment for a pre- existing condition that is unrelated to the 
indication under  study and has not worsened in an unexpected way since signing informed 
consent;  
• Treatment on an emergency outpatient basis for an event not fulfilling any of the definitions 
of a SAE given above and not resulting in hospi[INVESTIGATOR_174847];  
• Social reasons and r espi[INVESTIGATOR_064]’s general 
condition. 
 
Suspected Unexpected Serious Adverse Drug Reaction (S[LOCATION_003]R) :  Any unexpected SAE 
considered as related to the IP  or to a study specific procedure.  
Overdose :  An overdose i s an administration of the IP at a higher dose than the highest dose already 
tested in clinical studies or higher than known therapeutic doses or higher than the dose planned 
according to the schedule of administration. 
CONFIDENTIAL and PROPRIETARY  Page 103 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Overdose is not be considered an AE.  However, if the patient experiences an AE/SAE related to 
this overdose, it should be reported as such.  
 
11.B INTENSITY, R ELATIONSHIP AND O UTCOME E VALUATION 
11.B.1 Intensity  
The intensity of AEs/SAEs will be graded according to the NCI -CTCAE version 4.03 (dated 14 
June 2010). 
Should an event be missing in the CTCAE, the following 5- point scale is to be used:  
• Mild:  Discomfort noticed, but no disruption of normal daily activity  
• Moderate:   Discomfort sufficient to affect normal daily activity  
• Severe:   Inability to work or perform normal daily activity  
• Life-threatening:  Risk of death at the time of the event  
• Fatal:   The patient died  
 
The correspondence between the 2 scales is as follows:  
CTCAE  5 point scale  
1 Mild  
2 Moderate  
3 Severe  
4 Life threatening  
5 Death  
 
 
11.B.2 Relationship to the IP  
The relationship to the IP of each AE/SAE will be evaluated by [CONTACT_315159] “global 
introspection” method using the following levels:  
CONFIDENTIAL and PROPRIETARY  Page 104 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Not related :  The temporal relationship of the clinical event to the administration of the IP 
makes a causal relationship unlikely; and other drugs, therapeutic interventions or underlying 
conditions provide a sufficient explanation for the observed event.  
• Related :  The temporal relationship of the clinical event to the administration of the IP makes 
a causal relationship possible; and other drugs, therapeutic interventions or underlying 
conditions do not provide a sufficient explanation for the observed event.  A clear -cut temporal 
association with improvement on cessation of the study drug or  recurrence upon rechallenge 
may also be observed.  
 
11.B.3 Outcome  
The outcome is rated as follows:  
• recovered,  
• not recovered,  
• recovered with sequelae,  
• fatal,  
• unknown. 
 
NOTE ON "FATAL" : this outcome is to be used only for the event leading to death.  The 
outcome of all other events at the time of the death must be reported ; if 
ongoing at the time of death , the outcome of those other events should 
be reported as "not recovered".  
 
11.C TIME P ERIOD FOR COLLECTION  
From the date of signature [CONTACT_315202], only SAEs caused by a protocol -required proce dure (e.g., SAEs related to invasive 
procedures such as biopsies) will be collected and reported to the  Spons or as specified in 
Section  11.E . 
After the initiation of IP and up to [ADDRESS_387815] dose of IP, all AEs and SAEs should be 
collected and recorded on the eCRFs as described in S ection  11.D  and SAE reported to the  Sponsor 
as specified in S ection  11.E . 
CONFIDENTIAL and PROPRIETARY  Page 105 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387816]-study SAEs  (i.e., occurring more than [ADDRESS_387817] dose of IP ), and evaluated by [CONTACT_315160] t he Sponsor indefinitely even 
after study closure as specified in S ection  11.E .  These would however not be reported in the eCRF.  
 
11.D ADVERSE E VENT M ANAGEM ENT  
11.D.1 Reporting  
Any AE/SAE directly observed (physical examinat ion, laboratory test, or other assessments), 
mentioned by [CONTACT_315161]- directive questioning at each visit 
during the study, will be reported by [CONTACT_57672] “Adverse Events”  page of the eCRF 
as follows : 
• AE te rm (i.e., the nature of the event with self -explanatory  and concise medical terminology 
[indicate a diagnosis or syndrome instead of symptoms ]), 
• date of onset and date of end (i.e.,  actual dates when the event starts and is resolved rather than 
dates when t he Investigator is informed),  
• outcome, 
• intensity,  
• relation to Pexa- Vec, sorafenib or study procedure ( e.g., IT injection)  
• action taken regarding Pexa -Vec, sorafenib  
• action taken re garding the event,  
• evaluation of seriousness. 
 
AE requiring therapy must be  treated with recognized standards of medical care to protect the 
health and wellbeing of the patient.  Any treatment given will be reported on the page 
"Concomitant medication" of the eCRF.   
The Sponsor or its representative reserves the right to ask for f urther information on any AE/SAE 
that may be considered of interest or when the event is not previousl y documented in the IB (new 
occurrence) and is thought to be related to Pexa- Vec, sorafenib, the combination or a study specific 
procedure . 
 
CONFIDENTIAL and PROPRIETARY  Page 106 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387818] visit planned by [CONTACT_760]:  
• AE evaluated as related to Pexa- Vec and/or sorafenib or to a study specific procedure , 
• SAEs,  
• any other significant A E as recommended by [CONTACT_1034]. 
 
11.D.[ADDRESS_387819] the nature of the event, the start and end 
date,  the relationship to the IP and the treatment (if applicable) of the event. 
 
11.E SERIOUS ADVERSE EVENT M ANAGEMENT  
11.E.[ADDRESS_387820] be reported by [CONTACT_315162] 24 hours of 
occurrence or knowledg e of the event.  The I nvestigator will also complete the “SAE Form” to be 
provided to the Sponsor or its representative as specified  in the SAE reporting guidelines located 
in the  Investigator site file.  SAE related documentation, if any, must be kept at the study site in 
the Investigator site file . 
 
11.E.2 Follow -Up 
Follow -up information (e.g., complications or progression of the initial SAE) must be notified as 
soon as possible to the Sponsor or its representative using a new SAE form with the box "follow -
up" t icked.  New information must be sent to the Sponsor or its representative within [ADDRESS_387821] 
further information as needed.  
All SAE s will be followed until the final outcome is known. 
 
CONFIDENTIAL and PROPRIETARY  Page 107 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 11.E.3 Notifications  
The Sponsor or its representative will be responsible for reporting S[LOCATION_003]Rs and any follow -up 
information to Regulatory Authorities and to central Ethics Committees  (ECs) as per local 
regul ation.  In case of a S[LOCATION_003]R, the Sponsor or its representative will inform all Investigators 
involved in any study with Pexa- Vec that such an event occurred . 
The Sponsor or its representatives will provi de copi[INVESTIGATOR_315068] y 
authorities to the Investigator for inclusion in the Investigator site file . 
The Investigator is responsible for informing local Institutional Review Boards ( IRBs) / 
Institutional Ethics Committee ( IECs) / Research Ethics Boards ( REBs ), Institutional Bio safety 
Committees ( IBCs ), and other required institutional committees of S[LOCATION_003]Rs and any follow -up 
information as per local regulations. 
 
11.F SPECIAL  SITUATIONS  
11.F.[ADDRESS_387822] be reported to the Sponsor or its representative, 
documented and followed- up as described in Section  11.E . 
 
11.F.2 Pregnancy 
A patient’s treatment ( Pexa -Vec or sorafenib) must be discontinued immediately if she becomes 
pregnant.  
If a patient or their partn er becomes pregnant during the active study participation phase and up to 
6-weeks of last Pexa- Vec dose or s orafenib dose, the Investigator must report the pregnancy to the 
Sponsor or its representative, using a “Pregnancy form” within 24 hours of the site ’s awareness of 
the pregnancy.  
NOTE : If a patient’s partner becomes pregnant, the Sponsor or its representat ives will make 
every effort to obtain consent from the partner to collect data on the pregnancy.  
 
Pregnancies have to be followed by [CONTACT_315163], collecting information about the pregnancy, the new -born medical status follow up on 
the status of the infant until 8 –12 weeks of age.  
CONFIDENTIAL and PROPRIETARY  Page 108 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387823] be reported. 
 
11.F.3 Overdose  
Any overdose should be reported to the Sponsor’s representative and  documented and followed-
up using an “Overdose form”.  In addition, any associated symptoms should be reported as an AE 
or SAE  as per instructions in Section  11.D  and Section  11.E , respectively . 
 
11.F.[ADDRESS_387824] be reported to 
the Sponsor or its represent ative by [CONTACT_315164] 24 hours of the site’s awareness 
of the event as per  the instructions in Section  11.E . 
Deaths that occur outside of this reporting period but that are the outcome of an unr esolved AE or 
SAE will also be reported to the Sponsor or its representative on a dedicated  eCRF page . 
In addition, if the patient’s death occurred within [ADDRESS_387825] recent dose of Pexa- Vec, or 
death was >[ADDRESS_387826] formalin- fixed and flash frozen tissue specimens 
from normal organs examined as well as from as many tumor site(s) as possible to assess the 
biodistribution and s afety of Pexa- Vec in humans.  Special histopathology stains for Pexa- Vec 
replication and gene expressio n, virus -induced cytopathic effects, and inflammatory infiltration 
(characterize immune cells in tissues) may be performed.   Tissue specimens may be ret ained by 
[CONTACT_941] S ponsor for up to 2 years after sampling for these purposes.  
A copy of the death certificat e should be obtained.  
If an autopsy is performed, a copy of the autopsy report should be obtained by [CONTACT_315165].  
 
CONFIDENTIAL and PROPRIETARY  Page 109 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 12 STATISTICAL CONSIDERATIONS  
12.A OVERVIEW  
The primary objective of this study is to determine and compare overall survival (time to death) 
based on a stratified re -randomization test, for patients receiving Pexa- Vec followed by [CONTACT_44369] 
(Arm A) versu s those receiving sorafenib (Arm B) in patients  with advanced HCC  without prior 
systemic therapy . 
Secondary objectives are to determine and compare TTP, PFS, ORR, DCR, and to determine 
patient  TSP,  QoL, safety and tolerability of Pexa- Vec followed by [CONTACT_315166] (Arm A) compared 
to sorafenib (Arm  B).  
Other objectives include  TIR, DoR  and tumor size evolution over time.  In addition, overall 
survival , PFS and TTP  will be analyzed in patients exhibiting tumor response  or in subgroups of 
patients . 
Details of th e statistical analyses will be spec ified prospectively in a SAP . 
 
12.B SAMPLE SIZE DETERMIN ATION  
Efficacy will be evaluated comparing the overall survival  in the Pexa -Vec arm (Arm  A, Pexa- Vec 
followed by s orafenib) with the s orafenib arm (Arm B).  
Unlike chemothe rapy, cancer immunotherapi[INVESTIGATOR_315069] a cellular immune response, followed by [CONTACT_315167].  Thus, a design anticipating a 6- month delayed se paration of 
the Kaplan -Meier curves was applied.  The hazard ratios are described as a function of time 
recognizing differences before and after separation of curves.  
It is assumed that Pexa- Vec does not reduce the hazard of overall survival  during the fir st 6 months 
of treatment (HR  = 1.[ADDRESS_387827] 6 months ), while it reduces the hazard by 40% thereafter (HR  
= 0.6 after 6 months ).  The median overall survival  in the control arm is expected to be 
approximately 11 months . 
Based on the aforementioned  assumptions, and assuming a 1:[ADDRESS_387828] with a power of 
86% (assuming that HR  = [ADDRESS_387829] 6 months  and 0.6 thereafter)  using a stra tified log -rank 
test at a 1 -sided cumulative 2.5% level of significance.  This corresponds to a HR smaller than or 
equal to 0.83 at the final analysis to declare a significant treatment benefit.   For this analysis, the 
CONFIDENTIAL and PROPRIETARY  Page 110 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387830] (based on the s tratified log -rank test) will be computed and 
compared to the threshold defined as 0.021 (if the analysis is perf ormed at 474 events exactly) due 
to the alpha adjustment induced by [CONTACT_315168] ( using an α -spending function 
due to Lan- DeMets ( Gordon 1983) with O’Brien -Fleming type ( O’Brien  1979) stoppi[INVESTIGATOR_315070]).   If the p -value is lower than this boundary, the treatment will be considered 
as effective.  
A first interim analysis for futility will be performed when 190 deaths (40% of the required events 
for final analysis) are documented in the ITT population with a stoppi[INVESTIGATOR_315071]  
= 1.1.  The p -value of the re -randomization test (based on the stratified log -rank test) will be 
computed and compared to the threshold corresponding to HR  = 1.1.  If exactly [ADDRESS_387831] been crossed.  
A second  interim analysis for efficacy will be performed when 379 deaths ( 80% of the required 
events for final analysis) are documented in the ITT population.  An α -spending function due to 
Lan-DeMets with O’Brien -Fleming t ype stoppi[INVESTIGATOR_3106] (as implemented in EAST® 6.3) will 
be used for the interim efficacy analysis.   If the i nterim analysis is performed after exactly  
379 events, the O’Brien -Fleming boundary for efficacy consists in using a significance level equal 
to 0.012 ( corresponding  to a HR  equal to 0.79) .  If the p -value of the re -randomization test (based 
on the stratif ied log -rank test) is lower than this threshold, the efficacy boundary will have been 
crossed .   
The nominal p- values  and critical value s used to declare statistical significance at the time of 
interim and final  analys es may be slightly different as  based on the actual number of deaths that 
have been documented at the time of analysis.  
Assuming a non- uniform enrolment and about 5% lost to follow -up or withdrawal of consent rate, 
a total of [ADDRESS_387832] patient.  
 
12.C ANALYSIS POPULATIONS  
The ITT population will comprise all randomized patie nts.  Following the intent -to-treat principle, 
patients will be analyzed according to the treatment and stratum that they were assigned to at 
CONFIDENTIAL and PROPRIETARY  Page 111 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387833] one dose of any one 
component of the study treatment ( Pexa-Vec or sorafenib) .  The occurrence of death also 
constitutes a valid safety assessment.  Patients will be  analyzed according  to the treatment they 
actually received .  The safety population will be the population for safety and drug exposure 
analyses.  
Patients with no post -baseline assessments will be listed.  
The PP population will comprise all patients from t he ITT population without any major protocol 
deviations who have completed a minimum exposure  requirement.  In Arm A, the minimum 
exposure is at leas t one Pexa- Vec injection and in Arm B, the minimum exposure consists in at 
least 2 weeks  of sorafenib .  Howe ver, if a patient progressed as per Investigator radiology data, 
discontinued for AE , or died before the minimum exposure requirement could be met, that patient 
will still be included in the PP  population.  
 
12.D METHODS OF ANALYSIS  
12.D.1 General C onsiderations  
Statistical summaries will be produced using SAS software version  9.2 or higher.  
Continuous variables will be described using the number of observations (N), arithmetic mean 
(Mean), standard deviation, minimum (MIN), median (Median), and maximum (MAX).   
Categ orical variables will be summarized by [CONTACT_315169] (N) and percentage (%).  Proportions will 
be estimated with their exact (binomial) 95% CIs when appropriate . 
 
12.D.2 Disposition of P atients  
The number of screening failure patients and reasons for screening failur e will be summarized.  A 
patient listing will be provided with the reason of screening failure.  
The disposition data will be presented by [CONTACT_315170] a summary tab le on the ITT  population:  
• The num ber of patients randomized 
• The number of patients included in each population 
CONFIDENTIAL and PROPRIETARY  Page 112 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • The number of patients excluded from the populations and reasons for exclusion 
• The number of patients who are still on treatment ( Pexa- Vec or s orafenib)  
• The number of patients who have completed:  
 The end of treatment visit  
 The safety follow -up visit  
• The number of patients who discontinued Pexa- Vec and reasons for discontinuation Pexa- Vec 
• The number of patients who discontinued s orafenib and reasons  for discontinuation the 
sorafeni b 
• The number of patients who discontinued sorafenib before or after progression 
• The number of patients who were followed for overall survival  after end of study treatment s  
• The number of patients who discontinued the study during the survival follow -up for  overall 
survival  and reasons for discontinuation during this follow -up (lost to follow -up, withdrawal 
of consent)  
 
12.D.3 Demographic and Baseline C haracteristics  
Baseline demographi cs and disease characteristics data will be lis ted and summarized by [CONTACT_54012]. 
Qualitative data (e.g., gender, ethnic origin, PS) will be summarized by [CONTACT_315171], and quantitative data (e.g., age and body weight) will be summarized 
by [CONTACT_315172] e statistics (mean, standard deviation, median, minimum, and maximum) 
for each treatment arm.  
The numbers and percentage of patients with relevant medical history/current medical conditions 
will be presented by [CONTACT_2939], system organ class and preferr ed term.  
 
12.D.4 Treatments ( Study T reatment, Concomitant T herapi[INVESTIGATOR_014])   
The safety population will be used for all summaries and listings about treatments. 
 
CONFIDENTIAL and PROPRIETARY  Page 113 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 12.D.4.a  Study Treatment s (Pexa- Vec and S orafenib)  
Exposure to Pexa -Vec will be provided by [CONTACT_315173]  (in pfu, corrected if not complete) and the cumulative dose (sum of doses received during 
each injection) .  In addition, number of Pexa- Vec doses received (partial doses will be counted as 
one dose) will be categoriz ed (0 , 1, 2 or 3) and summarized. 
Exposure of Sorafenib will be provided by [CONTACT_315174] , the dose (in 
mg/day), and the information about dose reduction by [CONTACT_2939].   Number of patients who 
received the planned dose and who had a dos e reduction during the study will be summarized. 
In addition, total duration of study treatment (including Pexa- Vec and Sorafenib) will be listed and 
summarized by [CONTACT_2939].  
Sorafenib compliance will be summarized for each treatment arm.  This will b e based on the 
number of tablets dispensed and used as reported in the eCRF. 
 
12.D.4.b Concomitant M edications  
Medications and/or non- drug therapi[INVESTIGATOR_252591]  8. 
The concomitant medication s (i.e., ongoing at the start of study treatment or taken during the 
course of the study) will be coded using the WHO Drug Dictionary  and will be listed and 
summarized by [CONTACT_315175].  
Any prior medications or significant non -drug therapi[INVESTIGATOR_315072].  
 
12.D.5 Efficacy  
12.D.5.a  Primary E fficac y Analysis:  Overall Survival  
Overall survival  is defined as the time from randomization unt il death from any cause.  For patients 
not known to have died at the time of the analysis, overall survival  will be censored on the date 
they were last known to be alive.  If a patient withdraws early, overall survival will not be censored 
at the date of w ithdrawal unless this is the date they were last known to be alive.  Date of death 
will be obtained from the death certificate (preferable) or from a written statement from the 
primary care or attending physician, or from death registry data.  
CONFIDENTIAL and PROPRIETARY  Page 114 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387834] stratified by [CONTACT_315176]- sided 
2.5% level in the ITT population with etiology, extrahepatic disease, vas cular invasion, 
performance status and AFP levels as covariates in the model.  
Overall survival  will be presented descriptively for each treatment arm using Kaplan -Meier curves.   
Summary statistics from the Kaplan -Meier distribution will be determined, inc luding median 
overall survival  and 25% and 75% quartiles with corresponding 95% CIs.  The proportions of 
patients alive at 6, 12, 18, and 24 months , along with corresponding 95% CIs, will also be provided 
by [CONTACT_2939].  
 
12.D.5.a.1 Supportive Analysis  
Estimates of  the HRs (Arm A over Arm B) with 95% CIs will be obtained from a proportional 
hazard (PH) model stratified by [CONTACT_245632]  (i.e., region) with etiology, extrahepatic 
disease, vascular invasion, performance status and AFP levels as covariates in th e model .  In order 
to take the delayed effect into account, the model will allow for a time dependent treatment effect.  
In particular, it is expected that the Pexa -Vec effect can only be seen after about [ADDRESS_387835] will be conducted to check the statistical 
significance of the interaction.  
 
Sensitivity A nalysis  
• An unstratified  re-randomization test will be performed to assess the robustness of the results.  
• In addition, a stratified and an unstratified log- rank test will be performed .  HR (together with 
associated 95% CI) resulting from an unstratified Cox model will also be pre sented.  
Following the ITT principle, patients will be analyzed according to the treatment arm and strata 
they were assigned to at  randomization.  
The Kaplan -Meier curves, re -randomization test, log-rank test and the Cox model analyses will 
also be repeated on the PP set.  
 
12.D.5.b Secondary E fficacy A nalyses  
A hierarchical testing strategy will be adopted, TTP will be compared between the 2  treatment 
arms if the primary endpoint overall survival  is statistically significant.   If TTP is statistically 
CONFIDENTIAL and PROPRIETARY  Page 115 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 signific ant (i.e., p < 0.025) then PFS will be compared between the treatment groups and finally 
ORR will be analyzed.  
The analyses of the secondar y efficacy endpoints will be performed on the ITT population and a 
subset will be  repeated on the PP population.  
 
12.D.5.b.1 Time  to Tumor Progression (TTP)  
• Time to Tumor Progression (TTP) is defined as the time from randomization to the date of first 
documented radi ographic tumor progression; TTP does not include deaths.  If a patient has not 
had a TTP event at the cut -off date for  analysis, TTP will be censored at the date of last 
evaluable tumor assessment before the cut -off. 
If a progression is observed after [ADDRESS_387836] occurrin g evaluable tumor assessment before 
missing; for a progression observed after a single missing or non- evaluable tumor assessment, the 
actual date of disease progression will be used.  
A re-randomization test using stratified log rank test stratified for region  will be performed at the 
one-sided 2.5% level to compare the 2 treatment arms.  HR (together with associated 95%  CI) 
resulting fro m the stratified Cox model will also be presented.   
TTP will be presented descriptively for each treatment arm separately using Kaplan Meier curves.  
Summary statistics from the Kaplan Meier distributions will be determined, including median TTP 
and 25% and 75% quartiles with corresponding 95%  CIs.  The proportions of patients remaining 
progression free at 3, 6, and 9 months , along with 95% CIs will also be provided by [CONTACT_2939].   
 
Sensitivity A nalyses:  
• Analyses will be repeated in the same way except that  unstratified re-randomization test will 
be used.  HR (together with associated 95% CI) resulting from an unstratified Cox model will 
also be presented.   In addition, a stratified and an unstratified log- rank test will be performed.  
• Analyses will be repeat ed in the same way except that TTP will not be censored if a progression 
is observed after [ADDRESS_387837] 1.1  criteria  as exploratory analyses . 
 
CONFIDENTIAL and PROPRIETARY  Page 116 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 12.D.5.b.2 Progression F ree Survival (PFS)  
Progression free survival (PFS)  is defined as the time from randomization to the date of first 
documented radiographic tumor progression or death due to any ca use, whichever occurs first.  If 
a patient has not had a PFS event at the cut -off date for analysis, PFS will be censored at the date 
of last evaluable tumor assessment before the cut -off. 
If a progression is observed after [ADDRESS_387838] occurring evaluable tumor assessment before 
missing; for a progression observed after a single missing or non- evaluable tumor assessment, the 
actual date of disease progressi on will be used.  
A re-randomization test using stratified log  rank test stratified for region  will be performed at the 
one-sided 2.5% level  to compare the 2 treatment arms .  HR (together with associated 95%  CI) 
resulting from the stratified Cox model will a lso be presented.   
PFS will be presented descriptively for each treatment arm separately using Kaplan -Meier curves.   
Summary statistics from the Kaplan -Meier distributions will  be determined, including median PFS 
and 25% and 75% quartiles with correspondin g 95% CIs.  The proportions of patients remaining 
progression- free at 3, 6 , and 9 months, along with 95% CIs will also be provided by [CONTACT_2939]. 
 
Sensitivity A nalyses:  
• Anal yses will be repeated in the same way except that unstratified re -randomization  test will 
be used.  HR (together with associated 95% CI) resulting from an unstratified Cox model will 
also be presented.   In addition, a stratified and an unstratified log- rank test will be performed.  
 
• Analyses will be repeated in the same way except that  TTP will not be ce nsored if a progression 
is observed after [ADDRESS_387839] 1 .1 criteria as exploratory 
analyses.  
 
CONFIDENTIAL and PROPRIETARY  Page 117 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 12.D.5.b.3 Overall Response Rate (ORR)  
Overall response rate (ORR) is defined as the proportion of patients whose best overall res ponse 
is either CR or PR.  The best overall response is the best response recorde d from the randomization 
until disease progression.  
Proportions of patients with a best overall respo nse of CR or PR will be presented by [CONTACT_315177] 95% C Is.  The Chi -square test  will be used to compare the [ADDRESS_387840] to the ORR at a 1 -sided 2.5% level of significance.   As a sensitive analysis, a two -
sided  95% CI for  the difference in proportion of patients whose best overall response is either CR 
or PR, stratified by [CONTACT_245632], will be computed by [CONTACT_2329] t he method of Yan and Su 
(Yan 2010).  
Secondary endpoint a nalyses will be performed based on central assessments using mRECIST for 
HCC and will be repeated both locally and cent rally using  RECIST  1.1 criteria as exploratory 
analyses.  
 
12.D.5.b.4 Disease Control Rate ( DCR) 
Disease control rate (DCR) is defined as the proportion of patients whose best overall response  is 
either CR, PR , or SD.  
Proportions of patients with a best overall response of CR, PR , or SD will be presented by 
[CONTACT_315178] 95% CIs .  The Chi-square test will be used to compare the 
[ADDRESS_387841] to the DCR at a 1 -sided 2.5% level of significance.  As a sensitive 
analysis, a two -sided  95% C I for the difference in proportion of patients whose best overall 
response is ei ther CR, PR or SD, stratified by [CONTACT_245632], will be computed by [CONTACT_315179] ( Yan 2010).  
Secondary endpoint a nalyses will be performed based on central assessments using mRECIST for 
HCC and will be repeated both locally and centrally using  RECIST 1.1 criteria as exploratory 
analyses.  
 
12.D.5.b.5 Time to Symptomatic Progression (TSP)  
Time to s ymptomatic progression (TSP) is defined as the time from randomizatio n until the first 
documented event of symptomatic progression defined as a decre ase of 4  points or more from 
baseline in the FHSI -8 questionnaire or a decrease in ECOG performance status to 4, or death.  If 
CONFIDENTIAL and PROPRIETARY  Page 118 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387842] occurring FHSI -8 or ECOG 
assessment before missing; for a progression o bserved after a single missing or non -evaluable 
FHSI -[ADDRESS_387843] stratified for region  will be performed at the one -sided 2.5% level to compare the 
2 treatment arms.  HR (together  with associated 95%  CI) resulting from the stratified Cox model 
will also be presented.   
TSP will be presented descriptively for each treatment arm separately using Kaplan -Meier curves.  
Summary statistics from the Kaplan -Meier distributions will be  determined, including median TSP 
and 25% and 75% quartiles with corresponding 95%  CIs.  The proportions of patients remaining 
progression- free at 3, 6 , and 9 months, along with 95% CIs will also be provided by [CONTACT_2939].  
 
Sensi tivity  Analyses:  
• Analys es will be repeated in the same way except that unstratified log -rank test will be used.  
HR (tog ether with associated 95% CI) resulting from an unstratified Cox model will also be 
presented.  
 
12.D.5.c  Exploratory  Efficacy  Analysis  
As mentioned in the secondary endpoints paragraph, TPP, PFS , ORR , and DCR  will be assessed 
both locally and centrally  using RECIST  1.1.  In addition, the following endpoints will be assessed:  
 
12.D.5.c.1   Time to Initial Response (TIR)  
The Time to Initial Response  (TIR)  is defined as the time from r andomization until the first 
documented response (CR or PR).  Patients who did not achieve a resp onse will be censored at last 
adequate tumor assessment date otherwise.  
A Kaplan -Meier curve will be constructed for each treatment arm.  Median TIR and 25% and 75% 
quartiles will be presented along with 95% CIs for each treatment arm.  In addition, the Ka plan-
Meier estimates with 95% CI s at 3, 6, and 9 months  will be presente d by [CONTACT_2939].  
CONFIDENTIAL and PROPRIETARY  Page 119 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387844] 1.1 criteria.   
 
12.D.5.c.2  Duration of R esponse  (DoR)  
Duration of response (DoR) applies only to patients whose best overall response is CR or PR.  The 
DoR is defined as the time from the  first docum ented response (CR or PR) until the event defined 
as first documented disease progression .  If a patient has not had a DoR event at the cut -off date 
for analysis, DoR wi ll be censored at the date of last evaluable tumor assessment before the cut -
off. 
If a progression is observed after [ADDRESS_387845] occurring evaluable tumor  assessment before 
missing assessments; for a progression observed after a single missi ng or non- evaluable tumor 
assessment, the actual date of disease progression will be used.  
DoR wi ll be summarized by [CONTACT_2939].  A Kaplan -Meier curve will be constru cted for each 
treatment arm.  Median DoR and 25% and 75% quartiles will be presented al ong with 95% CIs for 
each treatment arm.  In addition, the Kaplan- Meier estimates with 95% CI s at 3, 6, and [ADDRESS_387846] 1.1 criteria.  
 
CONFIDENTIAL and PROPRIETARY  Page 120 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387847] to overall survival , PFS  and TTP in subgroups 
of patients (if the number of patients is  sufficient)  according to minimization criteria  and other 
criteria described in the SAP . 
Efficacy of Pexa- Vec will also be evaluated with respect to overall su rvival , PFS and TTP  in 
patients subdivided according to the presence or not of an objective response (CR or PR) , if the 
number of patients with CR or PR is sufficient .  These analyses will be interpreted with due 
caution. 
Analyses based on radiological endpoints will be perf ormed based on central assessments using 
mRECIST for HCC and will be repeated using both local and central RECIST 1.[ADDRESS_387848] to overall survival  by [CONTACT_315123] (instead of  the date of randomization).  
A Kaplan -Meier curve will be constructed for each treatment arm.  Median overall survival , PFS , 
or TTP and 25%  and 75% quartiles w ill be presented along with 95% CIs for each treatment arm.  
In addition, the Kaplan -Meier estima tes with 95% CI s at 3, 6, and [ADDRESS_387849]  treatment dose will be 
flagged in the listings.  
CONFIDENTIAL and PROPRIETARY  Page 121 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 The assessment of safety will be based mainly on the fr equency of AEs and on the number of 
laboratory values th at fall outside of predetermined ranges.  Other safety data (e.g., ECG, vital 
signs) will be cons idered as well and reported as AEs . 
Overall incidence of AEs and SAEs will be evaluated for each arm of treatment and for the study 
as a whole.  
AEs will be cod ed and tabulated using the MedDRA classification scheme and based on NCI 
CTCAE v4.03:  14 June 2010.  All AEs, AEs leading to discontinuation, and SAEs recorded during 
the study will be listed and su mmarized by [CONTACT_315180], s everity 
(grade), relationship to each study treatment component ( Pexa- Vec and sorafenib) and treatment 
arm.  AEs related to study procedure will be also listed. 
AEs will be summarized by [CONTACT_315181].  Data will be presented by s ystem organ c lass, preferred term and maximum grade.  A patient 
with multiple occurrence of an AE will be counted only once in the AE category.  
 
Laboratory A bnormali ties 
The summaries will include all laboratory assessments  collected no later than 28  days after study 
treatment discontinuation.  All laboratory assessmen ts will be listed and those collected during 
28 days  after study treatment discontinuation will be flagged in the listings.  
All laboratory values will be conve rted into SI units and the severity grade calculated using 
appropriate common terminology criteri a for AEs (NCI CTCAE, version 4.03).  A listing of 
laboratory values will be provided by [CONTACT_13754] p arameter, patient, and treatment arm.  A separate 
listing will display notable laboratory abnormalities (i.e., newly occurring CTCAE Grade 3 or 
Grade 4 laboratory toxicities).  The frequency of laboratory abnormalities will be displayed by 
[CONTACT_315182].  
 
12.D.7 Quality of L ife (QoL)  
Quality of life  (QoL)  will be measured with the validated cancer -specific patient reported 
outcomes instrument to evalu ate the differences over time  between the [ADDRESS_387850] 
QoL ass essments will be summarized by [CONTACT_315183].  
CONFIDENTIAL and PROPRIETARY  Page 122 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387851] baseline 
score during the treatment period will be included in the change from baseline analyses 
(assessments after disease progression will be excluded).  A general li near model that includes 
treatment and the baseline stratifica tion factor in the model will be used to compare the actual and 
change from baseline in the sub- scale scores at each scheduled time point of assessment.  
Additionally, a repeated measurements an alysis model, (implemented via SAS PROC MIXED) 
that includes t erms for treatment, baseline stratification factor, baseline value and time of visit by 
[CONTACT_315184] [ADDRESS_387852] to changes in the QoL 
domain s cores longitudinally over time.  
Time to definitive deterioration in the global health status / QoL  scale, and in each of the secondary 
scales, will be compared  between the [ADDRESS_387853] 
and at one -sided type  I error rate as of 2.5%.  The distributions will be presented descriptively 
using Kaplan- Meier curves.  Summary statistics from the Kaplan -Meier distributions  will be 
determined, including the median time to definitive 5% deterioration and the proportions  of 
patients without definitive 5% deterioration at 3 and 6 mo nths.  Both point estimates and 95% CI s 
will be presented.  
 
12.D.[ADDRESS_387854] is to measure resource 
use in physical units as used by [CONTACT_315185].  The second stage is to add costs to these r esources 
using prices or unit costs.  Costs will be assessed according to countries specificity and from a 
societal perspective.  
CONFIDENTIAL and PROPRIETARY  Page 123 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387855] states and transition probabilities will be 
assigned for movement between them over a discrete time period.  Six health states will be ch osen 
to represent the natural history of the disease:  
• First-line treatment with Pexa- Vec,  
• First-line treatment with sorafenib following Pexa- Vec, non -progress ive advanced disease,  
• First-line treatment with sorafenib following Pexa- Vec, progressive advanced disease,  
• BSC , 
• Palliative Care,  
• Death.  
 
Sensitivity analysis to test the robustness of the model to changes in values for input variables will 
be performed.   Thus, in order to assess the overall impact of uncertainty on the model results, we 
will apply pr obabilistic sensitivity analysis.  The outcomes of probabilistic sensitivity analysis are 
going to be:  
• An acceptability curve to provide the prob ability of Pex a-Vec to be more cost efficient than 
Sorafenib for the possible range of “willingness -to-pay” val ues given the uncertainty of the 
input model parameters.  
• A cost -effectiveness plan  
The markov model will be able to adapt to any required sub- group analysis b y changing the input 
parameters of the model (clinical parameters, utilities and costs adaptation s).  Additionally, the 
model will support any desired country adaptation by [CONTACT_315186]. 
Cost-effectiveness will be expressed as incremen tal cost -effectiveness ration per life- years gained.  
Cost-utility will be expressed in terms of the additional cost -effectiveness ration (ICER) per 
quality -adjusted life -year (QALY) gained.   Individual patient -level data will be used to quant ify 
costs dur ing the study and quality of life referred as utility will be assessed by [CONTACT_43433]- 5D 
(EQ5D -3L) questionnaire.  The health outcome should be quality -adjusted life -year (QALY) based 
on EQ5D -3L but the results of specific HRQoL questionnaire (FACT -G) migh t be presented for 
CONFIDENTIAL and PROPRIETARY  Page 124 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387856] -utility analysis will adopt a time -horizon over w hich the costs and 
benefits of alternative treatments may vary.  
 
CONFIDENTIAL and PROPRIETARY  Page 125 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387857] the study in complianc e with the pr otocol and according to the 
International Conference on Harmonisation ( ICH) Guidelines for Good Cl inical Practices (E6), 
the Declaration of Helsinki, and all regulatory and institutional requirements, including those for 
patient privacy, informed consent, IRB/IEC/REB review and approval, source documentation, and 
record retention  and including any loca l regulation.  
 
13.A PATIENT PRIVACY  
Patient medical information obtained for the purposes of this trial will be considered confidential 
and will not be disclos ed to anyone not directly concerned with the trial prior written permission .  
Upon the patient’s reque st and written permission, medical information may be given to his/her 
personal physician or other appropriate medical personnel responsible for the patient’s  welfare.  
Patient confidentiality requirements of the region(s) where the t rial is conducted will be met.  
However, data generated for this study , with full access,  must be available for inspection upon 
request to representatives of the Food and Drug Admini stration ( FDA ) or other national or local 
health authorities; t he Sponsor  or its representatives; the associated IRB/IEC/REB and other 
institutional committees, as required; and/or as required by [CONTACT_2371].  
Patients will be identified only by [CONTACT_315187]’s nu mber.  However , release of research results 
or data that reveal patient names or other identifiers , such as photographs, audio or videotapes, 
must be carried out in accordance with the Department of Health and Human Services proposed 
Standards for Privacy of  Individual Health information, [ADDRESS_387858] be obtained from the patient and 
IRB/IEC/REB (or other institutional committee delegated to represent patient priva cy 
considerati ons) prior to the release of such information.  Identifiable patient data may not be  used 
for purposes of promoting the IP. 
In the US, a written Health Insurance Portability and Accountability Act (HIPAA) authorization 
must be signed by [CONTACT_941] s tudy participa nt before participating in the study to permit the use and 
disclosure of his/her per sonal health information as stated in the written authorization.  Any other 
applicable laws and other country -specific regulations must also be followed. 
 
CONFIDENTIAL and PROPRIETARY  Page 126 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 13.B IRB/IEC/REB  
This study must have the approval of a properly -constituted IRB/IEC/REB.   Before the IP may be 
used to treat patients, the Investigator will provide the Sponsor  or its representatives with a copy 
of the IRB/IEC/REB approval letter stating that the  study protocol and ICF have been reviewed 
and approved.  A copy of the approved ICF and other doc uments, as requested, will be provided 
to the S ponsor  or its representatives.  
 
13.C INSTITUTIONAL BIOSAF ETY COMMITTEE (IBC) 
In the US, this study must have the appro val of an IBC, which has been created under the guidance 
of the National Institutes of Health (N IH) to ensure proper monitoring and conduct of gene transfer 
protocols.  In other countries, other requirements for biosafety or infection control may apply a nd 
will be followed, as applicable.  
 
13.D INFORMED CONSENT  
Written consent will be obtained from the pa tient before he/she can participate in the study.   The 
content and proc ess of obtaining informed consent will be in accordance with all applicable 
regulatory re quirements.  
Prior to the initiation of any procedures relating to the study, a patient’s consent  shall be 
documented by [CONTACT_2224] a consent form written in the patient’s native language that has been 
approved by [CONTACT_1201]/IEC/REB and that is signed and pe rsonally dated by [CONTACT_315188] .  The person who conducted the informed conse nt discussion shall sign and personally 
date the consent form .  A copy of the signed and dated informed consent will be given to the 
patient .  The Investigator must keep each patient’s original, signed and dated consent form on file 
for inspection by a reg ulatory authority or authorized party at any time.  
Depending on national regulations, an authorized person other than t he Investigator may inform 
the patient,  sign and date the consent form.  
During the patient’s participation in the trial, whenever importa nt new information becomes 
available that may be relevant to the  patient's consent, t he consent form will be updated 
accordingly  for IRB/IEC/REB approval.  The patient should be informed in a timely manner if 
new information becomes available that may be r elevant to the subject’s willingness to continue 
participation in the trial.  The communication of this information should be documented.  The 
approved revise d consent form will be signed and dated by [CONTACT_102].  
CONFIDENTIAL and PROPRIETARY  Page 127 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019  
13.E REVIEW COMMITTEE 
13.E.1 Data Monitoring Committe e (DMC)  
The DMC will conduct periodic safety and efficacy review s (every 4 months) and review the data 
from both interim analyses .  The role, process and cons titution of the DMC will be specified in a 
separate DMC Charter.  Its main mission will be to eval uate the benefit  versus risk, to ensure the 
integrity of the data are respected at all times throughout the study and to give recommendations 
on its further c onduct.  
 
13.E.[ADDRESS_387859] of I nvestigators in volved in the study.  Meetings of the Steering Committee  
will be held approximately every 6  months and the Sponsor’s representatives will attend each 
meeting.   The Steering Committee  will be responsible for ensuring the study is being conducted 
with the hi ghest scientific and ethical standards and will provide input to the study protocol and 
potentia l modifications of the protocol.  The Steering Committee  will review reports relevant to 
the conduct of the study and may attend the open session of the DMC mee ting. 
 
CONFIDENTIAL and PROPRIETARY  Page 128 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 14 STUDY ADMINISTRATION 
14.A DOCUMENTS  
14.A.1 Investigator’s Brochure  
The Investigator will review the current version of the Pexa- Vec IB, including Appendix  B: 
Pexa- Vec Guidelines , which contains detailed information regarding warnings, precautions, 
contraindica tions, AEs, recommendations for managing the potential for virus transmission to 
health care wor kers and patient contacts, and other significant data pertaining to the IP.  It is 
obligatory that the Investigator be familiar with all sections of this docume nt, and ensures adequate 
training of relevant study personnel, prior to initiation of the study.   New information between 
Pexa- Vec IB updates will be communicated in the form of an IB Attachment or letter.  
 
14.A.[ADDRESS_387860] be  submitted to National Health Authorities and the 
IRB/IEC/REB with a revised ICF, if necessary and as locally requested.   Written documentation 
of IRB/IEC/REB a pproval must be received before the amendment may take effect.  
 
14.A.[ADDRESS_387861] be substantiated by [CONTACT_315189]’ original source 
documents.  The electronic system should allow a ll corrections to the eCRFs to be  dated and 
traceable to the individual making the correction.  The Investigator will ensure that all e CRFs are 
completed accurately.   A copy (electronic or paper) of all e CRFs will be retained by [CONTACT_315190]. 
  
14.B  QUALITY CONTROL AND QUALITY ASSURANCE  
14.B.1 Study Monitoring  
The Sponsor  or its representatives will monitor the site at appropriate intervals to ensure protocol 
and Good Cli nical Practice (GCP) compliance and accurate data recor ding.  The frequency of 
monitoring may va ry depending on enrollment rate and the quality of data collected.  The 
Investigator and staff are expected to cooperate and provide all relevant study document ation upon 
CONFIDENTIAL and PROPRIETARY  Page 129 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387862] also be 
granted at any ti me for inspection by [CONTACT_315191] , the Sponsor  
or its repre sentatives , the associated IRB/IEC/REB and other institutional committees, as required , 
and/or as required by [CONTACT_2371]. 
 
14.B.[ADDRESS_387863] retain  the following:  protocols ; amendments ; IRB/IEC/REB approvals ; IBC 
approvals (if applicable) ; copi[INVESTIGATOR_891] 1572;  completed, signed, dated consent forms ; 
patient medical records and original source documents; e CRFs; dr ug accountability records; all 
study -related  correspondence; and any other documents pertaining to the conduct of the study.  
According to ICH (E6), essential documents should be retained until at least [ADDRESS_387864].  These documents 
should be retained for a longer period, however, if required by [CONTACT_56859] o r by [CONTACT_315192] S ponsor.  It is the responsibility of the S ponsor to inform 
the Investigator/Institution as to when these documents no longer need to be retained.  
 
14.D STUDY TERMINATION 
The Sponsor  retains the right to terminate the study or termina te a study site and remove all the 
study materials from the study site at any time.   Specific instances that may precipi[INVESTIGATOR_8179]: 
CONFIDENTIAL and PROPRIETARY  Page 130 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 • Completion of the study at an investigat ional site  
• Unanticipated adverse medical experiences in th is or other studies indicating a potential health 
hazard caused by [CONTACT_280607]  
• Significant protocol deviation and/or lack of compliance and coopera tion on the part of the 
Investigator, including but not limited to: failure to obtain signed ICF  prior to initiating study 
related procedures; unsatisfactory patient enrollment with regard to quality or quantity; 
deviation from protocol requirements without prior approval from the Sponsor ; or inaccurate 
and/or incomplete data recording on a recurrent  basis  
• Investigator withdrawal from participation in study  
• Lack of patient recruitment at an investigational site  
• Withdrawal of investigational drug from invest igational use  
• Termination of this study by [CONTACT_941] S ponsor  or Health Authority  
• In the event of prema ture termination of the study or a site, the Sponsor  will work with the 
Investigator(s) to arrange safety follow -up for all patients exposed to Pexa -Vec.  The F ollow -
Up plan will be communicated to the IRB/IEC/REB, IBC (as applicable), and Regulatory 
authorities.  
 
14.E PUBLICATION AND PRES ENTATION POLICY 
The results of this study may be published or presented at scientific meetings.   If this is envisaged, 
the co -authors agree to su bmit all manuscripts or abstracts to the Sponsor  prior to scientific meeting 
or journal submission allowing for reasonable time to review, consistent with SillaJen policy.  This 
allows the S ponsor to protect proprietary information and to provide medical/s cientific review.  
For intellectual property protection purposes, SillaJen can request the coauthors to delay 
publication or presentation of results.  
Consistent with Good Publication Practices ( Graf  2009) , authorship is to follow the criteri a 
outlined by [CONTACT_4717] , and/or follow the policies  
outlined by [CONTACT_315193].  Financial support for medical writing assistance or 
travel provided to the authors is also to be acknowledged.  
In accordance with consistent editorial practice, the Sponsor  supports the publication of prim ary 
study results from multicenter studies in their entirety prior to any secondary analyses.  Publication 
of individual center data unless ancillary study/data  is discouraged.  A publication in which the 
CONFIDENTIAL and PROPRIETARY  Page 131 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 contribution of the S ponsor’s personnel exceeded that of conventional monitoring will be 
considered for co -authorship provided all other criteria of International Committee of Medical 
Journal Editors  are met.  
 
14.F ARCHIVING  
14.F.[ADDRESS_387865] be notified if the Investigator assigns the study 
documentation to another party or moves it to another location.  
 
14.F.2 Trial M aster F ile 
The Sponsor , or representative  will archive the trial master file  in accordance with GCP and 
appli cable regulatory re quirements and  will inform the  Investigator when the archiving of the study 
documentation is no longer required.  
 
CONFIDENTIAL and PROPRIETARY  Page 132 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387866]  
Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, et al.  OPTiM: 
A ran domized phase III trial of talimogene laherparepvec (T -VEC) versus subcutaneous (SC) 
granulocyte -macrophage colony -stimulating factor ( GM-CSF) for the treatment (tx) of unresected 
stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31:suppl ; abstr LBA9008. 
Beecham J and Knapp M. Costing psychiatric interventions. In: Measuring Mental Health Needs 
(2nd edn) ed. G. Thornicroft; 2001; pp. 200–224. Ga skell.  
Bosch FX, Ribes J, and Borras J. Epi[INVESTIGATOR_315073]. Semin Liver Dis. 
1999;19:271–85. 
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of 
a multi- mechanistic cancer -targeted oncolytic pox virus in humans. Nature 2011;477:99–102. 
Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Pat t R, Daneshmand M, et al. Oncolytic 
vaccinia virus disrupts tumor -associated vasculature in humans. Cancer Res. 2013;73:1265–75. 
Bruix J, Sherman M, Practice Gu idelines Committee, American Association for the Study of Liver 
Diseases. Management of Hepatocellular Carcinoma. Hepatology. 2005;42:1208–36. 
Cainap C, Qin S, Huang W -T, Chung I -J, Pan H, Cheng, Y, et al. Phase III trial of linifanib versus 
sorafenib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol.  
2013;30;Suppl 4, abstr 249. 
Calle EE, Rodriguez C, Walker -Thurmond K, and Thun MJ. Overweight, Obesity, and Mortality 
from Cancer in a Prospectively Studies Cohort of U.S. Adults.  N Engl J Med. 2003;348:1625–38.  
Calv isi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee J -S, et al. Ubiquitous Activation of Ras 
and Jak/Stat Pathways in Human HCC. Gastroenterol. 2006;130:1117–28.  
Canadian Cancer Society. Canadian Cancer Statistics 20 08. 
Catalano OA, Choy G, Zhu A, Hahn PF, and Sahani DV.  Differentiation of malignant thrombus 
from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of 
diffusion- weighted MR imaging.  Radiology. 2010;254:154− 62. 
Chan SL, Chong CC, Chan AW, Poon DM, and Chok KS. Management of hepatocellular 
carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol.  
2016;22:7289− 300. 
CONFIDENTIAL and PROPRIETARY  Page 133 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387867] 
Her-2/neu tumor antigen by [CONTACT_315194].  Int J Cancer.  2004;111:86–95. 
Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib (BAY 43 -9006) 
inhibits tumor growth and vascularization and induces tumor apopt osis and hypoxia in RCC 
xenograft models. Cancer Chemother Pharmacol.  2007;59:561–74. 
Chase M, Chung RY, and Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 
transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998;16:444–48. 
Chen  RT and Lane JM. Myocarditis: the unexpected return of smallpox vaccine adverse events.  
Lancet. 2003;362:1345- 46. 
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in 
patients in the Asia -Paciﬁc region with advanced hepatocellular carcinoma: a phase III 
randomised, double -blind, placebo- controlled trial. Lance t Oncol. 2009;10:25–34. 
Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in 
advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol.  
2013;31:4067–75. 
Choi H, Charnsangavej C, de Castro Faria  S, Tamm EP, Benja min RS, Johnson MM, et al. CT 
evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a 
quantitative analysis correlated with FDG PET findings. AJR Am J Roen tgenol  2004;183:1619–
28. 
Choi H, Charnsa ngaej C, Faria SC,  Macapi[INVESTIGATOR_315074], Burgess MA, Patel SR, et al. Correlation of 
computed tomography and positron emission tomography in patients with metastatic 
gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal o f 
new computed tom ography response criteria. J Clin Oncol 2007;25:1753–59. 
Deuffic S, Poynard T, Buffat L, and Valleron AJ. Trends in primary liver cancer. Lancet 
1998;351:214–15. 
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vacc ination with 
irrad iated tumor cells engineered to secrete murine granulocyte- macrophage colony -stimulating 
factor stimulates potent, specific, and long -lasting anti- tumor immunity. Proc Natl Acad Sci U S 
A 1993;90:3539–43. 
CONFIDENTIAL and PROPRIETARY  Page 134 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387868] R, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer.  
2009;45:228–47. 
El-Serag HB. Epi[INVESTIGATOR_315075]. Clin Liver Dis.  2001;5:87–107. 
El-Serag HB. Epi[INVESTIGATOR_315076] s and hepatocellular carcinoma.  Gastroenterology.  
2012;142:1264–73. 
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM. Estimates of worldwide burden 
of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893917 
Ferlay J , Steliarova -Foucher E, Lortet -Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer 
incidence and mortality patterns in Europe: e stimate s for 40 countries in 2012. Eur J Cancer.  
2013;49:1374–403. 
Forner A, Ayuso C, Varela M, Rimola J , Hessheimer AJ, d e Lope CR, et al. Evaluation of tumor 
response after locoregional therapi[INVESTIGATOR_315077]: are response evaluation criteria 
in solid tumors reliable? Cancer 2009;115:616–23. 
Forner A, Llovet JM, and Bruix J. Hepatocellular c arcinoma. Lancet. 2012; 379:1245–55. 
Gondolesi GE, Roavaie S, Munoz L, Kim -Schluger L, Schiano T, Fishbein TM, et al. Adult living 
donor liver transplantation for patients with hepatocellular carcinoma. extending UNOS priority 
criteria. Ann Surg. 2004;239:142–49. 
Goodgame B, Shaheen NJ, Galan ko J, and El -Serag HB. The risk of end stage liver disease and 
hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J 
Gastroenterol 2003;98:2535–42. 
Gordon Lan KK and DeMets DL. Dis crete sequential boundaries for clinical trials.  Biometrika  
1983;70(3):659–63.  
Graf C, Battisti WP, Bridges D, Bruce -Winkler V, Conaty JM, Ellison JM, et al. Research Methods 
& Reporting. Good publication practice for communicating company sponsored medi cal research: 
the GPP2 guidelines. BMJ. 2009;339: b4330. 
Hanahan D. and Weinberg RA. The hallmarks of cancer. Cell.  2000; 100:57–70. 
Hashimoto E, Yatsuji S, Toba ri M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular 
carcinoma in patients with nonalcohol ic steatohepatitis. J Gastroenterol  2009;44:89–95. 
CONFIDENTIAL and PROPRIETARY  Page 135 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387869] chemotherapeutic agents. Nat Med 1997;3:639–45. 
Hengstschläger M, Pfeilstöcker M, and Wawra E. Thymidine kinase expression. A marker for 
malignant c ells. Adv Exp Med Biol. 1998;431:455–60. 
Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, et al. Sequential Therapy With JX -594, 
A Targeted Oncolytic Poxvirus, Followed by [CONTACT_315195]: Preclinical 
and Clinical Demonstration of  Combination Efficacy. Mol Ther  2011:19(6);1170–79. 
Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose -finding clinical 
trial of oncolytic immunotherapeutic v accinia JX -594 in liver cancer.  Nat Med. 2013;19:329–36 
Herdman M, Gu dex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary 
testing of the new f ive-level version of EQ -5D (EQ -5D-5L). Qual Life Res.  2011;20:1727–3. 
Hermiston TW and Kuhn I. Armed therapeutic viruses: strategies and challe nges to armin g 
oncolytic viruses with therapeutic genes. Cancer Gene Ther  2002;9:1022– 35. 
Hermiston TW and Kirn D H. Genetically based therapeutics for cancer: similarities and contrasts 
with traditional drug discovery and development. Mol Ther  2005;11:496–507. 
Hodi FS , Lee SJ, McDermott DF, Rao UNM, Butterfield LH, Tarhini AA, et al . Multicenter, 
randomized phase II trial of GM -CSF (GM) plus ipi[INVESTIGATOR_125] (Ipi) versus I pi [INVESTIGATOR_315078] : E1608. J. Clin Oncol. ASCO Annual Meeting Abstracts. 2013:31(June 20 
Supplement);CRA9007. 
Hoos A. Evolution of end points f or cancer immunotherapy trials.  Ann Oncol. 2012;[ADDRESS_387870] 8:viii 
47–52. 
Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, et al. A Mechanistic Proof -
of-concept Clinical Trial With JX-594, a Targeted Multi- mechanistic Oncolytic Poxvirus, in 
Patients With Metastatic Melanoma. Mol Therapy  2011; 19:1913–22. 
Ito Y, Tak eda T, Umeshita K, Sakon M, Wakasa K, Matsuura N, et al. Fas antigen expression in 
hepatocellular carcinoma tissues. Oncol Rep. 1998;5:41–44. 
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib a s 
first-line therapy i n patients with unresectable, advanced hepatocellular carcinoma: results from 
the randomized phase III BRISK -FL study. J Clin Oncol. 2013;31:3517–24. 
CONFIDENTIAL and PROPRIETARY  Page 136 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Katsafanas GC and Moss B. Vaccinia virus intermediate stage transcription is complemented by 
[CONTACT_315196]-GTPase- activating protein SH3 domain -binding protein (G3BP) and cytoplasmic 
activation/proliferation -associated protein (p137) individually or as a heterodimer.  J Biol Chem.  
2004; 279:[ZIP_CODE]–17. 
Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, e t al. Systemic armed o ncolytic and 
immunologic therapy for cancer with JX -594, a targeted poxvirus expressing GM -CSF. Mol Ther 
2006;14:361–70. 
Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, et al. Oncolytic and immunotherapeutic 
vaccinia induces antib ody-mediated complemen t-depende nt cancer cell lysis in humans. Sci 
Transl Med. 2013;5: 185ra163. 
Kirn DH, Wang Y, Le Boeuf F, Bell J, and Thorne SH. Targeting of interferon- beta to produce a 
specific, multi- mechanistic oncolytic vaccinia virus. PLoS Med. 2007;4:e353. 
Kirn DH and Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi -mechanistic 
therapeutic class for cancer. Nat Rev Cancer  2009;9:64–71. 
Lencioni R and Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular 
carcinoma. Sem in Liver Di s 2010;30:52–60. 
Lencioni R1, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. First interim analysis of 
the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its 
treatment with sorafeNib) non -interv entional st udy. Int J Clin Pract. 2012;66:675–83. 
Lencioni R. New data supporting modified RECIST (mRECIST) for Hepat ocellular Carcinoma.  
Clin Cancer Res.  2013;19:1312–4. 
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu A, et al. Design and endpoints 
of clinical trials in hepatocellular carcinoma. JNCI 2008a;100:698–711. 
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J -F, et al. Sor afenib in advanced 
Hepatocellular Carcinoma (HCC). N Engl J Med  2008b; 359:378–90. 
Llovet JM, Decaens  T, Raoul J L, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with 
advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: 
results from the randomized phase III BRISK -PS study. J Clin Oncol. 2013;31:3509–16. 
Martuza RL , Malick A, Markert JM, Ruffner KL, and Coen DM. Experimental therapy of human 
glioma by [CONTACT_3553] a genetically engineered virus mutant. Science 1991;252:854–56. 
CONFIDENTIAL and PROPRIETARY  Page 137 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et a l. 
Intratum oral recombinant GM -CSF-encoding virus as gene therapy in patients with cutaneous 
melanoma.  Cancer Gene Ther  1999;6:409–22. 
Mori S, Yamasaki T, S akaida I, Takami T, Sakaguchi E, Kimura T, et al. Hepatocellular carcinoma 
with nonalcoholic steatohepatitis. J  Gastroenterol. 2004;39:391–96. 
Niederau C, Fisher R, Sonnenberg A, Stremmel W, Trampi[INVESTIGATOR_315079], and Strohmeyer G. Survival 
and causes of death in c irrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl 
J Med. 1985;313: 1256–62. 
O'Brien PC and Fleming TR. A multiple testing procedure for clinical trials. Biometrics.  
1979;35(3):549–56. 
Parato KA, Senger D, Forsyth PA, and Bell JC. Recent progress in the battle between oncolytic 
viruses and tumours. Nat Rev Cancer 2005;5:965 –76. 
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The Oncolytic Poxvirus 
JX-594 Selectively Replicates in and Destroys Cancer Cells Driv en by [CONTACT_315197]. Mol Ther. 2012;20:749–58. 
Park BH, Hwang T, Li u TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic 
poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. 
Lancet Oncol 2008;9:533–42. 
Quirk M, Kim YH, Saab S, and Lee EW. Management of hepatocellul ar carcinoma with portal 
vein thrombosis. World J Gastroenterol. 2015;21:3462–71. 
Scalone L, Ciampi[INVESTIGATOR_147929] R, Fagiuoli S, Gardini I, Fusco F, Gaeta L, et al. Comparing the 
performance of the standard EQ -5D 3L with the new version EQ -5D 5L in patients  with ch ronic 
hepatic diseases.  Qual Life Res.  2013;22:1707–16. 
Semela D and Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864–
80. 
Siegel  R, Ma J, Zou Z, and Jemal A. Cancer statistics, 2014. CA Cancer J Clin.  2014;64:9–29.  
Simonetti RG,  Camma C, Fiorello F, Politi F, D’Amico G, Pagliaro L. Hepatocellular carcinoma. 
A worldwide problem and the major risk factors. Dig Dis Sci.  1991;36:962–72. 
CONFIDENTIAL and PROPRIETARY  Page 138 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . [ADDRESS_387871] with a previously unknown oncolytic virus. Nat Med  
2000;6:821–25. 
Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Ka nji F, et al. Rational strain selection 
and engineering creates a broad -spectrum, syste mically effect ive oncolytic poxvirus, JX-963. J 
Clin Invest.  2007;117:3350–8. 
Todo T, Martuza RL, Dallman MJ, and Rabkin SD. In situ expression of soluble B7- 1 in the 
context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res  
2001;61:153–61. 
Villanueva A, Newell P, Chiang DY, Friedman SL, and Llovet JM. Genomics and signaling 
pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55–76.  
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, and Rong H. BAY 43- [ADDRESS_387872] spectru m oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor 
tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.  2004;64:7099–109.  
Yan X and Su XG. Stratified Wilson and Newcombe Confidence Intervals for Multiple Bino mial 
Proportions. Stat Biopharm Res 2010;2;329–35.  
Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon JK, et al. Antiviral chemotherapy 
facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin 
Invest.  2005;115( 2) 379– 87.  
Yoo HY, Patt CH, Geschwind JF, and Thuluvath PJ. The outcome of liver transplantation in 
patients with hepatocellular carcinoma in the [LOCATION_002] between 1988 and 2001:  5- Year 
survival has improved significantly with time. J Cl in Oncol, 2003; J21;:4329–433. 
Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, et al. Visualization of 
tumors and metastases in live animals with bacte ria and vaccinia virus encoding light -emitting 
proteins. Nat Biotechnol. 2004;22:313–20. 
Zhu AX, Kan g Y-K, Rosmorduc O, Evans TRJ, Santoro A, Ross PJ, et al. Biomarker analyses and 
association with clinical outcomes in patients with advanced hepatocellular  carcinoma (HCC) 
treated with sorafenib with or without erlotinib in the phase III SEAR CH trial. J C lin Oncol 
2014a;32:suppl; abstr 4028. 
CONFIDENTIAL and PROPRIETARY  Page 139 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. EVOLVE -1: Phase 3 study of 
everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol  
2014b;32:suppl 3; abstr 172. 2014b Gastrointes tinal Cancers Symposium.  
 
CONFIDENTIAL and PROPRIETARY  Page 140 of 142 
Protocol JX594 -HEP024 (A mendment  2) FINAL  
SillaJen, Inc . 26 June 2019 APPENDIX A : 
SCHEDULE OF ACTIVITIES  
CONFIDENTIAL and PROPRIETARY  Page 141 of 142 
Protoco l JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  26 June 2019  
 

CONFIDENTIAL and PROPRIETARY  Page 142 of 142 
Protoco l JX594 -HEP024 (Amendment 2 ) FINAL  
SillaJen, Inc.  26 June 2019  
